BGB -A317 -306 BeiGene 
Protocol Amendment  5.0 
CONFIDENTIAL  Page 1 CLINICAL STUDY PROTOCOL  TITLE PAGE  
A Randomized, Placebo -Controlled, Double -Blind Phase 3 Study to Evaluate 
the Efficacy and Safety of Tislelizumab (BGB -A317) in Combination With 
Chemotherapy as First -Line Treatment in Patients with Unresectable, Locally 
Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma  
Brief Title:  
A study of tislelizumab (BGB -A317) in combination with chemotherapy as first -line treatment in 
participants  with advanced esophageal squamous cell carcinoma   
Protocol Number:  BGB -A317 -306 
Amendment Number:  5.[ADDRESS_500411]:  Tislelizumab (BGB -A317)  
Regulatory Agency  
Identification Number(s):  EudraCT Number 2018 -000587 -28 
Sponsor:  BeiGene, Ltd.  
c/o BeiGene [LOCATION_003], Inc.  
[ADDRESS_500412] Floor  
San Mateo, [LOCATION_004] [ZIP_CODE]  
[LOCATION_003]  
Approval Date:  See electronic signature  
[CONTACT_112684] [CONTACT_7171]:  BeiGene Medical Officer  
Phone: [PHONE_8264]  
Email: [EMAIL_7609]  
Approved Date 3/13/[ADDRESS_500413] Number [STUDY_ID_REMOVED]

BGB -A317 -[ADDRESS_500414] read the protocol, appendices, and accessory materials related to study BGB -A317 -306 
and agree to the following:  
• To conduct this study as described by [CONTACT_397734] y accessory materials.  
• To protect the rights, safety, and welfare of the patients under my care.  
• To provide oversight to all personnel to whom study activities have been delegated.  
This includes personnel at my site as well as personnel working in any fac ility where 
study activities are my responsibility.  
• To control all investigational products provided by [CONTACT_397735].  
• To conduct the study in accordance with all applicable laws and regulations, the 
requirements of the ethics committee of record for my clinical site, and current GCP 
as outlined by [CONTACT_12212] E6(R2).  
• To obtain approval for the protocol and all written materials provided to patients 
before initiating the study at my site.  
• To obtain informed co nsent – and updated consent in the event of new information or 
amendments – from all patients enrolled at my study site before initiating any 
study -specific procedures or administering investigational products to those patients.  
• To maintain records of each  patient’s participation and all data required by [CONTACT_397736].  
Acceptance of this protocol constitutes my agreement that no confidential information contained 
herein will be published or disclosed without prior written app roval from BeiGene, Ltd. or one of 
its affiliates, unless and only to the extent required by [CONTACT_774].  
Name:    [CONTACT_1641]:   Institution :   
      
Signature:   [CONTACT_1782] :   
    
Approved Date 3/13/[ADDRESS_500415] 2019  Substantial  
BGB -A317 -306 Amendment 1.0  19 September 2018  Substantial  
Original protocol  13 February 2018  Not applicable  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 4 PROTOCOL AMENDMENT SUMMARY OF CHANGES   
This Protocol Amendment 5.0 replaces the previous Protocol Amendment 4.0. The amendment 
is considered substantial based on the criteria set forth in Regulation (EU) No 536/2014  of the 
European Parliament and the Council of the EU. The primary purpose of this amendment is to : 
• Add description of  unblinding  and placebo discontinuation of the study  after its interim 
analysis . 
A few clarifications or non-substantial  updates have also been made and summarized in this 
summary.  
Additionally,  some  editorial and formatting changes  or corrections  have also been made but are 
not included in this summary.  
Approved Date 3/13/[ADDRESS_500416] 
those changes  at that time.  
Section  3.7 End of Study  Added description of a rollover study. Updated the 
language regarding patients who may benefit from 
tislelizumab could be offered the option to continue 
treatment after study closeout . Clarify there would be option s for 
patients  to continu e treatment  after 
study closeout .  
Section  1.4.2  Toxicology  Updated the language to comply with GLP.  Text was revised for consistency with 
sponsor’s protocol template . 
Section  3.4 End of Treatment/S afety  
Follow -up, 
Appendix  1 Schedule of Assessments  Added the requirement of patients completing an 
End-of-Treatment/ Safety  Follow -up Visit before 
continuing in a long -term extension/ posttrial supply 
study.  Clarify the  request for the 
End-of-Treatment/Safety Follow -up 
Visit  
Section  9.2.2  Secondary Efficacy Analysis  Updated the patient -reported outcome endpoint 
language  Text was revised for consistency with 
sponsor’s protocol template . 
Appendix  1 Schedule of Assessments  Added language that allows for PK and ADA sample 
collection and patient -reported outcome collection to 
stop after patients finish the 3 -year follow up.  Remove unneces sary examinations 
after the 3 -year follow -up 
Throughout document  Changed “immune -related adverse events ” to 
“immune -mediated adverse events .” Text was revised for consistency with 
sponsor’s protocol template . 
Section  5.1.3  Cisplatin,  
Section  5.1.4  Oxaliplatin,  
Section  5.1.5  5-Fluorouracil,  
Section  5.1.6  Capecitabine,  
Section  5.1.7  Paclitaxel  Added that the labels descri bed are for drugs supplied 
by [CONTACT_3552] . Clarif ied the labels are for drugs 
supplied by [CONTACT_397737].  
Approved Date 3/13/[ADDRESS_500417] sourced for the participating country.  Updated the text for clarity.  
Sectio n 5.2 Dosage, Administration, and 
Compliance  Added language that the sponsor or designee will 
either supply or reimburse sites where the sponsor is 
required to provide chemotherapy doublet products.   Updated the text for clarity.  
Section  13 Ethics/Protection of Human 
Patients  Updated language to  comply with ICH  GCP and local 
regulations . Text was revised for consistency  with 
the protocol template . 
Clinical Study Title Page , Investigator 
Signature [CONTACT_3490] , Protocol Synopsis   Updated the current study information per the current 
regulations and guidance . To update for administrative purposes  
Document History  Added Document History page  Text was revised for consistency with 
the protocol  template . 
.
Approved Date 3/13/[ADDRESS_500418] OF ABBREVIATIONS AND TERMS  ................................ ................................ ................ 25 
1. INTRODUCTION  ................................ ................................ ................................ ......28 
1.1. Backgro und Information on Esophageal Carcinoma  ................................ .................. 28 
1.2. Current Treatment of Esophageal Carcinoma and Unmet Clinical Needs  ................. 28 
1.3. Anti-PD-1 Therapy for Esophageal Squamous Cell Carcinoma  ................................ 30 
1.4. Background Information on Tislelizumab  ................................ ................................ ..33 
1.4.1.  Pharmacology  ................................ ................................ ................................ ............. 33 
1.4.2.  Toxicology  ................................ ................................ ................................ .................. 33 
1.4.3.  Clinical Pharmacology  ................................ ................................ ................................ 34 
1.4.4.  Prior Clinical Experience of Tislelizumab  ................................ ................................ .34 
1.5. Study Rationales  ................................ ................................ ................................ ......... 38 
1.5.1.  Rationale for Tislelizumab in the Treatment of Esophageal Carcinoma  .................... 38 
1.5.2.  Rationale for Selection of Tislelizumab Dose  ................................ ............................ 38 
1.5.3.  Rationale for Matched  Placebo in Combination with Chemotherapy as the 
Comparator  ................................ ................................ ................................ ................. 39 
1.6. Benefit -Risk Assessment  ................................ ................................ ............................ 39 
2. STUDY OBJECTIVES AND ENDPOINTS  ................................ .............................. 40 
2.1. Study Objectives  ................................ ................................ ................................ ......... 40 
2.1.1.  Primary Objective  ................................ ................................ ................................ .......40 
2.1.2. Secondary Objectives  ................................ ................................ ................................ .40 
2.1.3.  Exploratory Objectives  ................................ ................................ ............................... 40 
2.2. Study Endpoints  ................................ ................................ ................................ .......... 41 
2.2.1.  Primary Endpoint  ................................ ................................ ................................ ........ 41 
2.2.2.  Secondary Endpoints  ................................ ................................ ................................ ..41 
2.2.3.  Exploratory Endpoints  ................................ ................................ ................................ 41 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 8 3. STUDY DESIGN  ................................ ................................ ................................ .......42 
3.1. Summary  of Study Design  ................................ ................................ .......................... 42 
3.2. Screening Period  ................................ ................................ ................................ ......... 43 
3.3. Treatment Period  ................................ ................................ ................................ ........ 43 
3.4. End of Treatment/Safety Follow -up ................................ ................................ ........... [ADDRESS_500419] udy (End of Study for an Individual Patient)  .......... 46 
3.7. End of Study  ................................ ................................ ................................ ............... 46 
3.8. Enrollment of Japanese Patients  ................................ ................................ ................. 47 
4. STUDY POPULATION  ................................ ................................ ............................. 48 
4.1. Inclusion Criteria  ................................ ................................ ................................ ........ 48 
4.2. Exclusion Criteria  ................................ ................................ ................................ .......49 
5. STUDY TREATMENT  ................................ ................................ .............................. 52 
5.1. Formulation, Packaging, and Handling  ................................ ................................ ......52 
5.1.1.  Tislelizumab  ................................ ................................ ................................ ............... 52 
5.1.2.  Matched Placebo  ................................ ................................ ................................ ......... 52 
5.1.3.  Cisplatin  ................................ ................................ ................................ ...................... 52 
5.1.4.  Oxali platin  ................................ ................................ ................................ .................. 53 
5.1.5.  5-Fluorouracil  ................................ ................................ ................................ ............. 53 
5.1.6.  Capecitabine  ................................ ................................ ................................ ............... 53 
5.1.7.  Paclitaxel  ................................ ................................ ................................ ..................... 54 
5.2. Dosage, Administration, and Compliance  ................................ ................................ ..54 
5.2.1.  Tislelizumab  ................................ ................................ ................................ ............... 55 
5.2.2.  Matched Placebo  ................................ ................................ ................................ ......... 55 
5.2.3.  Chemotherapy Doublet A: Platinum (Cisplatin or Oxaliplatin) in Combination 
with 5 -Fluorouracil  ................................ ................................ ................................ .....56 
5.2.4.  Chemotherapy Doublet B: Platinum (Cisplatin or Oxaliplatin) in Combination 
with Capecitabine  ................................ ................................ ................................ .......56 
5.2.5.  Chemotherapy Doublet C: Platinum (Cisplatin or Oxaliplatin) in Combination 
with Paclitaxel  ................................ ................................ ................................ ............ 57 
5.3. Overdose  ................................ ................................ ................................ ..................... 58 
Approved Date 3/13/[ADDRESS_500420] Accountability  ................................ ..................... 59 
5.5. Dose Delay or Modification  ................................ ................................ ....................... 59 
5.5.1.  Dose Delay or Modification for Tislelizumab/Placebo  ................................ .............. 60 
5.5.2.  Dose Delay, Interruption, or Modifications for Chemotherapy  ................................ .60 
5.5.3.  Blinding  ................................ ................................ ................................ ...................... 65 
6. PRIOR AND CONCOMITANT THERAPY  ................................ ............................. 67 
6.1. Concomitant Therapy  ................................ ................................ ................................ .67 
6.1.1.  Permitted Concomitant Medications  ................................ ................................ .......... 67 
6.1.2.  Prohibited Concomitant Medications/Procedures  ................................ ...................... 68 
6.1.3.  Restricted Concomitant Medications/Procedures  ................................ ....................... 68 
6.2. Potential Interactions Between the Study Drugs and Concomitant Medications  .......68 
7. STUDY ASSESSMENTS AND PROCEDURES  ................................ ...................... 71 
7.1. Screening  ................................ ................................ ................................ .................... 71 
7.1.1.  Demographic Data and Medical History  ................................ ................................ ....71 
7.1.2.  Females of Childbearing Potential and Contraception  ................................ ............... 72 
7.1.3.  Informed Consent and Screening Log  ................................ ................................ ........ 72 
7.1.4.  Pulmonary Function Tests  ................................ ................................ .......................... 72 
7.2. Enrollment  ................................ ................................ ................................ .................. 72 
7.2.1.  Confirmation of Eligibility  ................................ ................................ ......................... 72 
7.2.2.  Patient Numbering  ................................ ................................ ................................ ......72 
7.2.3.  Enrollment/Randomization  ................................ ................................ ......................... 72 
7.3. Tislelizumab and Comparator Drug Dispensation  ................................ ..................... 73 
7.4. Safety Assessments  ................................ ................................ ................................ .....73 
7.4.1.  Vital Signs  ................................ ................................ ................................ .................. 73 
7.4.2.  Physical Examinations  ................................ ................................ ................................ 73 
7.4.3.  Eastern Cooperative Oncology Group Performance Status  ................................ ........ 73 
7.4.4.  Laboratory Safety Tests  ................................ ................................ .............................. 74 
7.4.5.  Cardiac Enzyme Monitoring  ................................ ................................ ....................... 74 
7.4.6.  Electrocardiograms  ................................ ................................ ................................ .....74 
7.4.7.  Adverse Events  ................................ ................................ ................................ ........... 74 
7.4.8.  Hepatitis B and C Testing  ................................ ................................ ........................... 74 
7.5. Tumor and Response Evaluations  ................................ ................................ .............. 75 
Approved Date 3/13/[ADDRESS_500421] Abnormalities  ................................ ................................ ................... 87 
8.4. Definition of a Serious Adverse Event  ................................ ................................ .......87 
8.5. Suspected Unexpected Serious Adverse Reaction  ................................ ..................... 88 
8.6. Timing, Frequency, and Method of Capturing Adverse Events and Serious 
Adverse Events  ................................ ................................ ................................ ........... 88 
8.6.1.  Adverse  Event Reporting Period  ................................ ................................ ................ 88 
8.6.2.  Reporting Serious Adverse Events  ................................ ................................ ............. 89 
8.6.3.  Eliciting Adverse Events  ................................ ................................ ............................ 90 
8.6.4.  Disease Progression  ................................ ................................ ................................ ....90 
8.6.5.  Deaths  ................................ ................................ ................................ ......................... 91 
8.6.6.  Pregnancies  ................................ ................................ ................................ ................. 91 
8.6.7.  Expedited Reporting to Health Authorities, Investigators, Institutional Review 
Boards, and Independent Ethics Committees  ................................ ............................. 91 
8.6.8.  Assessing and Recording Immune -Mediated Adverse Events  ................................ ...91 
8.6.9.  Recording Infusion -Related Reactions  ................................ ................................ .......92 
Approved Date 3/13/[ADDRESS_500422]  ................................ ................................ .......92 
8.7.1.  Managing Infusion -Related Reactions  ................................ ................................ .......92 
8.7.2.  Severe Hypersensitivity Reactions and Flu -Like Symptoms  ................................ .....94 
8.7.3.  Immune -Mediated Adverse Events  ................................ ................................ ............ 94 
9. STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION  ................. 96 
9.1. Statistical Analysis  ................................ ................................ ................................ ......96 
9.1.1.  Randomization Methods  ................................ ................................ ............................. 96 
9.1.2.  Analysis Sets  ................................ ................................ ................................ ............... 96 
9.1.3.  Patient Disposition  ................................ ................................ ................................ ......96 
9.1.4.  Demographic and Other Baseline Characteristics  ................................ ...................... 96 
9.1.5.  Prior and Concomitant Medications  ................................ ................................ ........... 97 
9.2. Efficacy Analyses  ................................ ................................ ................................ .......97 
9.2.1.  Primary Efficacy Analysis  ................................ ................................ .......................... 97 
9.2.2.  Secondary Efficacy Analysis  ................................ ................................ ...................... 98 
9.2.3.  Exploratory Efficacy Analysis  ................................ ................................ .................... 99 
9.3. Safety Analyses  ................................ ................................ ................................ ........ 100 
9.3.1.  Extent of Exposure  ................................ ................................ ................................ ...100 
9.3.2. Adverse Events  ................................ ................................ ................................ ......... 100 
9.3.3.  Laboratory Analyses  ................................ ................................ ................................ .101 
9.3.4.  Vital Signs  ................................ ................................ ................................ ................ 101 
9.3.5.  Ophthalmologic Examination  ................................ ................................ ................... 101 
9.4. Pharmacokinetic Analysis  ................................ ................................ ........................ 101 
9.5. Immunogenicity Analyses  ................................ ................................ ........................ 101 
9.6. Sample Size Consideration  ................................ ................................ ....................... 101 
9.7. Interim Analyses  ................................ ................................ ................................ .......102 
10. STUDY COMMITTEES AND COMMUNICATION  ................................ ............ 103 
10.1.  Blinded Independent Review Committee  ................................ ................................ .103 
10.2.  Independent Data Monitoring Committee  ................................ ................................ 103 
11. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  ................................ ................................ ............................. 104 
11.1.  Access to Information for Monito ring ................................ ................................ ......104 
11.2.  Access to Information for Auditing or Inspections  ................................ .................. 104 
12. QUALITY ASSURANCE AND QUALITY CONTROL  ................................ .......105 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 12 12.1.  Regulatory Authority Approval  ................................ ................................ ................ 105 
12.2.  Quality Assurance  ................................ ................................ ................................ .....105 
12.3.  Study Site Inspections ................................ ................................ ............................... 105 
12.4.  Drug Accountability  ................................ ................................ ................................ .105 
13. ETHICS/PROTECTION OF HUMAN PATIENTS  ................................ ................ [ADDRESS_500423]/Independent Ethics Committee  ................................ ....[ADDRESS_500424] KEEPI[INVESTIGATOR_1645]  ................................ .................... 110 
14.1.  Data Collection and Management Responsibilities  ................................ .................. 110 
14.1.1.  Data Collection  ................................ ................................ ................................ ......... 110 
14.1.2.  Data Management/Coding  ................................ ................................ ........................ 110 
14.2.  Data Integrity and In -House Blinding  ................................ ................................ ......110 
14.3.  Study Records Retention  ................................ ................................ .......................... 111 
14.4.  Protocol Deviations  ................................ ................................ ................................ ..112 
14.5.  Publication and Data Sharing Policy  ................................ ................................ ........ 112 
14.6.  Study and Study Center Closure  ................................ ................................ ............... 112 
14.7.  Information Disclosure and Inventions  ................................ ................................ ....113 
15. REFERENCES  ................................ ................................ ................................ ......... 115 
APPENDIX  1. SCHEDULE OF ASSESSMENTS  ................................ ................................ ..118 
APPENDIX  2. CLINICAL LABORATORY ASSESSMENTS  ................................ .............. 123 
APPENDIX  3. ECOG PERFORMANCE STATUS ................................ ................................ .124 
APPENDIX  4. THE RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
(RECIST) GUIDELINES, VERSION 1.1  ................................ ................................ 125 
APPENDIX  5. PRE-EXISTING  IMMUNE DEFICIENCIES OR AUTOIMMUNE 
DISEASES  ................................ ................................ ................................ ................ 134 
APPENDIX  6. NEW YORK HEART ASSOCIATION FUNCTIONAL 
CLASSIFICATION  ................................ ................................ ................................ ..135 
APPENDIX  7. IMMUNE -MEDIATED ADVERSE EVENT EVALUATION AND 
MANAGEMENT  ................................ ................................ ................................ .....136 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 13 APPENDIX  8. CHRONIC KIDNEY DISEASE EPI[INVESTIGATOR_397664] (CKD -EPI) EQUATION  ................................ ....................... 147 
APPENDIX  9. CONTRACEPTION GUIDELINES AND DEFINITIONS OF 
“WOMEN OF CHILDBEARING POTENTIAL”, “NO CHILDBEARING 
POTENTIAL”  ................................ ................................ ................................ ........... 148 
APPENDIX  10. EORTC -QLQ -C30 QUESTIONNAIRE  ................................ ........................ 150 
APPENDIX  11. EORTC QLQ -OES18 QUESTIONNAIRE  ................................ .................... 152 
APPENDIX  12. EQ-5D-5L QUESTIONNAIRE ................................ ................................ ......153 
APPENDIX  13. FLOW CHART  ................................ ................................ .............................. 155 
APPE NDIX  14. AMERICAN JOINT COMMITTEE ON CANCER TNM 
CLASSIFICATION OF CARCINOMA OF THE ESOPHAGUS AND 
ESOPAGOGASTRIC JUNCTION (7TH ED, 2010)  ................................ ................. [ADDRESS_500425] -Line Treatment and Outc omes for Esophageal Squamous Cell Carcinoma  .......... 30 
Table 2.  Selection and Timing of Dose for Each Patient  ................................ .............................. 54 
Table  3: BGB -A317 -306 Dose Reduction Level of Chemotherapy  ................................ ......... 61 
Table  4: Guidance for Duration of Recording New or Worsening Adverse Events in 
Both Treatment Arms  ................................ ................................ ................................ .89 
Table 5.  Timeframes and Documentation Methods for Reporting Serious Adverse Events 
to the Sponsor or Designee  ................................ ................................ ......................... 89 
Table 6.  Treatment Modification for Symptoms of Infusion -Related Reactions Due to 
Study Drug(s)  ................................ ................................ ................................ .............. 93 
Table 7.  Im mune -Mediated Adverse Events  ................................ ................................ ................ 95 
Table 8.  Stoppi[INVESTIGATOR_274353] (in p -Value and Z Score) of Primary Analysis of Overall 
Survival  ................................ ................................ ................................ ....................... [ADDRESS_500426] OF FIGURES   
Figure 1.  Study Schema  ................................ ................................ ................................ ................ 42 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 14 SYNOPSIS   
Name [CONTACT_790]/Company:  BeiGene, Ltd.  
Investigational Medicinal Product:  Tislelizumab (BGB -A317)  
Title of Study:  A randomized, placebo -controlled, double -blind Phase 3 study to evaluate the efficacy 
and safety of tislelizumab (BGB -A317) in combination with chemotherapy as first -line treatment in 
patients with unresectable, locally advanced, recurrent or metastatic esophageal squam ous cell 
carcinoma  
Protocol Identifier:  BGB -A317 -306 
Amendment Version: 5.0  
Regulatory Agency Identifier Number(s): EudraCT Number 2018 -000587 -28  
Number of Patients:  Approximately 622  
Study Centers:  At least 120 centers internationally  
Study Objectives:  
Primary:  
• To evaluate and compare the overall survival (OS) following treatment with tislelizumab in 
combination with chemotherapy compared to placebo in combination with chemotherapy when 
given as fi rst-line treatment in patients with unresectable, locally advanced recurrent or 
metastatic ESCC  
Secondary:  
• To evaluate and compare the efficacy of tislelizumab in combination with chemotherapy 
compared to placebo in combination with chemotherapy as a first -line treatment in 
unresectable, locally advanced recurrent or metastatic ESCC as measured by [CONTACT_3988] -free 
survival (PFS), objective response rate (ORR), and duration of response (DOR) assessed by [CONTACT_397738] (RECIST) version (v)  1.1 
• To evaluate and compare the efficacy of tislelizumab in combination with chemotherapy with 
the efficacy of placebo in combination with chemotherapy as a first -line treatment in 
unresectable, locall y advanced recurrent or metastatic ESCC as measured by [CONTACT_397739] -1 (PD -L1) visually estimated combined positive score 
(vCPS) ≥ 10% subgroup  
• To evaluate and compare health -related quality of life (HRQoL) based on patient -reported 
outcomes (PROs) between tislelizumab in combination with chemotherapy and placebo in 
combination with chemotherapy  
• To compare the safety between tislelizumab in combination with chemotherapy and placebo in 
combination with chemotherapy  
Explorat ory: 
• To characterize the disease control rate (DCR) with tislelizumab in combination with 
chemotherapy assessed by [CONTACT_76954] v1.1  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 15 • To evaluate PFS, ORR, DOR, and DCR assessed by [CONTACT_397740] 
(BIRC) per RECIST v1.1  
• To assess PFS after next line of treatment (PFS2)  
• To evaluate the potential association of biomarkers with patient prognosis, response , or 
resistance to tislelizumab in combination with chemotherapy  
• To assess the pharmacokinetics of tislelizumab in combinat ion with chemotherapy  
• To assess host immunogenicity to tislelizumab in combination with chemotherapy  
Study Endpoints:  
Primary:  
• OS - defined as the time from the date of randomization until the date of death due to any cause  
Secondary:  
• PFS - defined as the time from the date of randomization to the date of first documentation of 
disease progression assessed by [CONTACT_76954] v1.[ADDRESS_500427] 
• ORR - defined as the proportion of patients whose best overall response (BOR) is  complete 
response (CR) or partial response (PR) assessed by [CONTACT_76954] v1.1  
• OS in the PD -L1 vCPS ≥ 10% subgroup  
• HRQoL - defined as scores of the European EORTC QLQ -C30 (QLQ -C30), its esophageal 
cancer module - EORTC QLQ -OES18 (OES18), and  the European Quality of Life 5 -
Dimension 5 -Level (EQ -5D-5L) 
• DOR - defined as the time from the first determination of an objective response until the first 
documentation of progression assessed by [CONTACT_76954] v1.[ADDRESS_500428] 
• The incidence and severity of adverse events (AEs) according to National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI -CTCAE)  v4.03  
Exploratory:  
• DCR - defined as the proportion of patients whose BOR is CR, PR, and stable disea se (SD) 
assessed by [CONTACT_76954] v1.1  
• PFS, ORR, DOR, and DCR assessed by [CONTACT_397741] v1.1  
• PFS2 - defined as the time from randomization to the objective disease progression after next 
line of treatment or death from any cause, whichever occurs first  
• To explore biomarkers in tumor tissues and/or blood samples before and after study treatment 
and/or at progressive disease (PD )/reoccurrence, and the association between these biomarkers 
and clinical efficacy, disease  status, and resistance. Biomarker assessment will consist of PD -
L1 expression, gene expression profiling (GEP), tumor mutation burden (TMB)/microsatellite 
instability (MSI)/mutation profile, and tumor -infiltrating immune cells. Other assessments may 
be conducted as al lowed by [CONTACT_427].  
• Assessments of pharmacokinetics of tislelizumab when given with chemotherapy  
• Assessments of immunogenicity of tislelizumab to determine the incidence of anti -drug 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 16 antibodies (ADA)  
Study Design:  
This is a randomized, placebo -controlled, double -blind, global Phase 3 study comparing OS following 
treatment with the anti -programmed cell death protein -1 (PD -1) monoclonal antibody tislelizumab in 
combination with standard chemotherapy compared to placebo in combination with chemotherap y 
when given as the first -line treatment in patients with unresectable, locally advanced recurrent or 
metastatic  ESCC who have Stage IV unresectable ESCC at first diagnosis (ie, Stage IV disease at the 
original diagnosis of ESCC) or who have unresectable, locally advanced recurrent or metastatic disease 
with at least a 6 -month treatment -free interval, if definitive treatment (neo -adjuvant or adjuvant 
treatment chemotherapy, chemo -radiation therapy and/or surgery) was given. Staging criteria for this 
study a re defined by [CONTACT_267516] (AJCC), 7th  Edition ( Edge et al 2010 ). 
After providing written informed consent, completing all screening assessments, and being confirmed 
as eligible for study participation, approximately 622 patients will be randomized 1:1 to receive either 
tislelizumab in combination with a chemotherapy dou blet (Arm A) or placebo with a chemotherapy 
doublet (Arm B). The choice of chemotherapy must be determined prior to randomization.  
Patient randomization will be stratified by [CONTACT_716] 3  factors:  
• Geographic region (Asia [excluding Japan] vs Japan vs R est of World)  
• Prior definitive therapy (yes vs no)  
• Investigator choice of chemotherapy (platinum with fluoropyrimidine vs platinum with 
paclitaxel)  
After randomization, patients will begin double -blind treatment with one of the following regimens.  
• Arm A :   
o Tislelizumab + chemotherapy doublet  
o The chemotherapy doublet will consist of:  
▪ Platinum (cisplatin or oxaliplatin) and a fluoropyrimidine (capecitabine or 
5-fluorouracil [5 -FU])  
OR 
▪ Platinum (cisplatin or oxaliplatin) and paclitaxel  
• Arm B :   
o Placebo + chemotherapy doublet  
o The chemotherapy doublet will consist of:  
▪ Platinum (cisplatin or oxaliplatin) and a fluoropyrimidine (capecitabine or 
5-FU) 
OR 
▪ Platinum (cisplatin or oxaliplatin) and paclitaxel  
The platinum agent may be cisplatin or oxaliplatin (excep t in China, Taiwan, Japan, and countries 
where oxaliplatin substitution is not permitted) according to site or investigator preference or standard 
Approved Date 3/13/[ADDRESS_500429] practice. If platinum treatment is stopped, the non -platinum agent 
(fluoropyrimidine or paclitaxel) may continue at the regular schedule.  
The study design schema is as follows:  
 
Abbreviations: BIRC , blinded independent review committee; chemo, chemotherapy; DCR, disease control rate; 
DOR, duration of response; ESCC, esophageal squamous cell carcinoma; HRQoL, health -related quality of life; 
ICC, investigator choice of chemotherapy; ORR, objective res ponse rate; OS, overall survival; PD -L1, 
programmed cell death protein ligand -1; PFS, progression -free survival; PFS2, PFS after next line of treatment; 
vCPS, visually estimated combined positive score.  
Study Assessments:  
Response to treatment will be ass essed by [CONTACT_397742]. Tumor imaging (computed 
tomography [CT] with or without contrast or magnetic resonance imaging [MRI]) must be performed 
within 28 days prior to randomization. On -treatment tumor assessments will occur every 6 weeks 
(± 7 days) for the first 48  weeks, then every 9 weeks (± 7 days) based on RECIST v1.1,  regardless of 
treatment delays, until disease progression. Patients who discontinue study treatment early for reasons 
other than documented radiographic disease progression ( eg, toxicity) will continue to undergo tumor 
assessments following the original plan until the patient experiences disease progression, withdraws 
consent, is lost to follow -up, or dies, or until the study completes, whichever occurs first. Investigators 
Study Population:  
unresectable, locally 
advanced recurrent or 
metastatic ESCC  
Arm A  
Tislelizumab in 
combination with 
chemotherapy  
Screening  
 
•Treatment until disease 
progression, intolerable 
toxicity, or withdrawal for 
other reasons  
•Safety Follow -up & Survival 
Follow -up 
----------------------------------  
Primary endpoint :  
•OS 
Secondary endpoints : 
•PFS, ORR, and DOR 
assessed by [CONTACT_1697]  
•OS in the PD-L1 vCPS ≥ 
10% subgroup  
•HRQoL  
•Adverse events  
Exploratory endpoints : 
•DCR  
•PFS, ORR, DOR, and DCR 
assessed by [CONTACT_14988]  
•PFS2  
•Correlation of biomarker 
results to response and/or 
resistance to treatment   
•Pharmacokinetics  
•Assessment of 
immunogenicity  
Arm B  
Placebo in combination 
with chemotherapy  
Randomization & 
Stratification:  
n=622 eligible patients  
•1:1 randomization to 
tislelizumab+chemo 
or placebo+chemo  
Stratification  
•Geographic region 
(Asia [excluding 
Japan] vs Japan vs 
Rest of World ) 
•Prior definitive 
therapy (yes vs no)  
•ICC (platinum/  
fluoropyrimidine vs 
platinum/paclitaxel)  
Approved Date 3/13/[ADDRESS_500430] in the treatment of cancer.  
HRQoL will be measured via 3 validated patient -reported outcomes (PROs) instruments: the QLQ -
C30, OES18, and the EQ -5D-5L at baseline, after randomization, prior to dosing or any clinical 
activities at every treatment cycle for the first 6  cycles, then eve ry other cycle afterwards, and at the 
End-of-Treatment (EOT) Visit.  
All AEs will be reported during the study (AEs from the time of the first dose and serious adverse 
events (SAEs) from the time of signing of informed consent) and for up to [ADDRESS_500431] dose of 
study drug(s) (including chemotherapy) or until initiation of another anticancer therapy, whichever 
occurs first. Immune -mediated  AEs (serious or non -serious) should be reported up to [ADDRESS_500432] dose of tislelizumab, regardless of whether the patient starts a new anticancer therapy. The 
investigator should report any SAEs that are assessed as related to tislelizumab treatment, at any time 
after treatment discontinuation. AEs will be graded according to NCI CTCAE v4.03.  
Safety and  efficacy monitoring will be performed by [CONTACT_223233] 
(IDMC). The IDMC may recommend modifications to the study, including termination due to safety 
and/or efficacy concerns. The functions and membership of the IDMC will be des cribed in an IDMC 
Charter.  
The IDMC convened on 20 April 2022 to review the efficacy and safety data of the preplanned interim 
analysis (data cutoff date of 28 February 2022, with 422 death events which corresponds to 86.5% of 
the number of total planned d eath events for the final analysis [488  OS events ]). After reviewing the 
data, the IDMC confirmed that the study met the specified 1 -sided p -value boundary for superiority of 
the primary endpoint and recommended to unblind/unmask the study due to compellin g efficacy. Based 
on the IDMC recommendation, a decision was made to unblind all patients, and inform all investigators 
and IRB/IEC as required. Patients randomized to Arm B were to discontinue placebo after unblinding.  
Duration of Patient Participation:  
Duration of study participation will vary by [CONTACT_4676], depending on the duration of treatment and 
treatment outcomes. Each patient treatment course will include:  
• Screening up to 28 days  
• Treatment until disease progression (or other reason for  discontinuation before progression)  
o In select cases, patients may continue treatment beyond disease progression. See 
Section  3.6.[ADDRESS_500433] practice. If platinum treatment is stopped, the non -platinum agent 
(fluoropyrimidine or paclitaxel) may conti nue at the regular schedule, if appropriate.  
• End of Treatment (EOT)/Safety Follow -up Visit up to [ADDRESS_500434] dose  
• Survival Follow -up Visits every 3 months until death (or other reason before death)  
Study Population: Patients with unresectable, locally advanced recurrent or metastatic ESCC who 
have Stage IV unresectable ESCC at first diagnosis (ie, Stage IV disease at the original diagnosis of 
ESCC) or who have unresectable, locally advanced recurrent or metastatic disease with at l east a 
6-month treatment -free interval, if prior definitive therapy (chemotherapy, chemo -radiation therapy or 
surgery) was given. Appendix  13 conta ins a flow chart to help determine which patients are appropriate 
for this study.  
Prior to opening full enrollment in Japan, close monitoring measures will be taken to observe the safety 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 19 and tolerability of the combination of tislelizumab with cisplatin an d 5-FU in ESCC in Japanese 
patients as described in Section  3.8. 
Key Eligibility Criteria:  
The following are key disease -specific criteria. For the complete list of eligibility criteria for this study, 
please refer to Section  4. 
• Key inclusion criteria  
o Pathologically (histological ly) confirmed diagnosis of ESCC  
o Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced 
recurrent or metastatic disease (per AJCC 7th Edition,  Appendix  14), if there is prior 
neoadjuvant/adjuvant therapy with platinum -based chemotherapy , a treatment -free 
interval of at least 6 months is required  
• Key exclusion criteria  
o Palliative radiation treatment for ESCC within 4 weeks of study treatment initiation  
o Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC   
o Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent 
drainage or medical intervention (clinically significant  recurrence requiring an 
additional intervention within 2 weeks of intervention)  
o Evidence of complete esophageal obstruction not amenable to treatment  
o Received prior therapi[INVESTIGATOR_107900] -1, PD -L1 or PD -L2 
o Unintentional weight loss ≥ 5% within 1 month pri or to randomization or Nutritional 
Risk Index  (NRI) < 83.5 ( Appendix  15) per investigator’s choice  
Investigational Product, Dose, and Mode of Administration:   
Tislelizumab will be administered at a dose of 200 mg intravenously (IV) on Day 1 of every 21 -day 
cycle. Tislelizumab will be given in combination with 1 of the 3 chemotherapy doublets listed bel ow. 
The platinum agent may be cisplatin or oxaliplatin (except in China, Taiwan, Japan, and countries 
where oxaliplatin substitution is not permitted) according to site and investigator preference or standard 
practice as determined prior to randomization.  
o Platinum (cisplatin or oxaliplatin) + 5 -FU:  
o Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W  
o 5-FU 750 to 800 mg/m2 IV continuous infusion over 24 hours daily on Days 1 to 5 Q3W  
o Platinum (cisplatin or oxaliplatin) + capecitabine:  
o Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W  
o Capecitabine 1000 mg/m2 orally (PO) twice daily (BID) on Days 1 to 14 Q3W  
o Platinum (cisplatin or oxaliplatin) + paclitaxel:  
o Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 or 2 Q3W  
▪ Depending on local guidelines, cisplatin may be given in [ADDRESS_500435] be between 60 t o 80 mg/m2 per cycle.  
o Paclitaxel 175 mg/m2 IV on Day 1 Q3W  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 20 Reference Therapy, Dose, and Mode of Administration:   
Matched placebo will be administered on Day 1 of every 21 -day cycle. Matched placebo will be given 
in combination with 1 of the 3 chemotherapy doublets listed below. The platinum agent may be 
cisplatin or oxaliplatin (except in China, Taiwan, Japan, and co untries where oxaliplatin substitution is 
not permitted), according to site or investigator preference or standard practice as determined prior to 
randomization.  
o Platinum (cisplatin or oxaliplatin) + 5 -FU:  
o Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W  
o 5-FU 750 to 800 mg/m2 IV continuous infusion over 24 hours daily on Days 1 to 5 Q3W  
o Platinum (cisplatin or oxaliplatin) + capecitabine:  
o Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W  
o Capecitabine 1000 mg/m2 orally BID on  Days 1 to 14 Q3W  
o Platinum (cisplatin or oxaliplatin) + paclitaxel:  
o Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 or 2 Q3W  
▪ Depending on local guidelines, cisplatin may be given in [ADDRESS_500436] be between 60 to 80 mg/m2 per cycle.  
o Paclitaxel 175 mg/m2 IV on Day 1 Q3W  
Statistical Methods  
The primary endpoint of OS in the Intention -to-Treat (ITT) analysis set will be tested at a one -sided 
alpha of 0.025.  By [CONTACT_397743] ( 2009 ), if the null hypothesis for OS in the 
ITT analysis set is rejected, the corresponding alpha will be shifted to the hypothesis tests of the 
secondary endpoints PFS by [CONTACT_397744], ORR by [CONTACT_397745], OS in the PD -L1 vCPS ≥  10% subgroup, and HRQoL in the ITT analysis set, which will 
be tested sequentially. The inferential test will be stopped at the first non -significant endpoint.  
Analysis Sets:  
• The ITT analysis set includes all randomized patients. It will be the primary analysis 
population for the efficacy analysis  
• The Safety analysis set includes all patients who received at least 1 dose of study treatment. It 
will be the primary analysis population for safety analysis  
• The Pharmacokinetics (PK) analysis set includes all patients who are receive at least [ADDRESS_500437]  dose PK data are available  
• The ADA analysis set includes all patients who have a baseline and at least [ADDRESS_500438] -baseline 
ADA result  
Primary Efficacy Endpoint Analysis:  
OS in the ITT analysis set : 
The null hypothesis to be tested is:  
H0:  OS in Arm A  ≤ OS in Arm B  
Approved Date 3/13/[ADDRESS_500439] the alternative:  
H1:  OS in Arm A > OS in Arm B  
The primary analysis of OS will be carried out when approximately [ADDRESS_500440] using 
stratification factors of pooled geographic region ( Asia [including Japan] vs Rest of World ), prior 
definitive therapy (yes vs no), and the investigator’s choice of chemotherapy (ICC) option (platinum 
with fluoropyrimidine vs platinum with paclitaxel). A  one-sided significance level of 0.025 will be 
used for the OS testing.  
The median OS and the cumulati ve probability of OS at every 3 months including 9 -month OS and 
18-month OS, if estimable, will be calculated for each treatment arm and presented with 2 -sided 
95% confidence intervals (CIs). Kaplan -Meier survival probabilities for each arm will be plotted  over 
time. OS rate at [ADDRESS_500441] will be estimated by [CONTACT_6486] a Cox regression  model to the OS times including 
treatment arm as a cov ariate and region of enrollment and prior definitive therapy as strata.  From this 
model, the HR of OS  will be estimated and presented with a 2 -sided 95% CI.  
Primary Analyses of OS  
There will be 1 interim analysis of OS utilizing the O’Bri en-Fleming boundar y approximated by  
[CONTACT_397746] -Shih-DeCani spending function with the gamma parameter set at -4. The interim analysis will 
be performed at the time when approximately 423 death events (87 % of the target number of OS 
events) among the [ADDRESS_500442] been observed. Stoppi[INVESTIGATOR_397665] p-value and Z score for primary analyses of OS are shown in the table below. The 
boundaries will be updated according to the actual numbers of events in the interim and final analyses, 
and the revised alpha level due to alpha shifting as described above, u sing the above pre -specified 
alpha spending function.  
Stoppi[INVESTIGATOR_274353] (in p -value and Z score) of Primary Analysis of  
Overall Survival  
Endpoint  Analysis  Analysis  
Time 
(month)  # Events  p-value1 (Z score) for 
Efficacy  Approximate HR 
Threshold  
OS Interim 
analysis  33 423 < 0.0145 (>  2.18)  0.809  
Final 
analysis  40 488 < 0.0216 (>  2.02) 0.833  
Abbreviations: HR = hazard ratio; OS  = overall survival  
1one-sided  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 22 Secondary Efficacy Endpoint Analyses:  
Progression Free Survival (PFS)  
There will be one analysis of PFS in the ITT analysis set, which will be carried out after superiority of 
OS in the ITT analysis set has been demonstrated. Similar statistical analysis methods used for OS 
testing will be applied to PFS analysis.  
The p -value from one -sided, stratified log -rank test will be presented using the stratification factors of 
pooled geographic regions (Asia [including Japan] vs Rest of World), prior definitive therapy (yes vs 
no), and ICC option.  
PFS assessed by [CONTACT_397747] -Meier method in the ITT analysis 
set. The PFS censoring rule will follow [LOCATION_002] (US) Food and Drug Administration (FDA) 
Guidance for Industry, Clinical Trial Endpoints for Approval of Cancer drugs and Biologics (FDA 
2018 ). Data for patients without disease progression or death at the time of analysis will be censored at 
the time of the last tumor assessment. Data for patients who are lost to follow -up prior to documented 
disease pro gression will be censored at the last tumor assessment date when the patient is known to be 
free of disease progression. Data for patients who start to receive new anti -cancer therapy will be 
censored at the last tumor assessment date prior to the introduc tion of a new therapy.  
The median PFS and the cumulative probability of PFS at every 3 months, including 6 -month PFS, if 
estimable, will be calculated for each treatment arm and presented with 2 -sided 95% CIs. Kaplan -Meier 
estimates of PFS for each arm wi ll be plotted over time. The PFS rate at 6  months based on the Kaplan -
Meier estimate will be compared between the 2 treatment arms for landmark analysis.  
HR estimated from a Cox regression model will be presented with its 95% CI.  
OS in the vCPS ≥ 10% subgr oup: 
This analysis for the PD -L1 vCPS ≥ 10% subgroup is similar as the OS analysis in the ITT analysis set.  
Other secondary efficacy endpoints  
ORR per RECIST v1.1 by [CONTACT_397748] a Cochran -Mantel -
Haenszel (CMH ) test, adjusting for stratification factors of pooled geographic region, prior definitive 
therapy, and ICC options. Patients with no post -baseline response assessment (for any reason) will be 
considered non -responders. The 2 -sided 95% CIs for the odds rat io in ORR will be calculated along 
with Clopper -Pearson 95% CIs of ORR for each treatment arm.  
DOR assessed by [CONTACT_397749]. Median DOR per arm, if estimable, will be presented.  
HRQoL will be analyzed and compared between the treatment arms via the post -baseline scores of 
QLQ -C30’s Global Health Status/QoL (GHS), functional scales and symptom scores and symptoms 
single item scores, QLQ -OES18’s index score and symptoms scales and s ingle item scores, and EQ -
5D-5L descriptive scale scores as well as the visual analogue scale (VAS) scores. Observed values and 
changes from baseline will be summarized using descriptive statistics. A mixed -effect model analysis 
for measuring clinically me aningful changes post -baseline  will be performed  using the patient -reported 
outcome endpoints of GHS, physical function, and fatigue domains of QLQ -C30 and dysphagia, reflux, 
pain and eating of QLQ -OES18.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 23 Time to clinically meaningful deterioration in the  aforementioned scales will be estimated using the 
Kaplan -Meier method  and Cox regression model. Deterioration thresholds will be defined based on the 
published 10 -point EORTC threshold , and  a secondary deterioration threshold based on data may be 
explored . 
Exploratory Efficacy Analyses:  
BOR is defined as the best response per RECIST v1.1 by [CONTACT_397750], progressive disease (PD) or start of new anti -cancer treatment. The proportion and its 
corresponding Clopper -Pearson 95% CI for each of the response categories (CR, PR, SD, and PD) will 
be presented by [CONTACT_2939].  
DCR will be analyzed similarly as ORR in the ITT analysis set.  
To calculate PFS2, data from patients without disease progressi on after next line of treatment or death 
at the time of analysis will be censored at the last time known to be alive. Kaplan -Meier method as 
described in the PFS and OS analyses will be used in the analysis of PFS2.  
In addition, PFS, ORR, DOR, and DCR asse ssed by [CONTACT_397751] v1.1 are summarized 
similarly the data assessed by [CONTACT_397752].  
Exploratory biomarkers may also be assessed.  
Safety Analyses:  
Safety will be assessed by [CONTACT_397753] -CTCAE v4.03. 
Laboratory values (eg, hematology, clinical chemistry, coagulation, and urinalysis), dosing, vital signs, 
ECGs, and physician examinations will also be evaluated in defining the safety profile of each 
treatment arm. Descriptive s tatistics will be used to analyze all safety data in the Safety analysis set.  
Extent of exposure to each study drug will be summarized descriptively as the number of doses 
received (number and percentage of patients), duration of exposure (days), cumulativ e total dose 
received per patient (mg), dose intensity, and relative dose intensity.  
Verbatim description of AEs will be mapped to the Medical Dictionary for Regulatory Activities 
(MedDRA®) terms and graded per NCI CTCAE v4.0 3. All treatment -emergent AEs (TEAEs) will be 
summarized. A TEAE is defined as an AE that had an onset date or a worsening in severity from 
baseline (pre -treatment) on or after the first dose of study drug up to [ADDRESS_500443] laboratory 
data will be summarized by [CONTACT_479]. Changes in vital signs will also be summarized by [CONTACT_765].  
Sample Size Considerations:  
The initial sample size calculation was based on the primary ef ficacy analysis of PFS and OS in the 
comparison between tislelizumab in combination with chemotherapy arm and placebo plus 
chemotherapy arm in the ITT analysis set. Hazard ratios in PFS and OS were assumed as 0.65 and 
0.73, respectively, with median PFS of  5 months and OS of 9 months in the comparator arm. A total of 
480 patients would be enrolled in a 1:1 randomization over a 17 -month period at enrollment rates of 10 
patients/month in the first month, 20 patients/month in the second month and 30 patients/m onth in the 
Approved Date 3/13/[ADDRESS_500444] a 
power of 90% with an alpha of 0.005. A group sequential testing of OS would be performed. The 
interim analysis was planned after approximately 67%  of the total planned death events had occurred 
(241). The final analysis of OS would be performed when approximately [ADDRESS_500445] been 
observed. The sample size calculation of OS was based on overall power of 82% and an alpha level of 
0.02.  
The p revious version of protocol amendment 3.[ADDRESS_500446] and in creased usage of subsequent 
immunotherapi[INVESTIGATOR_397666] -oncology trials in the second -line 
ESCC ( Kojima et al 2019 ; Kato et al 2019 ; Huang et al 2019 ).  
By 24 November 2020, enrollment was completed with 649 randomized patients. In the current 
protocol amendment, BIRC -assessed PFS has been removed from the primary efficacy analysis based 
on the results from  KEYNOTE -590 ( Kato et al 2020 ) in the first-line treatment of ESCC. OS is the sole 
primary efficacy endpoint. The HR for OS is assumed to be 0.74 at the time of final analysis after an 
initial 1 -month delayed treatment effec t (eg, assuming HR  = [ADDRESS_500447] month), the number of deaths 
required in the final analysis will be approximately 488 with 90% power by [CONTACT_167889]. The planned 
interim analysis with a power of 81% will occur after [ADDRESS_500448] been observed. A 5% an nual 
dropout rate is assumed and one -sided alpha of 0.025 is used in the sample size calculation.  
Approved Date 3/13/[ADDRESS_500449]  aspartate aminotransferase  
BGB -A317  humanized monoclonal antibody directed at PD -1; tislelizumab  
BID twice daily  
BIRC  blinded independent review committee  
BSA  body surface area  
CI confidence interval  
CKD -EPI [INVESTIGATOR_397667] -Mantel -Haenszel  
CR complete response  
CT computed tomography  
DCR  disease control rate  
DOR  duration of response  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture (system)  
EORTC QLQ -C30 European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire -Core 30  
EORTC QLQ -OES18  European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire -Oesophagus Cancer Module  
EOT  end of treatment  
EQ-5D-5L European Quality of Life 5 -Dimension 5-Level  
ESCC  esophageal squamous cell carcinoma  
ESMO  European Society for Medical Oncology  
FDA  Food and Drug Administration  
FDG -PET fluorodeoxyglucose -positron emission tomography  
GC gastric carcinoma  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HBcAb  hepatitis B core antibody  
Approved Date 3/13/[ADDRESS_500450]  
IRT Interactive Response Technology  
ITT Intent -to-Treat  
IV intravenous(ly)  
MedDRA  Medical Dictionary for Regulatory Activities  
MMF  mycophenolate mofetil  
MRI  magnetic resonance imaging  
NCCN  National Comprehensive Cancer Network  
NCI-CTCAE  National Cancer Institute Common Terminology Criteria for Adverse 
Events  
OCT  optical coherence tomography  
ORR  objective response rate  
OS overall survival  
PD progressive disease  
PD-1 programmed cell death protein -1 
PD-L1 programmed cell death protein ligand -1 
PD-L2 programmed cell death protein ligand -2 
PET positron emission tomography  
PFS progression -free survival  
PFS2  PFS after next line of treatment  
PK pharmacokinetic(s)  
PR partial response  
Q2W  once every 2 weeks  
Q3W  once every 3 weeks  
Q4W  once every 4 weeks  
Approved Date 3/13/[ADDRESS_500451]  upper limit of normal  
US [LOCATION_002]  
vCPS  visually  estimated combined positive score  
Approved Date 3/13/[ADDRESS_500452] common 
cause of death from cancer ( Ferlay et al 2012 ). The incidence, prevalence, and histologic type of 
esophageal cancer varies between geographic regions, parti cularly between Western countries 
([LOCATION_002] [US] and Europe) and an area commonly referred to as the “esophageal cancer 
belt,” which is a geographic area stretching across Central -Eastern Asia from the Caspi[INVESTIGATOR_397668] ( Arnold et al 2015 ). To illustrate, an estimated 16,940 people in the US will be 
diagnosed with esophageal cancer and 15,690 people will eventually die of their disease in 2017 
(Siegel et al 2017 ). The predominant histologic type of these new diagnoses in the US will be 
adenocarcinoma. The 5 -year survival rates are 18.4% in the [LOCATION_002] ( Siegel et al 2017 ) and 
12% in Europe ( De Angelis et al 2014 ). In contrast, in China, an estimated 477,900 people will be 
diagnosed with esophageal cancer, 90% of which will be of the squamous cell carcinoma 
histology, and 375,000  people will die of this disease ( Chen et al 2016 ; Arnold et al 2015 ). The 
age-standardized 5 -year relative survival rate for patients in China diagnosed in 2003 to 2005 is 
20.9% ( Li et al 2017 ).  
Recognized risk factors for developi[INVESTIGATOR_397669], low intake of fruits and vegetables, drinking alcohol, 
smoking tobacco, chewing betel quid, and drinking liquids, such as ma te, at high temperatures, 
obesity, and chronic gastroesophageal reflux disease. Esophageal cancer of either histology is 
much more prevalent in men and more common in an older patient population ( Shah 2015 ).  
Advanced esophageal cancer is a rapi[INVESTIGATOR_110623]. More than two -thirds of patients diagnosed 
with esophageal cancer will have advanced or metastatic disease, with a median survival of 8 to 
10 months and an expected 5 -year survival rate < 5% ( Lin et al 2016 ; Drahos et al 2013 ). These 
data, combined with the relative lack of highly effective treatment, are indicative of the large 
unmet medical need in patients diagnosed with esophageal cance r. 
1.2. Current Treatment of Esophageal Carcinoma and Unmet Clinical 
Needs   
Esophageal cancer treatment is based on the extent of disease at presentation and tumor histology. 
Internati onal treatment guidelines are consistent in the approach to the treatment of this disease. 
Therapeutic treatment modalities include endoscopic resection for focal disease or esophagectomy 
with lymph node resection for larger tumors in patients who are cons idered medically fit ( Lordick 
et al 2016 ; NCCN Guidelines Version 1, 2017 ; Japanese Gastric Cancer Association 2017 ; Stahl 
et al 2009 ). Chemoradiation therapy may be given to those with larger tumors in the neo -adjuvant, 
peri adjuvant or in the adjuvant setting. Post -operative chemotherapy or chemoradiation is 
commonly given to patients who have positive  lymph nodes after R0 resection, or those with 
microscopic or macroscopic residual cancer (R1 and R2 resection, respectively) after surgery. 
Systemic regimens given in the pre -operative or peri -operative setting commonly include 
chemotherapy doublets which  include taxanes, platinum agents, fluorouracil, or irinotecan. Triplet 
combinations may also be considered, such as epi[INVESTIGATOR_14962], oxaliplatin and 
fluorouracil/capecitabine, but are more toxic and restricted to those patients with good 
performance status. In  the pre -operative or peri -operative setting, the choice of chemotherapy 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 29 regimen is made independent of the tumor histology ( Lordick et al 2016 ; NCCN Guidelines 
Version 1, 2017 ; Japanese Gastric Cancer Association 2017 ; Stahl et al 2009 ).  
The choice of systemic chemotherapy agents for patients who are not surgical candidates or those 
who have recurrent or metastatic disease that cannot be adequately treated with local therapy are 
like those described above, and are similar to treatments given to patients with advanced gastric 
cancer  (Lordick et al 2016 ). The choice of agents or regimen may be based on the patient’s 
performance status, and underlying comorbidities. Fluoropyrimidines (either 5 -Fluorouracil [5 -
FU] or capecitabine) as monotherapy or in  combination with either cisplatin or oxaliplatin, 
taxanes (either paclitaxel or docetaxel) given as monotherapy or with platinum agents, or 
irinotecan in combination with [ADDRESS_500453] -line ch emotherapy for advanced or metastatic disease ranges 
from 20% to 48% and 5 -year survival rates of lower than 30% with significant toxicity rates 
(Grunberger et al 2007 ). There is no global consensus on the optimal first -line treatment; but 
combination chemotherapy combination therapy is typi[INVESTIGATOR_397670] . Treatment regimens 
commonly include a platinum agent (cisplatin or oxaliplatin) in combination with paclitaxel or 5 -
FU (NCCN Guid elines Version 1, 2017 ). There are regional preferences for the chemotherapy of 
choice and may be based on the toxicity profile of each agent. The following table ( Table 1) 
summarizes the efficacy outcomes between the chemotherapy regimens allowed in this protocol. 
It should be noted that one publication summarizes data from retrospective analysis ( Liu et al 
2016 ). Given these caveats, the ORRs and median survival durations appear comparable amongst 
the various regimens.  
Approved Date 3/13/[ADDRESS_500454] -Line Treatment and Outcomes for Esophageal Squamous Cell Carcinoma  
Reference  Sample Size 
by [CONTACT_397754] 
(n) Treatment 
setting  Regimen  ORR 
(%) PFS 
(median 
months  OS 
(median 
months)  
Cisplatin + 5 -fluorouracil  
Bleiberg,  
1997  ESCC (44)  1st line  Cisplatin 100 mg/m2 IV Day 1 Q3W  
5-FU 1000 mg/m2 IV infusion over 24h 
Days 1 -5 Q3W  35 6.8 8.3 
Hayashi,  
2001  ESCC (36) 85% 1st line  Cisplatin 20 mg/m2 IV Day 1 -5 Q4W  
5-FU 800 mg/m2 IV infusion over 24h 
Days 1 -5 Q4W  33.3 N/A 7.2 
Lorenzen,  
2009  ESCC (30)  1st line  Cisplatin 75 -100 mg/m2 IV Day 1 Q4W  
5-FU 250 -1000 mg/m2 IV infusion over 
24h Days 1 -4 Q4W  13 3.6 5.5 
Liu, 
2016  ESCC (203)  1st line  Cisplatin 75 mg/m2 IV Day 1 Q3W  
5-FU 750 mg/m2 IV over 24h Days 1 -5 
Q3W  38.4 6.5 12.7 
Wang,  
2017  ESCC (48)  85% 1st line  Cisplatin 15 mg/m2 IV Day 1 -5 Q3W  
5-FU 750 mg/m2 IV infusion over 24h 
Days 1 -5 Q3W  46.8 4.9 8.9 
Cisplatin + capecitabine  
Lee, 
2008  ESCC (45)  1st line  Cisplatin 60 mg/m2 IV Day 1 Q3W  
Capecitabine 1250 mg/m2 BID PO Day   
1-14 Q3W  57.8 4.7 11.2 
Lee, 
2015  ESCC (46)  1st line  Cisplatin 75 mg/m2 IV Day 1 Q3W  
Capecitabine 1000 mg/m2 BID PO Day   
1-14 Q3W  57 5.1 10.5 
Cisplatin + paclitaxel  
Petrasch,  
1998  ESCC (18)     
EAC (6)  1st line  Cisplatin 50 mg/m2 IV Day 1 Q2W  
Paclitaxel 90 mg/m2 IV Day 1 Q2W  40 N/A 7.0 
Cho,  
2005  ESCC (32)  31% 1st line  Cisplatin 50 mg/m2 IV Day 1 Q2W  
Paclitaxel 90 mg/m2 IV Day 1 Q2W  41 5.0 7.0 
Huang,  
2013  ESCC (46)  1st line  Cisplatin 50 mg/m2 IV Day 2 Q2W  
Paclitaxel 150 mg/m2 IV Day 1 Q2W  56.5 5.6 17.0 
Liu, 
2016  ESCC (195)  1st line  Cisplatin 75 mg/m2 IV Day 1 Q3W  
Paclitaxel 175 mg/m2 IV Day 1 Q3W  42.5 7.9 13.5 
Abbreviations: 5 -FU, 5 -fluorouracil; BID, twice daily; EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell 
carcinoma; IV, intravenous; N/A, not applicable ; ORR, overall response rate; OS, overall survival; PFS, progression -free survival; 
PO, orally; Q2W, once every 2 weeks; Q3W, once every 3 weeks; Q4W, once every [ADDRESS_500455] been  enrolled to an 
ongoing Phase 1 clinical study. The median age of these enrolled patients is 62 years (range: 30 to 
80 years), 36 patients are men and 28 patients are of the white race. Prior to study enrollment, 
these patients had received a median of 2 ( range: 0 to 7) prior treatment regimens for their 
Approved Date 3/13/[ADDRESS_500456] 3 prior treatments. The duration of follow -
up in this study was 3.4 months (range: 0.2 to 10.6 months).  
Tislelizumab was administered for a median of 2 months (range: 0.2 to 10.6 months) in this 
patient cohort. All but 1 patient received tislelizumab at a dose of 5 mg/kg; 1 patient was treated at 
the 2  mg/kg dose.  
The majority (n  = 46) of patients experienced at least 1 treatment -emergent adverse event  
(TEAE). Twenty -three patients experienced a treatment -related adverse event (AE). The most 
common AEs reported in at least 3 patients in the esophageal cohort of any grade or causality 
included nausea, constipation, dysphagia, abdominal pain (including up per abdominal pain), 
diarrhea, vomiting, pneumonia, upper respi[INVESTIGATOR_1092], cough, dyspnea, pleural effusion, 
decreased appetite, hypercalcemia, fatigue, pyrexia, peripheral edema, back pain, arthralgia, 
myalgia, weight decrease, alkaline phosph atase increase, pruritus, headache, hypothyroidism, 
insomnia, proteinuria, infusion related reaction, and anemia. Of these events, nausea, fatigue, 
hypothyroidism, infusion related reaction, decreased appetite, and myalgia were reported as 
related to tisle lizumab in more than 2  patients. Twenty -two patients experienced an AE that was 
reported as National Cancer Institute Common Terminology Criteria for Adverse Events (NCI -
CTCAE) Grade 3 or higher; none of these events occurred in more than 3 patients.  
Serious adverse events (SAEs) were reported in 25 patients. The only SAE that occurred in more 
than 2 patients was pneumonia in 4 patients.  
Six patients who received tislelizumab at the 5 mg/kg dose died of causes reported as AEs: 
mediastinitis, sepsis, esoph ageal hemorrhage, pleural effusion, tumor hemorrhage, and 
hemoptysis. These events are recognized complications of esophageal carcinoma; none were 
considered related to study treatment.  
Radiographic anti -tumor activity results were available for 42 of the 49 enrolled patients. Of these 
patients, 6 experienced a partial response (PR). Three of these patients had squamous cell 
carcinoma and 3 had adenocarcinoma. Three of these responses were confirmed, and the 
remaining PRs were not confirmed per Response Eva luation Criteria in Solid Tumors (RECIST) 
v1.[ADDRESS_500457] response of stable disease (SD). 
There were no complete responses (CR) reported.  
At the time of the data cutoff, 12 patients were still receiving tisl elizumab treatment.  
Nivolumab  
Efficacy results in esophageal squamous cell carcinoma (ESCC) patients treated with nivolumab, 
an anti -programmed cell death protein -1 (PD -1) monoclonal antibody, were reported from an 
open -label, single -arm, multi -center Pha se 2 study ( Kudo et al 2017 ). This study enrolled 65 
patients with squamous cell esophageal carcinoma even though the study was designed to recruit 
patients with squamous, adenocarcinoma, or adeno -squamous cell histologies. T hese patients were 
considered refractory or intolerant to fluoropyrimidine, platinum, and taxane -based 
chemotherapi[INVESTIGATOR_014]. Patients were treated with nivolumab 3 mg/kg given IV once every 2 weeks 
(Q2W). Tumor response was assessed every 6 weeks. Median follow -up was 10.8 months 
(interquartile range: 4.9 to 14.3 months) and patients received a median of 3 nivolumab cycles 
(range: 1 to 10 cycles). The ORR by [CONTACT_397755] 17% (95% confidence 
interval [CI]: 10 to 28%) and 22% (95% CI: 14 to 33%)  by [CONTACT_3138]. The disease 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 32 control rate (DCR), defined as the number of patients with a CR or PR, and those with SD of any 
duration was 42% (95% CI: 31 to 54%) by [CONTACT_397756] 53% (95% CI: 41 to 65%) 
patients by [CONTACT_397757]. The median duration of OS was 10.8 months (95% CI:7.4 to 
13.9 months). The 2 -year OS was 17.2%. The median durations of progression -free survival (PFS) 
were 1.5 months (95% CI: 1.4 to 2.8  months) and 2.3  months (95% CI: 1.5 to 3.0 months), by 
[CONTACT_397758], respectively.  
Pembrolizumab  
KEYNOTE -028 ([STUDY_ID_REMOVED]), a multicohort, Phase 1b trial recruited advanced ESCC and 
adenocarcinoma patients with disease progression (PD) following standard therapy. Patients 
received pembrolizuma b 10 mg/kg Q2W. Response was assessed every [ADDRESS_500458] v1.1 by 
[CONTACT_107443]. In this cohort of 23 patients, 87% received ≥ 2 prior therapi[INVESTIGATOR_397671] e and 78% of 17 patients had ESCC. After a median follow -up of 7 months (range: 1 to 
33 months), ORR was 30% (95% CI: 13 to 53%). Median PFS was 1.8 months and median OS 
was 7  months. The median duration of response (DOR) was 15 months (range: 6 to 26 mont hs) 
(Doi et al 2017 ). 
KEYNOTE -590 ([STUDY_ID_REMOVED]) is a multicenter, randomized, double -blind, placebo -controlled 
Phase 3 study that enrolled 749 patients with metastatic or locally advanced esophageal or 
esophagogastric junction (GEJ) carcinoma who were not candidates for surgical resection or 
definitive chemoradiation. Patients were randomized (1:1) to receive either pembrolizuma b 
(200 mg on Day 1 every three weeks  [Q3W] ) or placebo (on Day 1 Q3W ) in combination with 
cisplatin (80 mg/m2 on Day 1 Q3W  for ≤ 6 cycles) plus 5-FU (800 mg/m2 per day on Days  [ADDRESS_500459] for 5-FU administration, for ≤ 35 cycles ). Treatment with 
pembrolizumab  or chemotherapy continued until unacceptable toxicity , disease progression , 
withdrawal, or 2 years . The major efficacy outcome measures were OS and PFS (assessed by [CONTACT_1275]). The pr e-specified analyses of OS and PFS were performed in the following 
subgroups : patients with ESCC, patients with ESCC with PD -L1-positive tumors with  combined 
positive score (CPS)  ≥ 10, and all patients . Additional efficacy outcome measures were ORR and 
DOR  assessed by [CONTACT_093].  Both patients with squamous (ESCC, 73%) and 
adenocarcinoma (27%) histologies were accrued. After a median follow -up of 10.8 months, t he 
interim analysis of KEYNOTE -590 demonstrated that pembrolizumab combined with 
chemothe rapy showed statistically significant and clinical meaningful improvement in OS 
compared with chemotherapy alone  in the all-patient population (HR 0.73, median OS 12.4 
months [pembro+chemo] versus 9.8 months  [chemo] , p < 0.0001 ), ESCC subgroup (HR 0.72, 
median OS 12.6 months [pembro+chemo] versus 9.8 months  [chemo] , p = 0.000 6), and ESCC 
PD-L1 CPS ≥ 10 subgroup (HR 0. 57, median OS 13.9 months [pembro+chemo]  versus 8.8 
months  [chemo] , p < 0.0001 ). A superior  PFS in both the all-patient population (HR 0. 65, median 
PFS 6.3 months [pembro+chemo]  versus 5.8 months  [chemo] , p < 0.0001 ) and the ESCC 
subgroup (HR 0. 65, median PFS 6.3 months [pembro+chemo]  versus 5.8 months  [chemo] , 
p < 0.0001 ) was also observed  in the pembrolizumab combined with chemotherapy group . ORR 
was 45% (95% CI: 39.9 % to 50.2%) versus 29.3%  (95% CI: 24.7% to 34.1%) and DOR was 8.3 
months (range: 1.2+ to 31.0+ months) versus 6.0  months (range: 1.5+ to 25.0+  months)  for 
pembrolizumab combined with chemotherapy and chemotherapy alone  groups , respectively  (Kato 
et al 2020 ). 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 33 1.4. Background Information on Tislelizumab   
1.4.1.  Pharmacology   
Tislelizumab (also known as BGB -A317) is a humanized, immunoglobulin G4 (IgG4) -variant 
monoclonal antibody against PD -1 under clinical development for the treatment of several human 
malignancies.  
Tislelizumab acts by [CONTACT_397759] -1 with high specificity as 
well as high affinity (dissociation constant [K D] = 0.15 nM). It competitively blocks binding 
efforts by [CONTACT_397760] -1 (PD -L1) and programmed cell death 
protein ligand -2 (PD -L2), thus inhib iting PD -1-mediated negative signaling in T -cells. In in vitro  
cell-based assays, tislelizumab was observed to consistently and dose -dependently enhance the 
functional activity of human T -cells and pre -activated, primary peripheral blood mononuclear 
cells.  In addition, tislelizumab has demonstrated antitumor activity in several allogeneic xenograft 
models, in which peripheral blood mononuclear cell were co -injected with human cancer cells 
(A431 [epi[INVESTIGATOR_131715]]) or tumor fragments (BCCO -028 [colon can cer]) into 
immunocompromised mice.  
The IgG4 variant antibody has very low binding affinity to gamma fragment crystallizable region 
(Fc) receptor IIIA (Fcγ -RIIIA) and complement 1q, a subunit of complement 1, by [CONTACT_397761], 
suggesting either low or no  antibody -dependent cellular cytotoxicity (ADCC) or complement -
dependent cytotoxicity (CDC) effects in humans ( Labrijn et al 2009 ). 
Please refer to the tislelizuma b Investigator’s Brochure  for additional details regarding nonclinical 
studies of tislelizumab.  
1.4.2.  Toxicology   
The toxicity and safety profile of tislelizumab was characterized in si ngle-dose intravenous (IV) 
toxicology studies in mice and monkeys , and in two separate repeat ed-dose IV toxicology studies 
in cynomolgus monkeys dosed once every two  weeks for 13 weeks . The tissue cross -reactivity 
was evaluated in the normal frozen tissues from both humans and monkeys. In addition, the 
potential off -target binding of tislelizumab was screened using the Retrogenix microarray and 
subsequently verified by [CONTACT_397762]. The cytokine release  assays were also evaluated using 
fresh human whole blood cells. Cynomolgus monkey was the only relevant species based on the 
target sequence homology and binding activity.  
Overall, no apparent toxicity was noted in mice or monkey s at single doses up to 1 00 mg/kg . No 
apparent tislelizumab -related toxicity was noted in the 13 -week repeat ed-dose monkey toxicology 
studies at doses up to 30 mg/kg. Apparent but likely immunogenicity -related toxicity was noted in 
individual monkeys given 60  mg/kg repeatedly. How ever, immunogenicity -related changes due to 
formation of antidrug antibodies ( ADAs ) and immune complex formation in nonhuman primates 
is generally considered not translatable to humans ( Vahle 2018 ). The 
No-Obser ved-Adverse -Effect Level of tislelizumab in the 13 -week monkey toxi cology  studies 
was considered to be 30 mg/kg , approximately 10 -fold higher than the clinical dose (200 mg, once 
every 3 weeks). The toxicokinetic profile was well characterized in cynomolgu s monkeys with 
dose-proportional increases in systemic exposure , without apparent accumulation or sex 
difference.  
Approved Date 3/13/[ADDRESS_500460] on 
cytokine release observed in the human whole bl ood assay. In addition, the Retrogenix microarray 
screen of > 6000 human proteins and follow -up verification by [CONTACT_397763] -target binding of tislelizumab.  
The safety profile of tislelizumab is considered adequa te to support the current Study BGB -A317 -
306.   
Refer to the tislelizumab Investigator’s Brochure  for more information regarding IV  toxicology 
studies . 
1.4.3.  Clinical Pharmacology   
In the Phase 1 BGB -A317 _Study_ 001 study  and Study BGB -A317 -102, interim pharmacokinetics 
(PK) analysis  (with a cut -off date of [ADDRESS_500461]  2017 ) was conduct ed using non -compartmen tal 
methods , using serum concentrations from patients who received doses of 0.5, 2.0, 5.0, 10  mg/kg 
Q2W and 2.0 mg/kg, 5.0 mg/kg, 200 mg once every 3 weeks (Q3W) (Phase 1a Part  1, 2, 3, and 
Phase 1b in Study BGB -A317_Study_001 ) and patients who received do ses of 200 mg Q3W in 
Phase 1 of Study BGB -A317 -102 (n = 19) . The maximum observed plasma concentration (C max) 
and the area under the plasma or serum concentration -time curve (AUC) increased in a nearly 
dose-proportional manner from 0.5 mg/kg to 10 mg /kg, after single -dose administration at steady 
state. Preliminary PK data from 27 patients who were administered 1 dose of 200  mg Q3W (Phase 
1a, Part 3 and Study BGB -A317 -102) showed tislelizumab concentrations between the range of 
concentrations observed  for patients who were administered 2 mg/kg and 5  mg/kg doses . The PK 
profile of tislelizumab was consistent between Chinese patients and Caucasian patients.  
Preliminary p opulation PK analysis using a [ADDRESS_500462] order elimination 
shows a systemic plasma clearance (CL) of tislelizumab  of 0.173 L/day, volume of distribution 
(Vd) in the central and peripheral compartments of 2.89  L and 1.7 6 L, respectively, and half -life of 
approximately  19 days.  Race, gender, and body weight are not signif icant covariates on the CL of 
tislelizumab , which supports fixed -dosing across different ethnic groups.  
For more detailed information, please refer to the tislelizumab Investigator’s Brochure .    
1.4.4.  Prior Clinical Experience of Tislelizumab   
As of 28 February 2018, there are 13 ongoing studies with tislelizumab, including monotherapy 
and combination studies in solid tumors and hematological malignancies. Of the ongoing 
monotherapy studies in solid tumors, available data from BGB -A317_Study_001  and BGB -A317 -
102 are summarized below (with a data cutoff date of [ADDRESS_500463] 2017). Of the ongoing 
combination studies, available data from BGB -A317 -206 (data cutoff date of 21 February 2018) 
and BGB -A317 -205 (data cutoff date of 13 June 2018) are summariz ed below. Please refer to the 
tislelizumab Investigator’s Brochure  for the most current data set.  
[IP_ADDRESS].  BGB -A317_Study_001 (Data Cutoff [ADDRESS_500464] 2017)   
Study BGB -A317_Study_001 is a 2 -stage study consisting of a Phase 1a dose -escalation and 
dose-finding component with 3 parts to establish the maximum tolerated dose (MTD), if any, a 
recommended Phase 2 dose (RP2D) for the Phase 1b, and  a flat dose (fixed dose) followed by a 
Approved Date 3/13/[ADDRESS_500465] 2017, in Phase 1a, 116 patients had recei ved tislelizumab at dose regimens 
including 0.5 mg/kg, 2 mg/kg, 5 mg/kg, or 10 mg/kg Q2W; 2 mg/kg or 5 mg/kg Q3W; and 200 
mg Q3W. In Phase 1b, 323 patients had received tislelizumab across 9 indication -expansion 
cohorts.  
Overall, for the 439 patients in t he study, the median age was 60.0 years, 53.8% of the population 
was male, and 65.6% of patients were white. The median number of prior anticancer therapy 
regimens was 2 (range: 0 to 12). The median treatment exposure duration was 2.50  months (range: 
0 to 23.0), and the median study follow -up duration was 5.56 months (range: 0.0 to 26.9). The 
recommended Phase 2 dose (RP2) was established as fixed dose of [ADDRESS_500466]  2017, there were 210  patients (47.8%) remaining on study.  
Preliminary Sa fety 
Of the 439 total patients in the Safety analysis set  for Study BGB -A317_Study_001, 240 (54.7%) 
experienced at least 1 treatment -emergent adverse event (TEAE) assessed as related to 
tislelizumab by [CONTACT_1755] 34 (7.7%) experienced at least 1 ≥ Grade [ADDRESS_500467] commonly occurring related TEAEs for patients treated with the tislelizumab 
monotherapy in Study BGB -A317_Study_001 were fatigue (12.8%), rash (7.7%), nausea (6.8%), 
diarrhea  (6.6%), and hypothyroidism (4.8%). The ≥ Grade 3  related TEAEs occurring in ≥ 2 
patients were pneumonitis (6 patients, 1.4%); colitis and alanine aminotransferase (ALT) 
increased (4 patients each, 0.9%); fatigue, type 1 diabetes mellitus, and aspartate aminotransferase 
(AST) increased (3 patients each, 0.7%); and diarrhea, gamma -glutamyltransferase (GGT) 
increased, and diabetic ketoacidosis (2  patients each, 0.5%). All other events occurred in single 
patients. Lastly, 18 patients (4.1%) experienced an infusion -related reaction; all were 
mild/moderate in severity.  
Preliminary Efficacy  
For patients in Phase 1a (n = 116, evaluable), there were [ADDRESS_500468] overall response (BOR) of stable disease.  
For patients in Phase 1b (n = 286 evaluable), a total of 2 6 patients had a confirmed response.  
Additionally, there were 101  patients with a BOR of stable disease.  
[IP_ADDRESS].  Study BGB -A317 -102 (Data Cutoff [ADDRESS_500469]  2017)   
This Phase 1/2 study was a dose verification of tislelizumab and an indication -expansion study of 
tislelizumab conducted in Chinese patients with advanced solid tumors.   
Overall, for the 123  patients in Study BGB -A317 -102, the median age was 54.0  years, 6 6.7% of 
the population was male, and 100% of patients were Asian (Chinese). The median number of prior 
anti-cancer therapy regimens was 2 (range: 0 to 9). The median treatment exposure duration was 
1.78 months (range: 0 to 8.0), and the median study follow -up duration was also 1.78  months 
(range: 0.0 to 8.0). As of [ADDRESS_500470] 2017, there were 113  patients (91.9%) remaining on study in 
Study BGB -A317 -102. Please refer to the tislelizumab Investigator’s Broc hure for the most 
current data set.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 36 Preliminary Safety  
Of the 123 total patients in the Safety analysis set for Study BGB -A317 -102, 69 (56.1%) 
experienced at least 1 TEAE assessed as related to tislelizumab by [CONTACT_1755] 10 (8.1%) 
were ≥  Grade  [ADDRESS_500471] increased 
(20 patients, 16.3%), ALT increased (17 patients, 13.8%), and blood bilirubin increased and 
anaemia (13 patients each, 10.6%). The ≥  Grade  3 related TEAEs occurring in ≥  [ADDRESS_500472] increased (3 patients, 2.4%) and ALT increased (2 patients, 1.6%). All other events occurred 
in single patients, including a case of retinal detachment (Grade 4).  
Preliminary efficacy data are not yet available.  
[IP_ADDRESS].  Study BGB -A317 -206 (Data Cutoff 21 F ebruary 2018)   
This multi -arm Phase 2 study, consisting of safety run -in and dose -extension phases, assessed 
tislelizumab in combination with platinum -based chemotherapy (by [CONTACT_109800]) as a 
potential first -line treatment for Chinese patients with lung cancer.  
As of 21 Feb 2018, 48 patients (median age: 62 years [range: 36 to 75]; 71% male; 
71% current/former smokers) received tislelizumab treatment (medi an: 3 cycles [range: 1 to 7]); 
[ADDRESS_500473] commonly 
reported ≥ 3 Grade  treatment -related AEs were neutropenia (20.8%) and anemia (12.5 %); the 
most common Grade 3 immune -mediated AEs (imAEs) were pyrexia (6.3%) and rash (6.3%). 
One sq -NSCLC patient experienced a fatal myocarditis/myositis following 1 cycle of 
paclitaxel/cisplatin; all other treatment -related AEs were managed/resolved by s tudy-drug 
interruption (n=15) or discontinuation (n=4) and appropriate treatment.  
Preliminary Efficacy  
Across the 4 cohorts, confirmed and unconfirmed partial responses were observed in 13 and 
9 patients, respectively.  
[IP_ADDRESS].  Study BGB -A317 -205 (Data Cutoff 13 Ju ne 2018)   
This is a Phase 2, multi -cohort study to investigate the safety, pharmacokinetics and preliminary 
antitumor activity of the anti -PD-[ADDRESS_500474] -line treatment in adults with inoperable, locally advanced or metastatic 
esophageal, gastric, or gastroesophageal junction (GEJ) carcinoma.  
As of 13 June 2018, in the ESCC cohort, 15 patients (median age: 61 years) w ere enrolled 
(93%  male; median treatment duration: 108 [21, 201] days; 3 patients received prior 
chemotherapy). In the GC (gastric carcinoma)/GEJ cohort, 15 GC/GEJ patients (median age: 57.9 
years) were enrolled (73% male; median treatment duration: 171 [2 1, 251] days). There were 5 
patients (33.3%) remaining on study treatment.  
Preliminary Safety  
In the ESCC cohort, a total of 22 patients experienced ≥1 tislelizumab - (n=8) or chemotherapy - 
(n=14) related AE. Two patients experienced a tislelizumab -related SAE (abnormal hepatic 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 37 function, pneumonitis); 4 patients experienced ≥1 chemotherapy -related SAE (thrombocytopenia, 
atrial fibrillation, fatigue, abnormal hepatic function, lung infection, decreased appetite). Rash 
(n=2) was the only i mAE reported in ≥2 pa tients. One patient experienced ≥ [ADDRESS_500475] and a fatal abnormal hepatic function.  
In the GC/GEJ cohort, 14 patients (93.3 %) experienced treatment -related AEs of any grade, most 
commonly asthenia (n=8, 53.3%), nausea (n=7, 46.7%), AST increase d (n=7, 46.7%), vomiting 
(n=6, 40.0%), ALT increased (n=6, 40.0%), Blood bilirubin increased (n=5, 33.3%), platelet 
count decreased (n=5, 33.3%), thrombocytopenia  (n=5, 33.3%), decreased appetite  (n=5, 33.3%). 
Nine patients (60.0 %) experienced ≥ [ADDRESS_500476] increased, 
ALT increased, blood bilirubin increased, neutrophil count decreased, amylase increased, lipase 
increased, vomiting, diarrhea, thrombocytopenia, granulocytopenia, decreased appetite, 
paronychia, all of which oc curred in 1 patient. Tislelizumab (BGB -A317) treatment -related AEs 
occurred in 10  patients (66.7%), commonly asthenia (n=4, 26.7%) ALT increased (n=3, 20.0%), 
AST increased (n=3, 20.0%). Tislelizumab (BGB -A317) treatment -related ≥ [ADDRESS_500477] increased, ALT increased, neutrophil count decreased, 
amylase increased, lipase increased, decreased appetite, all of which occurred in 1 patient. One 
tislelizumab (BGB -A317) treatment -related SAE was reported (AST increased, A LT increased).  
Preliminary Efficacy  
Preliminary efficacy data are not yet available.  
[IP_ADDRESS].  Immune -Mediated Reactions   
In patients treated with tislelizumab monotherapy, the following imAEs were observed:  
Acute hepatitis and abnormal liver function have been reported, including 1 patient with fatal 
hepatitis. Additionally, 3.2% of patients experienced treatment -related abn ormal liver function 
tests, and 1.4% of patients experienced immune -mediated hepatitis or hyperbilirubinaemia.  
Pneumonitis has been reported in 2.1% of patients, including 1 patient with fatal pneumonitis.   
Colitis has been reported in approximately 2% of  patients treated. Diarrhoea has been reported in 
6.6% of patients.  
Endocrinopathies have been reported including diabetes mellitus (hyperglycemia and 
ketoacidosis). In addition, thyroiditis, including thyrotoxicosis and hypothyroidism has been 
reported. Furthermore, hypophysitis has been reported in <  1% of patients treated.  
Other immune -mediated events (<  1% of patients with tislelizumab monotherapy except where 
noted): skin reactions (20.5%, including rash and pruritus); arthralgia (2.5%); haemolytic 
anaemia, nephritis, proteinuria (1.8%); encephalitis, neuropathy, arthritis, pancreatitis, stomatitis, 
uveitis, and dry eye (1.4%).   
Beyond patients treated with tislelizumab monotherapy, a case of fatal myocarditis and 
polymyositis was reported in 1 patie nt who received a single dose of tislelizumab, in combination 
with paclitaxel and cisplatin. The patient’s initial symptoms were dyspnea and tea -colored urine 2 
weeks after starting treatment. Elevated urine and serum cardiac and skeletal muscle enzymes 
were reported. The patient died of multi -organ failure 6 days later.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 38 1.5. Study Rationales   
1.5.1.  Rationale for Tislelizumab in the Treatment of Esophageal Carcinoma   
High levels of FcγR -expressing myeloid derived cells (eg, M2 macrophage, myeloid -derived 
suppressor cell [MDSC]) in tumor tissues predict a poor survival of tumor -bearing animal s after 
anti-PD-1 monoclonal antibody treatment; this is possibly due to Fc -FcγR -mediated 
antibody -dependent cell -mediated cytotoxicity (ADCC) or antibody -dependent cellular 
phagocytosis (ADCP) depletion of effector T -cells ( Gül and van Egmund  2015 ; Prieto et al 2015 ; 
Makarova -Rusher et al 2015 ; Beers et al 2016 ; Dahan et a l 2015 ). As a no - to low -FcγR -binding 
agent (thus causing minimal ADCC/ADCP effect), tislelizumab may theoretically show superior 
efficacy and lower toxicity in esophageal carcinoma. Available data from a clinical trial with other 
anti-PD-[ADDRESS_500478] 
both manageable safety profiles and promising antitumor activity in patients with esophageal 
carcinoma (Section 1.6). 
Finally, according to the latest data collected from the Phase [ADDRESS_500479] common 
side effects consistent with known class effects of other anti -PD-1 antibodies, as well as evidence 
for anti -tumor activity (Section 1.6). 
1.5.2.  Rationale for Selecti on of Tislelizumab Dose   
The PK, safety and efficacy data obtained from the first -in-human study BGB -A317_Study_001, 
as well as other clinical study data, were analyzed in aggrega te to determine the recommended 
dose for pi[INVESTIGATOR_397672]. The flat dose of 200 mg IV Q3W was selected for 
subsequent trials.  
Rates of treatment -related adverse events (AEs) and serious adverse events (SAEs) observed in 
patients receiving 2 mg/kg and 5 mg/kg Q2W and Q3W were comparable suggesting no clear 
dose dependence across these regimens. Similarly, confirmed objective response rates (ORRs) in 
patients treated with tislelizumab 2  mg/kg and 5 mg/kg Q2W ranged between 10% and 15%, 
compared  to a range of 15% and 38% for patients treated at 2 mg/kg and 5 mg/kg Q3W.   
According to PK data from BGB -A317_Study_001, Phase 1a, the CL of tislelizumab was found 
to be independent of body weight, ethnicity, and gender and the observed serum exposure o f a 
200-mg dose fell between serum exposure observed after 2 mg/kg and 5 mg/kg doses (dose range 
with comparable safety and efficacy rates).   
Additionally, no unexpected treatment -related AEs occurred in 200 mg fixed -dose cohort 
(BGB -A317_Study_001, Phase  1a, Part 3) when compared to body -weight -based cohorts. Of the 
evaluable patients treated (n = 13), 3 patients (23%) had a best overall response (BOR) of partial 
response (PR), 4 patients (31%) had a BOR of stable disease (SD) and 6 patients (46%) had a 
BOR of progressive disease (PD). Therefore, clinical activity with a manageable and tolerable 
safety profile is expected to be maintained in patients receiving tislelizumab 200 mg Q3W.  
In conclusion, tislelizumab 200 mg Q3W is the recommended dose for pi[INVESTIGATOR_397673].  
Approved Date 3/13/[ADDRESS_500480] of a chemotherapy dou blet in 
combination with a matched placebo. In this study, a “matched” placebo will be used, which will 
contain the same composition as the solution for the active drug (tislelizumab), except that no 
active drug will be present in the formulation. A placeb o is being used to preserve the scientific 
integrity of the study and reduce any potential observational or assessment bias. Patients in the 
placebo arm will still receive the recommended chemotherapy doublet for this patient population, 
minimizing the ris k generally associated with placebo -alone arms in controlled studies.  
1.6. Benefit -Risk Assessment   
Patients with unresectable recurrent or metastatic ESCC represent a population with  a great unmet 
medical need.  
Data from a Phase 1/2 clinical trial of nivolumab, a similar anti -PD-1 antibody, indicated an 
objective response of 22% (95% CI: 14% to 33%) that is durable, which suggests the potential 
efficacy of anti -PD-1 antibody for the treatment of patients with advanced ESCC (for additional 
discussion, see Section 1.1) (Kudo et al 2017 ). In a cohort of patients (n=49, 42 evaluable) with 
esophageal carcinoma treated with tislelizumab at 5  mg/kg in Phase 1b of Study 
BGB -A317_Study_001, PR was observed in [ADDRESS_500481] been treated with tislelizumab monotherapy at clinically relevant 
doses (≥  2 mg/kg) and in combination. The safety profile is consistent with known class effects of 
anti-PD-1 antibodies and included mostly mild/moderate AEs. Very few Grade 3/[ADDRESS_500482] been generally reversible and manageable with s tudy drug 
interruption and/or steroid treatment. For further discussion on safety profile of tislelizumab, 
please refer to the Investigator’s Brochure . 
Given the unmet medical need and limited treatment options in this indication, the benefit/risk 
assessment, based on available tislelizumab Phase 1 data and the publication from nivolumab and 
pembrolizumab, is considered favorable. To assess the potential benefit and safety of tislelizumab 
in combination w ith chemotherapy over chemotherapy alone, a randomized, blinded trial 
comparing tislelizumab to placebo will be conducted.   
An Independent Data Monitoring Committee (IDMC) will be established to regularly monitor the 
safety of tislelizumab when compared w ith placebo. An interim analysis for OS superiority test is 
planned in the study (Section 9.7). 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 40 2. STUDY OBJECTIVES AND ENDPOINTS   
2.1. Study Objectives   
2.1.1.  Primary Objective   
• To evaluate and compare the overall survival (OS) following treatment with 
tislelizumab in combination with chemotherapy compared to placebo in combination 
with chemotherapy whe n given as first -line treatment in patients with unresectable, 
locally advanced recurrent or metastatic ESCC  
2.1.2.  Secondary Objectives   
• To evaluate and compare the efficacy of tisleliz umab in combination with 
chemotherapy compared to placebo in combination with chemotherapy as a first -line 
treatment in unresectable, locally advanced recurrent or metastatic ESCC as measured 
by [CONTACT_16625], ORR, and DOR assessed by [CONTACT_76954] v1. 1 
• To evaluate and compare the efficacy of tislelizumab in combination with 
chemotherapy with the efficacy of  placebo in combination with chemotherapy as a 
first-line treatment in unresectable, locally advanced recurrent or metastatic ESCC as 
measured by [CONTACT_397764]-L1 visually  estimated combined positive score  (vCPS ) ≥ 
10% subgroup . PD-L1 expression will be assessed centrally using the  VENTANA 
PD‑L1 (SP263) assay . The vCPS is the total percentage of the tumor area  covered by 
[CONTACT_397765] -L1 membrane staining and tumor‑associated immune  cells with 
PD-L1 staining at any intensity  
• To evaluate and compare health -related quality of life (HRQoL) based on patient -
reported outcomes (PROs)  between tislelizumab in combination with chemotherapy 
and placebo in combination with chemotherapy  
• To compare the safety between tislelizumab in combination with chemotherapy and 
placebo in combination with chemotherapy  
2.1.3.  Exploratory Objectives   
• To characterize the DCR with tislelizumab in combination with chemotherapy 
assessed by [CONTACT_76954] v1.1  
• To evaluate PFS, ORR , DOR , and DCR  assessed by [CONTACT_397766] ( BIRC ) per RECIST v1.1  
• To assess PFS after next line of treatment (PFS2)  
• To evaluate the potential association of biomarkers with patient prognosis, response , or 
resistance to tislelizumab in combination with chemotherapy  
• To asse ss the pharmacokinetics of tislelizumab in combination with chemotherapy  
• To assess host immunogenicity to tislelizumab in combination with chemotherapy  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 41 2.2. Study Endpoints   
2.2.1.  Primary Endpoint   
• OS - defined as the time from the date of randomization until the date of death due to 
any cause  
2.2.2.  Secondary Endpoints   
• PFS - defined as the time from the date of randomization to the date of first 
documentation of disease progression assessed by [CONTACT_76954] v1.[ADDRESS_500483]  
• ORR - defined as the proporti on of patients whose BOR is CR or PR assessed by [CONTACT_76955] v1.1  
• OS in the PD-L1 vCPS  ≥ 10% subgroup  
• HRQoL - defined as scores of the European EORTC QLQ -C30 (QLQ -C30), its 
esophageal cancer module - EORTC QLQ -OES18 (OES18), and the Europea n Quality 
of Life 5 -Dimension  5-Level (EQ -5D-5L) 
• DOR - defined as the time from the first determination of an objective response until 
the first documentation of progression assessed by [CONTACT_76954] v1.[ADDRESS_500484]  
• The i ncidence and severity of adverse events according to NCI -CTCAE  v4.03  
2.2.3.  Exploratory Endpoints   
• DCR - defined as the proportion of patients whose BOR is CR, PR, and SD assessed by 
[CONTACT_76954] v1.1  
• PFS, ORR , DOR , and DCR  assessed by [CONTACT_397741] v1.1  
• PFS2 - defined as the time from randomization to the objective disease progression after 
next line of treatment or death from any cause, whichever occurs first  
• To explore  biomarkers in tumor tissues and/or blood samples before and after study 
treatment and/or at PD/reoccurrence, and the association between these biomarkers and 
clinical efficacy, disease status, and resistance. Biomarker assessment will consist of PD -
L1 exp ression, gene expression profiling (GEP), tumor mutation burden 
(TMB)/microsatellite instability (MSI)/mutation profile, and tumor -infiltrating immune 
cells. Other assessments may be conducted as allowed by [CONTACT_427].  
• Assessments of pharmacokinetics of tislelizumab when given with chemotherapy  
• Assessments of immunogenicity of tislelizumab by [CONTACT_397767] (ADA)  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 42 3. STUDY DESIGN   
3.1. Summary of Study Design   
The study design schematic is presented in Figure 1.  
Figure 1.  Study Schema  
Abbreviations: BIRC , blinded independent review committee; chemo, chemotherapy; DCR, disease control rate; DOR, duration of 
response; ESCC, esophageal squamous cell carcinoma; HRQoL, health -related quality of life ; ICC, investigator choice of 
chemotherapy; ORR, objective response rate; OS,  overall survival; PD-L1, programmed cell death protein ligand -1; PFS, 
progression -free survival; PFS2, PFS after next line of treatment ; vCPS, visually  estimated combined positive score .  
The IDMC convened on 20 April 2022 to review the efficacy and safety data of the preplanned 
interim analysis  (data cutoff date of 28 February 2022, with 422 death events which corresponds 
to 86.5% of the number of total planned death events for the final analysis [488 planned death 
events ]). After reviewing the data,  the IDMC confirmed that the s tudy met the specified 1-sided 
p-value boundary for superiority  of the primary endpoint  and recommended to unblind/unmask 
the study due to compelling efficacy . Based on  the IDMC recommendation,  a decision was made 
to unblind all patients, and inform all investigators  and IRB/IEC as required . Patients randomized 
to Arm B were to discontinue placebo  after unblinding .  
For all study procedures see Section 7 and Appendix  1. 
Study Population:  
unresectable, locally 
advanced recurrent or 
metastatic ESCC  
Arm A  
Tislelizumab in 
combination with 
chemotherapy  
Screening  
 
•Treatment until disease 
progression, intolerable 
toxicity, or withdrawal for 
other reasons  
•Safety Follow -up & Survival 
Follow -up 
----------------------------------  
Primary endpoint :  
•OS 
Secondary endpoints : 
•PFS, ORR, and DOR assessed 
by [CONTACT_1697]  
•OS in the PD-L1 vCPS ≥ 10% 
subgroup  
•HRQoL  
•Adverse events  
Exploratory endpoints : 
•DCR  
•PFS, ORR, DOR, and DCR 
assessed by [CONTACT_14988]  
•PFS2  
•Correlation of biomarker 
results to response and/or 
resistance to treatment  
•Pharmacokinetics  
•Assessment of immunogenicity  
Arm B  
Placebo in combination 
with chemotherapy  
Randomization & 
Stratification:  
n=622 eligible patients  
•1:1 randomization to 
tislelizumab+chemo or 
placebo+chemo  
Stratification  
•Geographic region 
(Asia [excluding Japan] 
vs Japan vs Rest of 
World)  
•Prior definitive therapy 
(yes vs no)  
•ICC (platinum/  
fluoropyrimidine vs 
platinum/paclitaxel)  
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 43 3.2. Screening Period   
Screening evaluations will be performed within 28 days prior to randomization. Patients will sign 
the informed consent form (ICF) prior to undergoing any screening procedure. Pa tients who are 
suspected to have serious respi[INVESTIGATOR_397674] a history of thoracic radiotherapy will also take 
a pulmonary function test (refer to Section  7.1.4  and Appendix  1 for details). Screening 
evaluations may be repeated once within the screening period; the investigator is to assess 
preliminary patient eligibility according to the latest screening assessment results.  
Archival tumor tissue (formalin -fixed paraffin -embedded block or approximately 15 [at least 6] 
unstained slides) must be collected for purpose of biomarker analysis. If no archival samples are 
available, a fresh tumor biopsy at baseline is needed.  Refer to Section  7.7 for details.  
3.3. Treatment Period   
After completing all screening activities, eligible patients will be randomized in a 1:1 ratio to 
receive  either tislelizumab in combination with a chemotherapy doublet or placebo with a 
chemotherapy doublet. Randomization will be stratified according to geographic region (Asia 
[excluding Japan] vs Japan vs Rest of World), prior definitive therapy (yes vs no) , and 
investigator choice of chemotherapy (platinum with fluoropyrimidine vs platinum with paclitaxel; 
see Section  5.2).  
Patients will receive blinded treatment with one of the following:  
Tislelizumab [ADDRESS_500485] 
practice. If platinum treatment is stopped, the non -platinum agent (fluoropyrimidine or paclitaxel) 
may continue at the regular schedule, if appropriate. In both arms, treatme nt beyond the initial 
investigator -assessed, RECIST v1.1 -defined disease progression is permitted provided that the 
patient a) has investigator -assessed clinical benefit and b)  is tolerating study drug.  Specific 
requirements for post -progression continuat ion of patients treated with tislelizumab (or placebo) 
and chemotherapy are described in Section  3.6.1 . 
Radiological assessment of tumor -response status will be performed every 6 weeks (±  7 days) for 
the first 48 weeks, then every 9 weeks (±  7 days) after [ADDRESS_500486]  v1.1. Tumor 
response will be assessed by [CONTACT_397768]. Details ar e provided in Section  7.5. 
Safety will be assessed throughout the study by [CONTACT_42466]/SAEs (toxicity grades assigned 
per National Cancer Instit ute Common Terminology Criteria for Adverse Events [NCI -CTCAE] 
v4.03), and laboratory results. Vital signs, physical examinations, Eastern Cooperative Oncology 
Group (ECOG) performance status change, electrocardiogram (ECG) results, and other 
examinations will also be used for safety assessment. Safety assessments are further detailed in 
Section  7.4 and the Schedule of Assessments ( Appendix  1). 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 44 When a patient reaches 24 months of treatment (as measured from Cycle 1 Day 1):  
Patients may continue study therapy beyond [ADDRESS_500487] confirmed CR, PR, or SD, the treatment  can be 
stopped if the patient wishes. The decision should be based on the investigator’s evaluation, with 
the patient’s clinical benefit and risk taken into consideration. A treatment -interruption informed 
consent form must be signed by [CONTACT_397769]. The investigator should notify the 
sponsor that treatment will be stopped prior to the event. In such a case, the study assessments and 
procedures will be performed every 12 weeks (in conjunction with repeat radiographic imaging, 
as described in  Section  7.5) rather than every cycle.  
 
 
 
Blood samples of approximately 10 mL will be taken at baseline (predose on Day 1 of Cycle 1) 
for all  randomized patients to explore the association of blood -based biomarkers with response 
and prognosis to tislelizumab in combination with chemotherapy or chemotherapy alone. Written 
patient consent is required for blood sample collections.  
3.4. End of Treatment /Safety Follow -up  
The End -of-Treatment (EOT) Visit  and Safety Follow -up Visit  may be a combined visit.  The 
EOT/Safety Follow -up is conducted when the investigator determines that tislelizumab or placebo 
with chemotherapy will no longer be used. If routine laboratory tests (eg, hematology, serum 
chemistry) are completed within 7 days before the EOT/Safety F ollow -up visit, these tests need 
not be repeated. Tumor assessment is not required at the EOT/Safety Follow -up Visit provided 
that fewer than [ADDRESS_500488] assessment.  
Patients who discontinue treatment for any reason will be asked to return to the clinic for the 
EOT/Safety Follow -up Visit (to occur within 30 days [± 7 days] after the last dose of study 
treatment (including chemotherapy), or before the initiation of a new anticancer treatment, or 
before the first dose administration in the long-term extension /posttrial supply study for patients 
who are going to rollover to those studies , whichever occurs first.  In addition, telephone contacts 
with patients should be conducted to assess imAEs and concomitant medications (if appropriate, 
ie, associated with an imAE or is a new anticancer therapy) at 60 and 90 days (± 14 days ) after the 
last dose of study drug (including chemotherapy), regardless of whether the patient starts a new 
anticancer therapy. If patients report a suspected imAE at a telephone follow -up contact, the 
investigator should arrange an unscheduled visit if further assessment is indicated.  
All AEs, including SAEs, will be collected as described in Section  8.6.   
Patients who discontinue study treatment prior to disease progression will have their tumors 
assessed as outlined in Section  7.5. 
Approved Date 3/13/[ADDRESS_500489] dose.  
See Appendix  1 for assessments to be performed at the EOT/Safety Follow -up Visit.  
3.5. Survival Follow -up  
Patients who discontinue study drug for  reasons other than documented radiographic disease 
progression (eg, toxicity) will continue to undergo tumor assessments according to Section  7.5 
and the Schedule of Assessments ( Appendix  1), until the patient experiences radiographic disease 
progression, withdraws consent, is lost to follow -up, or dies, or until the study completes, 
whichever occurs first.  
Patients will be fol lowed for survival, and further anticancer therapy information  after 
discontinuation of study treatment via telephone calls, patient medical records, and/or clinic visits 
at least every 3  months (± 14 days) or more frequently to ensure data collection feas ibility after 
the Safety Follow -up Visit or as directed by [CONTACT_397770], loss to follow -up, withdrawal 
of consent, or study completion by [CONTACT_456]  (Section  3.7). Confirmed loss to follow -up is 
defined as ≥ 3 consecutive failures of contact[CONTACT_397771] , any 2 of which are ≥ 1 month apart,  via 
≥ [ADDRESS_500490] the right to discontinue study treatment  at any time for any reason. In addition, the 
investigator has the right to discontinue a patient from the study treatment at any time. Patients 
who discontinue study treatment for reasons other than radiographic disease progression as 
documented by [CONTACT_14988] s hould be followed for assessments of antitumor activity (Section  7.5), 
safety (Section  7.4), and survival (Section  3.5), if possible.  
The primary reason for discontinuation  from the study treatment should be documented on the 
appropriate electronic case report form (eCRF). Patients must discontinue study treatment for 
reasons which include, but are not limited to, the following:  
• Withdrawal by [CONTACT_397772] (s urvival/PFS2 data can still be collected and 
biospecimens analyzed beyond that date)  
• Pregnancy  
• Any medical condition that the investigator or sponsor determines may jeopardize the 
patient’s safety, if he or she were to continue the study treatment  
• Use of a ny concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, 
immunotherapy, or standard or investigational agents [including Chinese herbal medicine 
and Chinese patent medicines] for the treatment of cancer)  
• Patient noncompliance  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 46 Patients will be permitted to continue study drug(s) if pseudoprogression is suspected and/or there 
is a reasonable belief that the patient could derive benefit from study drug(s) after RECIST v1.1 
criteria for progressive disease ar e met, and if they meet all of the following criteria:  
• Absence of clinical symptoms and signs of disease progression (including clinically 
significant worsening of laboratory values)  
• Stable ECOG performance status ≤  1 
• Absence of rapid progression of dise ase or of progressive tumor at critical anatomical sites 
(eg, cord compression) that requires urgent alternative medical intervention  
• Investigators must obtain written informed consent for treatment beyond radiologic 
disease progression and inform patients  that this practice is not considered standard in the 
treatment of cancer  
The decision to continue study drug(s) beyond initial investigator -assessed progression must be 
discussed with the sponsor’s medical monitor and documented in the study records. Tum or 
assessment should continue as planned in patients receiving study drug(s) beyond initial 
investigator -assessed progression. Tumor assessment in these patients should continue until study 
treatment discontinuation.   
3.6.2.  Patient Discontinuation From Study (En d of Study for an Individual Patient)   
Patients may discontinue study for reasons which include, but are not limited to, the following:  
• Withdrawal by [CONTACT_397773] (no further data can be collected but biospecimens 
collected before that date can still be analyzed)  
• Death  
• Lost to follow up  
• Patients have completed all study assessments  
3.7. End of Study   
The end of study is defined as the timepoint when the final data for a clinical study have been 
collected, which is after the last patient has made the final visit to the study location.  
The sponsor has the right to terminate this study at any time. Reas ons for terminating the study 
early may include, but are not limited to, the following:  
The incidence or severity of AEs in this or other studies indicates a potential health hazard to 
patients  
• Overall patient enrollment is unsatisfactory  
• A rollover stud y becomes available  
The sponsor will notify each investigator if a decision is made to terminate the study. Should this 
be necessary, prematurely discontinued patients should be seen as soon as possible for an 
EOT/Safety Follow -up Visit.  
Approved Date 3/13/[ADDRESS_500491] -study drug supply program until tislelizumab is commercially available in 
the country of the patient’s residence.  
The investigators may be informed of additional procedures to be followed to ensure that adequate 
consideration is given to the protection of the patient’s interests. The investigator will be 
responsible  for informing Institutional Review Boards (IRBs)/Independent Ethics Committees 
(IECs) of the early termination of the study.  
The sponsor has the right to close a site at any time. The decision will be notified to the site in 
advance. Reasons for closing a site may include but are not limited to the following:  
• Excessively slow recruitment  
• Poor protocol adherence  
• Inaccurate or incomplete data recording  
• Noncompliance with Good Clinical Practice (GCP), applicable laws and regulations  
• Study activity is completed (ie, all patients have completed and all obligations have 
been fulfilled)  
3.8. Enrollment of Japanese Patients   
The safety of study treatment will be closely monitored in all patients throughout the course of the 
clinical study. Enrollment of Japanese patients will be gated to monitor for unexpected or new 
safety concerns. The safety cohort of approximately 10 Japanese patients (minimum of 5 per arm) 
will be treated and closely monitored during a 7 -day hospi[INVESTIGATOR_059], according to local practice. 
Following discharge from this initial hospi[INVESTIGATOR_059], pa tients will be monitored with weekly 
assessments for safety, as detailed in Appendix  1 (Schedule of Assessments). The Sponsor 
unblinded Drug Safety and Pharmacovigilance group will review unblinded SAE reports, and the 
IDMC will review all safety data after this safety cohort of Japanese patients completes 1  cycle, or 
at any time there is a  safety concern. DLT is defined in the IDMC charter and the occurrence of 
DLTs in patients who receive tislelizumab in combination with cisplatin and 5 -FU will be 
assessed independently by [CONTACT_31849].  During the IDMC review, enrollment in Japan will be held 
until the IDMC review is complete and the safety and tolerability is deemed acceptable.   
Approved Date 3/13/[ADDRESS_500492] meet all of the following criteria:  
1. Able to provide written informed consent and can understan d and agree to comply with the 
requirements of the study and the Schedule of Assessments  
2. Age ≥  18 years on the day of signing the informed consent form (or the legal age of 
consent in the jurisdiction in which the study is taking place)  
3. Pathologically (his tologically) confirmed diagnosis of ESCC  
Note: Patients with adenocarcinoma differentiation < 5% of the viable tumor sample are 
eligible  
4. Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced recurrent 
or metastatic disease (per A JCC 7th Edition, Appendix  14), if there is prior 
neoadjuvant/adjuvant therapy with platinum -based chemotherapy , a treatment -free interval 
of at least [ADDRESS_500493] v1.1  
Note: The target lesion(s) selected that are within the field of prior local therapy have 
subsequently progressed as defined by [CONTACT_393] v1.1  
6. ECOG Performance Status ≤ 1  
7. Adequate organ function as indicated by [CONTACT_132725] ≤ [ADDRESS_500494] the following laboratory values:  
i. Absolute neutrophil count ≥ 1.5 x 109/L 
ii. Platelets ≥ 100 x 109/L 
iii. Hemoglobin ≥  90 g/L 
NOTE: Patients must not have required a transfusion or growth factor support ≤  14 days 
before sample collection for neutrophil counts, platelets, or hemoglobin that were lower 
than required for the study.  
b. Serum creatinine ≤ 1.5 mg/100 mL (equivalent 130 µ mol/L).   
c. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (total bilirubin must be 
< [ADDRESS_500495] for patients with Gilberts syndrome).  
d. AST and ALT ≤ [ADDRESS_500496] and ALT ≤ [ADDRESS_500497] newly obtained or archival  tissue sample available for biomarker assessment.  
Approved Date 3/13/[ADDRESS_500498] be willing to use a highly effective method of birth 
control for the duration of the study (in accordance with the Contraception Guidelines in  
Appendix  9), ≥ [ADDRESS_500499] dose of tislelizumab, and ≥ [ADDRESS_500500] ≤ [ADDRESS_500501] be willing to use a highly effective method of birth control for the 
duration of the study , ≥ [ADDRESS_500502] dose of tislelizumab,  and for ≥ [ADDRESS_500503] be excluded from this study:  
1. Ineligible for treatment with any of the chemotherapy doublets of protocol -specified 
chemothera py 
2. Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC  
Note: Patients with prior systemic  concurrent chemotherapy in concurrent 
chemoradiotherapy  are eligible  
3. Palliative radiation treatment for ESCC within 4 weeks of stu dy treatment initiation  
4. Patients with evidence of fistula (either esophageal/bronchial or esophageal/aorta)  
5. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage 
or medical intervention (clinically significant recur rence requiring an additional 
intervention within 2 weeks of intervention)  
6. Evidence of complete esophageal obstruction not amenable to treatment  
7. Received prior therapi[INVESTIGATOR_107900] -1, PD -L1, or PD -L2 
8. Active leptomeningeal disease or uncontrolled brain me tastasis.  
a. Patients with a history of treated and, at the time of screening, stable central nervous 
system (CNS)  metastases are eligible, provided they meet all the following:  
i. Brain imaging at screening shows no evidence of interim progression , clinically 
stable for at least [ADDRESS_500504] measurable  and/or evaluable  disease outside the CNS  
iii. No ongoing requirement for corticosteroids as therapy for CNS disease ; off 
steroids 3 days prior to randomization; anticonvulsants at a stable dose are 
allowed  
iv. No stereotactic radiation or whole -brain radiation within 14 days prior to 
randomization  
b. Deleted  
i. Deleted  
9. Active autoimmune diseases or history of autoimmune diseases that may relapse.   
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 50 Note: Patients with the f ollowing diseases are not excluded and may proceed to further 
screening:  
a. Controlled Type I diabetes  
b. Hypothyroidism (provided it is managed with hormone replacement therapy only)  
c. Controlled celiac disease  
d. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)  
e. Any other disease that is not expected to recur in the absence of external triggering 
factors  
10. Any active malignancy ≤ 2 years before randomization except for the specific cancer 
under investigation in this stud y and any locally recurrent cancer that has been treated 
curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, 
carcinoma in situ of the cervix or breast)  
11. Any condition that required systemic treatment with either corticos teroids (>  10 mg daily 
of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before 
randomization  
Note: Patients who are currently or have previously been on any of the following steroid 
regimens are not excluded:  
a. Adrenal replacement  steroid (dose ≤ 10 mg daily of prednisone or equivalent)  
b. Topi[INVESTIGATOR_2855], ocular, intra -articular, intranasal, or inhaled corticosteroid with minimal 
systemic absorption  
c. Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for contrast 
dye allergy) or for the treatment of a non -autoimmune condition (eg, delayed -type 
hypersensitivity reaction caused by [CONTACT_13132])  
12. With history of interstitial lung disease, non -infectious pneumonitis or uncontrolled lung 
diseases including pulmonary fibr osis, acute lung diseases, etc.  
13. With infections (including tuberculosis infection, etc) requiring systemic antibacterial, 
antifungal or antiviral therapy within 14 days prior to randomization. Note: antiviral 
therapy is permitted for patients with chronic hepatitis B virus ( HBV ) or hepatitis C virus 
(HCV ) infection . 
14. A known history of HIV infection  
15. Any major surgical procedure requiring general anesthesia ≤ 28 days before randomization  
16. Prior allogeneic stem cell transplantation or organ transplantation  
17. Any of the following cardiovascular risk factors:  
a. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily 
living, ≤ 28 days before randomization  
b. Pulmonary embolism ≤ 28 days before randomization  
c. Any history  of acute myocardial infarction ≤ 6 months before randomization  
d. Any history of heart failure meeting [LOCATION_001] Heart Association Classification III or 
IV (Appendix  6) ≤ 6 months before randomization  
e. Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before 
randomization  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 51 f. Any history of cerebrovascular accident ≤ 6  months before randomization  
g. Uncontrolled hypertension: systolic press ure ≥  160 mmHg or diastolic pressure 
≥ 100 mmHg despi[INVESTIGATOR_6698] -hypertension medications ≤  28 days before randomization  
h. Any epi[INVESTIGATOR_397675] ≤  [ADDRESS_500505] study drug administration  
20. Was administered a live vaccine ≤ 4 weeks before randomization  
Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed.  
Intranasal vaccines are live vaccines and are not allowed.  
21. Underlying medical conditions (including laboratory abnormalities) or alcohol or drug 
abuse or dependence that will be unfavorable  for the administration of study drug or affect 
the explanation of drug toxicity or AEs or might impair compliance with study conduct.  
22. Concurrent participation in another therapeutic clinical trial  
23. Unintentional weight loss ≥ 5% within one month prior to r andomization or Nutritional 
Risk Index (NRI) < 83.5 ( Appendix  15) per investigator’s choice  
24. Pregnant or breastfeeding woman  
25. Patients receiving chemothe rapy doublet C (platinum and paclitaxel) must not have 
peripheral neuropathy ≥ Grade 2 at baseline  
26. With uncontrolled diabetes or > Grade [ADDRESS_500506] medical management or ≥ Gra de 3 
hypoalbuminemia ≤  14 days before randomization.  
27. Has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, 
etc) or any investigational therapi[INVESTIGATOR_6523] 14  days or 5  half-lives (whichever is shorter) of 
the first study drug ad ministration  
28. Patients with toxicities (as a result of prior anticancer therapy) which have not recovered 
to baseline or stabilized, except for AEs not considered a likely safety risk (eg, alopecia 
and specific laboratory abnormalities)  
29. Locally advanced es ophageal carcinoma that is resectable or potentially curable with 
radiation therapy per local investigator.  
30. Patients with untreated chronic hepatitis B or chronic HBV carriers whose HBV DNA is ≥ 
500 IU/mL or patients with active hepatitis C virus (HCV)  
Note: Patients who are inactive carriers or with treated and stable hepatitis B (detectable B 
surface antigen (HBsAg), HBV DNA < 500 IU/mL)  and patients with non-active hepatitis 
C can be enrolled. Management of prophylaxis antiviral therapy should be as per local 
guidelines.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 52 5. STUDY TREATMENT   
5.1. Formulation, Packaging, and Handling   
5.1.1.  Tislelizumab   
Tislelizumab is a monoclonal antibody formulated for IV injection in a single -use vial (20R glass, 
[LOCATION_002] P harmacopeia [USP] type I), containing a total of 100 mg of antibody in 10 mL of 
isotonic solution. Tislelizumab has been aseptically filled in single -use vials with a Flurotec -
coated butyl rubber stopper and an aluminum cap. Each vial is packaged into a si ngle carton box.  
The label will include at a minimum, the drug name, dose strength, contents, sponsor, protocol 
number, kit number, batch/lot number, directions for use, storage conditions, caution statements, 
retest or expi[INVESTIGATOR_5695], and space to enter the  patient number and name [CONTACT_6823]. The 
contents of the label will be in accordance with all applicable local regulatory requirements.  
The study drug must be kept at the temperature condition as specified on the label. Tislelizumab  
must be stored  at temperatures between 2ºC and 8ºC and protected from light.   
Refer to the Pharmacy Manual for details regarding IV administration, accountability, and 
disposal. Please also refer to the Investigator’ s Brochure  for other details regarding tislelizumab.  
5.1.2.  Matched Placebo   
All personnel at the study sites and all patients and the Sponsor will be blinded to study treatment.  
Matched  placebo will be provided in a single -use vial (20R glass, USP type I), containing 10 mL 
of isotonic solution. These single -use vials  contain a Flurotec -coated butyl rubber stopper and an 
aluminum cap . Each vial is packaged into a single carton box.  
The l abel will include at a minimum, sponsor, protocol number, kit number, batch/lot number, 
directions for use, storage conditions, caution statements, retest or expi[INVESTIGATOR_5695], and space to enter 
the patient number and name [CONTACT_6823]. The contents of t he label will be in accordance 
with all applicable local regulatory requirements.  
The vials must be kept at the temperature condition as  specified on the label. Vials must be stored 
at temperatures between 2ºC and 8oC and protected from light .   
Refer to the Pharmacy Manual for details regarding IV administration, accountability, and 
disposal.   
5.1.3.  Cisplatin   
Cisplatin  will be supplied in vials for infusion; however, the actual appearance and composition of 
the product may depend on the respective marketed product sourced for the participating countries   
For cisplatin supplied by [CONTACT_283691], t he label will include at a minimum, the drug 
name, dose strength, contents, sponsor, protocol number, kit number, lot number, directions for 
use, storage conditions, caution statements, retest or expi[INVESTIGATOR_5695], and space to enter th e patient 
number and name [CONTACT_4236]. The contents of the label will be in accordance with all 
applicable local regulatory requirements.  
Approved Date 3/13/[ADDRESS_500507] solution from light.  
For further details, see the manufacturer’s prescribing information for cisplatin.  
5.1.4.  Oxaliplatin   
Oxaliplatin will be supplied i n vials for infusion; however, the actual appearance and composition 
of the product may depend on the respective marketed product sourced for the participating 
countries.   
For oxaliplatin supplied by [CONTACT_283691], t he label will include at a minimum, the drug 
name, dose strength, contents, sponsor, protocol number, kit number, lot number, directions for 
use, storage conditions, caution statements, retest or expi[INVESTIGATOR_5695], and space to enter the patient 
number and name [CONTACT_4236]. The conten ts of the label will be in accordance with all 
applicable local regulatory requirements.  
The study drug must be kept at the temperature condition as  specified on the label.  
For further details, see the manufacturer’s prescribing information for oxaliplatin . 
5.1.5.  5-Fluorouracil   
5-FU will be supplied in vials for infusion; however, the actual appearance and composition of the 
product may depend on the respective marketed product sourced for the participating countries.  
For [ADDRESS_500508] be kept at the temperature con dition as  specified on the label.  
For further details, see the manufacturer’s prescribing information for 5 -FU. 
5.1.6.  Capecitabine   
Capecitabine will be supplied as tablets ; however, th e actual appearance and composition of the 
product may depend on the respective marketed product sourced for the participating countries.   
For capecitabine supplied by [CONTACT_283691], the label will include at a minimum, the drug 
name, dose streng th, contents, sponsor, protocol number, kit number, lot number, directions for 
use, storage conditions, caution statements, retest or expi[INVESTIGATOR_5695], and space to enter the patient 
number and name [CONTACT_4236]. The contents of the label will be in accordan ce with all 
applicable local regulatory requirements.  
The study drug must be kept at the temperature condition as specified on the label.  
For further details, see the manufacturer’s prescribing information for capecitabine.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 54 5.1.7.  Paclitaxel   
Paclitaxel will be supplied in vials for infusion ; however, the actual appearance and composition 
of the product may depend on the respective marketed product sourced for the pa rticipating 
countries.   
For paclitaxel  supplied by [CONTACT_283691], t he label will include at a minimum, the drug 
name, dose strength, contents, sponsor, protocol number, kit number, lot number, directions for 
use, storage conditions, caution state ments, retest or expi[INVESTIGATOR_5695], and space to enter the patient 
number and name [CONTACT_4236]. The contents of the label will be in accordance with all 
applicable local regulatory requirements.  
The study drug must be kept at the temperature condition as  specified on the label.  
For further details, see the manufacturer’s prescribing information for paclitaxel.  
5.2. Dosage, Administration, and Compliance   
Dosing schedules for both arms, br oken out by [CONTACT_397774], are provided in Table 2. One 
treatment cycle is 21 days in length.  
Table 2.  Selection and Timing of Dose for Each Patient  
Intervention  Drug  Dose  Study 
Day(s)  Frequency of  
Administration  Route of 
Administration  
Study Drug  Tislelizumab 
(BGB -A317)  200 mg  1 Q3W  Intravenous  
Matched Placebo  None  N/A 1 Q3W  Intravenous  
Chemotherapy 
Doublet A *** Cisplatin OR  
Oxaliplatin*  60-80 mg/m2 (cisplatin)  
130 mg/m2 (oxaliplatin)  1 Q3W  Intravenous  
5-Fluorouracil  750-800 mg/m2 1-5 Q3W  Intravenous  
Chemotherapy 
Doublet B *** Cisplatin OR  
Oxaliplatin*  60-80 mg/m2 (cisplatin)  
130 mg/m2 (oxaliplatin)  1 Q3W  Intravenous  
Capecitabine  1000 mg/m2 1-14 Twice a day  Oral 
Chemotherapy 
Doublet C *** Cisplatin OR  
Oxaliplatin*  60-80 mg/m2 (cisplatin)  
130 mg/m2 (oxaliplatin)  1 or 2**  Q3W  Intravenous  
Paclitaxel  175 mg/m2 1 Q3W  Intravenous  
Abbreviations: 5 -FU, 5 -fluorouracil; N/A, not applicable; Q3W, every 3 weeks.  
Note:  Platinum therapy may be stopped after [ADDRESS_500509] practice. If 
platinum treatment is stopped, the non -platinum a gent (fluoropyrimidine or paclitaxel) may continue at the 
regular schedule.  
* The platinum agent may be cisplatin or oxaliplatin (except in China, Taiwan, Japan , and countries  where 
oxaliplatin substitution is not permitted) according to site or investigat or preference or standard practice as 
determined prior to randomization.  
** For Chemotherapy Doublet C, cisplatin may be administered on Days [ADDRESS_500510] be betw een 60 to 80  mg/m2 per cycle.  
*** For sites where the sponsor is required to provide these products will either be supplied or reimbursed by [CONTACT_11154].  These products may be obtained by [CONTACT_397775].    
 
Approved Date 3/13/[ADDRESS_500511] dose of study drug is to be 
administered within 2 business days of randomization. Tislelizumab/placebo will be administered 
first, followed by [CONTACT_2669] a [ADDRESS_500512] treatment practices 
and guidelines. (note that in Chemotherapy Doublet B, capecitabine is given orally daily). All 
patients will be monitored continuously for AEs. Treatment modifications (eg, dose delay, 
reduction, interruption or discontinuation) will be  based on specific laboratory and adverse event 
criteria, and the investigator’s clinical assessment as described in Section 5.5. 
Alternate dose and  dosing schedules are allowed according to local and institutional guidelines.  
According to clinical practice in Japan, only the cisplatin + [ADDRESS_500513], a ≥ 30 -minute monitoring period is required in an area 
with resuscitation equipment and emergency age nts. 
The initial infusion (Cycle 1, Day 1) will be delivered over 60 minutes; if this is well tolerated, 
then the subsequent infusions may be administered over [ADDRESS_500514] not be  concurrently administered with any 
other drug (refer to Section  6). 
Guidelines for dose modification, treatment interruption, or discontinuation an d for the 
management of i mAEs and infusion -related reactions are provided in detail in Section  8.7 and 
Appendix  7.  
Refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and 
administration.  
5.2.2.  Matched Placebo   
All personnel at the study sites and all patients and the Sponsor will be blinded to study treatment. 
Administration of matched placebo will follow the guidance given for tislelizumab, as described 
in Section  5.2.1  above.  
Refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and 
administration.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 56 5.2.3.  Chemotherapy Doublet A: Platinum (Cisplatin or Oxaliplatin) in C ombination 
with 5 -Fluorouracil   
After all procedures/assessments have been completed as detailed in Appendix  1 and Section  3.2. 
Cisplatin will be administered on Day 1, given Q3W at a dose of 60 to 80 mg/m2 by [CONTACT_120355] 6 to 8 hours (or in doses consistent with local or country -specific treatment guidelines, or 
according to manufacturer standards or institutional standards). Oxaliplatin 130 mg/m2 IV on Day 
[ADDRESS_500515] practice as determined prior to randomization (except in 
China, Taiwan, Japan , and countries  where oxaliplatin substitution is not permitted). Also, 5 -FU 
will be administered o n Days 1 to 5, given Q3W at a dose of 750 to 800  mg/m2 by [CONTACT_151241] 24 hours. The actual infusion time of 5 -FU should be recorded, and a total infusion 
time of 120+/ - 3 hours is acceptable. The initial treatment of platinum (cisplatin or oxaliplatin) in 
combination with [ADDRESS_500516] doses of platinum and 5 -FU are dependent upon th e patient’s baseline body weight. 
Subsequent doses must be recalculated if the change of body weight from baseline ≥ 10%. 
Subsequent doses should not be recalculated if the change (increase or decrease) of body weight 
from baseline < 10% unless there is pe rsistent toxicity that requires dose adjustment. If the dose is 
recalculated because of a ≥ 10% change in body weight from baseline, this body weight will then 
be used as the new baseline to calculate the platinum and 5 -FU dose in subsequent cycles.  
Premed ication is recommended prior to infusion of cisplatin according to the manufacturer’s 
instructions. The premedication regimen should be determined by [CONTACT_397776]. Premedication may consist of hydratio n with 1 to 2 
liters of fluid infused 8 to 12 hours prior to dosing. The use of diuretics for fluid maintenance is 
allowable.  
There is a 3 -day window for all treatments in subsequent cycles if the cycle length is 21 days. If 
dosing is delayed due to admini strative or other reasons (holidays, intercurrent illnesses, etc.), the 
subsequent dosing visit should be scheduled as clinically appropriate.  
Patients will be monitored continuously for AEs and will be instructed to notify their physician 
immediately for  any and all AEs. Management of suspected adverse drug reactions may require 
temporary interruption and/or dose reduction of therapy.  
Please refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and 
administration.  
5.2.4.  Chemothera py Doublet B: Platinum (Cisplatin or Oxaliplatin) in Combination 
with Capecitabine   
After all procedures/assessments have been completed as detailed in Appendix  1 and Section  3.2, 
cisplatin will be administered on Day 1, given every 21 days at a dose of 60 to 80 mg/m2 by [CONTACT_170147] 6 to 8 hours (or in doses consistent with local or country -specific treatment 
guidelines, or according to manufacturer standards or institutional standards). Oxalipl atin 130 
mg/m2 IV on Day [ADDRESS_500517] practice as determined prior to randomization (except 
in China, Taiwan, Japan , and countries  where oxalipl atin substitution is not permitted). 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 57 Capecitabine will be self -administered orally twice daily, from the morning of Day 1 to the 
evening of Day 14 or from the evening of Day  1 to the morning of Day 15 of each 21 -day cycle at 
the recommended dose of 1000  mg/m2 twice daily (BID). The initial treatment of cisplatin in 
combination with capecitabine will be administered within [ADDRESS_500518] doses of platinum and capecitabine are dependent upon the patient’s baseline body 
weight. Subsequent doses must be recalculated if the change of body weight (increase or decrease) 
from baseline ≥ 10%. Subsequent doses should not be recalculated if the change (increase or 
decrease) of body weight  from baseline < 10% unless the emergence of toxicity requires dose 
adjustment. If the dose is recalculated because of a ≥ 10% change in body weight from baseline, 
this body weight will then be used as the new ba seline to calculate the platinum and capecitabine  
dose in subsequent cycles.   
Premedication is recommended prior to infusion of cisplatin according to the manufacturer’s 
instructions. The premedication regimen should be determined by [CONTACT_397776]. Premedication may consist of hydration with [ADDRESS_500519] be maintained according 
to local or institutional standards of care when administer ing cisplatin treatment.  
An adequate amount of supply of capecitabine will be dispensed to patients on Day 1 of each new 
cycle (Q3W). Each time study drug is dispensed, compliance will be evaluated and encouraged. 
Treatment compliance will also be monitore d by [CONTACT_397777]’s 
medical record and eCRF. If the number of capsules returned does not agree with the expected 
number, the patient should be counseled, and proper dosing reinforced. Capecitabine should be 
taken with wat er, within 30 minutes after a meal. Urinary output should be maintained according 
to local or institutional standards of care. If a dose of capecitabine is missed, the patient should 
take the next dose as scheduled. A double dose of capecitabine should not  be administered to 
make up for missed individual doses. Refer to the capecitabine prescribing information for 
additional details.  
Patients will be monitored continuously for AEs and will be instructed to notify their physician 
immediately for any and all AEs. Management of suspected adverse drug reactions may require 
temporary interruption and/or dose reduction of therapy.   
Please refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and 
administration.  
5.2.5.  Chemotherapy Doublet C: Platinum (Cisplatin or Oxaliplatin) in Combination 
with Paclitaxel   
After all procedures/assessments have been completed as detailed in Appendix  1 and Section  3.2, 
cisplatin will be administered on Day 1 or 2, given every 21 days at a dose of 60 to 80 mg/m2 by 
[CONTACT_12781] 6 to 8 hours (or in doses consistent with local or country -specific treatment 
guidelines, or according to manufacturer standards or institutional standards). Oxaliplatin 130 
mg/m2 IV on Day [ADDRESS_500520] practice as determined prior to randomization (except 
in China, Taiwan, Japan , and countries  where oxaliplatin substitution is not permitted). Depend ing 
on local guidelines, cisplatin may be given in 3  divided doses on Days 1, 2, and 3. The total dose 
Approved Date 3/13/[ADDRESS_500521] be between 60 to 80 mg/m2 per cycle. Also, paclitaxel will be administered on Day 1, 
given Q3W at a dose of 175 mg/mg2 by [CONTACT_12781] 3 h ours. The initial treatment of 
platinum (cisplatin or oxaliplatin) in combination with paclitaxel will be administered within [ADDRESS_500522] doses of platinum and paclitaxel are dependent upon the patient’s baseline body weight 
(increase or decrease) from baseline ≥ 10%. Subsequent doses should not be recalculated if the 
change (increase or decrease) of body weight from baseline < 10 %. If the dose is recalculated 
because of a ≥ 10% change in body weight from baseline, this body weight will then be used as 
the new baseline to calculate the platinum and paclitaxel  dose in subsequent cycles.   
Premedication is recommended prior to infusion of cisplatin according to the manufacturer’s 
instructions. The premedication regimen should be determined by [CONTACT_397776]. Premedication may consist of hy dration with 1 to 2 
liters of fluid infused 8 to 12 hours prior to dosing.  
Premedication is recommended prior to infusion of paclitaxel according to the manufacturer’s 
instructions and local standards. The premedication regimen should be determined by [CONTACT_397778]. Premedication may consist of an 
oral steroid (such as dexamethasone 8 to 20 mg or equivalent administered 6 to 12 hours orally or 
30 to 60 minutes IV before paclitaxel), an antihistamine (H1  antagonist) such as diphenhydramine 
hydrochloride [ADDRESS_500523], such as cimetidine 300  mg IV or 
equivalent), and an antiemetic (such as ondansetron 8 mg/kg IV or equivalent administered 30 to 
120 minutes before paclitaxel). Prem edication may be provided per local guidance and all 
medications will be documented on the CRF.  
There is a 3 -day window for all treatments in subsequent cycles if the cycle length is 21 days. If 
dosing is delayed due to administrative or other reasons (ho lidays, intercurrent illnesses, etc.), the 
subsequent dosing visit should be scheduled as clinically appropriate.  
Patients will be monitored continuously for AEs and will be instructed to notify their physician 
immediately for any and all AEs.  Management of suspected adverse drug reactions may require 
temporary interruption and/or dose reduction of therapy.  Patients receiving paclitaxel will need to 
be followed for safety and pregnancy for [ADDRESS_500524] dose.  
Please refer to the P harmacy Manual for detailed instructions on drug preparation, storage, and 
administration.  
5.3. Overdose   
Any overdose of tislelizumab ( defined as ≥ 600 mg of tislelizumab in a 24 -hour period ) or 
incorrect administration of study drug should be noted in the patient’s chart and on the appropriate 
eCRF. For chemotherapy, doses >20% of targeted total dose specified in this protocol represent an 
overdose, and the Sponsor should be notified as soon as possible. AEs associated with an 
overdose or incorrect administration of study drug will be recorded on the AE eCRF. Any SAEs 
associated with an overdose or incorrect administration are required to be reported within 24 
hours of awareness via SA E reporting process as described in Section  8.6. Supportive care 
measures should be administered as appropriate.  
Approved Date 3/13/[ADDRESS_500525] Accountability   
The investigational medicinal products (IMPs) required for completion of this study (tislelizumab 
[or placebo]) will be provided by [CONTACT_456], as required by [CONTACT_397779] -specific guidance. 
The investigational site will acknowledge receipt of IMPs. Any damaged shipments will be 
replaced.  
Accurate records of all IMP received, dispensed, returned, and disposed should be recorded on the 
site’s Drug Inventory Log . Refer to the Pharmacy Manual for details of IMP management.   
5.5. Dose Delay or Modification   
A dose delay is a deviation from prescribed dosing schedule  (ie, the drug is withheld beyond visit 
window). A dose interruption is an interruption of the intravenous infusion.  
Every effort should be made to administer the study drug(s) according to the planned dose and 
schedule. In the event of significant toxicit ies, dosing may be delayed and/or reduced based on the 
guidelines provided below. Reasons for dose modifications or delays, the supportive measures 
taken, and the outcome will be documented in the patient's chart and recorded in the eCRF.  
The dose modifica tion guidelines in this section are not intended to be a substitute for clinical 
judgment. Investigators may delay or modify doses in response to other reasons (eg, AEs, 
declining weight, lab findings, etc.) as appropriate.  
In case of chemotherapy -related toxicity, chemotherapy will be delayed until it resolves to 
baseline or ≤ Grade 1 (whichever is more severe) prior to administering the next dose of 
chemotherapy, with the exception of alopecia, Grade [ADDRESS_500526] the safety evaluation of the study drugs. Tislelizumab or 
placebo should continue as scheduled. If the AE resolves within 10 days, chemotherapy will be 
administered. The administration of chemotherapy and tislelizumab or placeb o will be 
resynchronized at the subsequent cycle, which will be scheduled according to the chemotherapy 
dose administration date. If the AE does not resolve within 10 days, chemotherapy will be 
omitted. If the AE resolves within 21 days, chemotherapy and t islelizumab or placebo will be 
administered on Day 1 of the next treatment cycle according to the original schedule.  
In case of tislelizumab or placebo -related toxicity, tislelizumab or placebo will be delayed until it 
resolves to baseline or ≤ Grade 1 (w hichever is more severe) prior to administering the next dose 
of tislelizumab or placebo, with the exception of alopecia, Grade [ADDRESS_500527] the safety evaluation of the study drugs. 
Chemotherapy should continue as scheduled. If the AE is resolves within 10 days, tislelizumab or 
placebo will be administered. The administration of chemotherapy and tislelizumab or placebo 
will be resynchronized at the subsequent cycle, which will be schedu led according to the 
chemotherapy dose administration date. If the AE does not resolve within 10 days, tislelizumab or 
placebo should not be given for the current cycle. If the AE resolves within 21 days, tislelizumab 
or placebo and chemotherapy will be ad ministered on Day 1 of the next treatment cycle according 
to the original schedule.  
In case of both tislelizumab/placebo and chemotherapy toxicity, treatment in any patient may be 
temporarily held if the toxicity is considered to be related to tislelizumab  or placebo and 
chemotherapy. If the administration delay is ≤ 10 days for any delayed drug, the delayed drug will 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 60 be administered; if the delay is >10 days, the delayed drug will be omitted in this cycle and the 
next cycle will be administered as planned as long as the AE resolves within 21 days. Other study 
drug (tislelizumab or placebo) delay principles will be the same with that in Section  5.5.1 ; Oth er 
chemotherapy delay principles will be the same with that in Section  5.5.2 . 
5.5.1.  Dose Delay or Modification for Tislelizumab/Placebo   
There will be no dose reduction for tislelizumab/placebo in this study.  
Dose delays < 12 weeks will be permitted. Investigators should make every effort to maintain 
dose intensity in patients.  
Patients may temporarily suspend study treatment if they experience toxicity that is considered 
related to tislelizumab or placebo and requires a dose to be withheld. If the administration delay is 
≤ 10 days, the delayed drug will be administered; if the delay  is > 10 days, the delayed drug will 
be omitted in this cycle and the next cycle will be administered as planned as long as the AE 
resolves within 21 days. If the study drug (tislelizumab or placebo) delay is > [ADDRESS_500528] be resolved to baseline or Grade 0 to 1 prior to administering the next dose, with 
the exception of alopecia or Grade 2 fatigue  or other stable AEs that are assessed by [CONTACT_397780]’ safety nor influential to the safety evaluation of the 
study drug(s) . A maximum of [ADDRESS_500529] chemotherapy dose administration 
date. If any chemotherapy agent is held for more than 2  cycles (6 weeks) from the anticipated 
treatment date, or the dose level -2 is not tolerated, chemotherapy should be permanently 
discontinued.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 61 Table  3: BGB -A317 -306 Dose Reduction Level of Chemotherapy  
Drug Dose  Level 1 (Standard level)  
(Every 3 weeks as a cycle)   Level -1 Level -2 
Cisplatin  60-80 mg/m2 60 mg/m2 40 mg/m2 
Oxaliplatin  130 mg/m2 100 mg/m2 80 mg/m2 
5-FU 750-800 mg/m2 600 mg/m2 400 mg/m2 
Capecitabine  1000 mg/m2, twice daily  (total  14 days)  750 mg/m2 500 mg/m2 
Paclitaxel  175 mg/m2 135 mg/m2 90 mg/m2 
Dose Modifications for Cisplatin  
A repeat course of cisplatin should not be given until the serum creatinine is below 1.5 mg/100 
mL, and/or the blood urea nitrogen (BUN) is below 25 mg/100 mL. A repeat course should not be 
given until circulating blood elements are at an acceptable level (platelets ≥  100 x 109 /L, white 
blood cell [WBC] ≥ 4 x 109 /L). Subsequent doses of cisplatin should not be given until an 
audiometric analysis indicates that auditory acuity is within normal limits.  
Adverse Event  Recommended Cisplatin Dose  
Serum creatinine ≥ 1.5 mg/100 mL  Hold treatment until serum creatinine 
< 1.5 mg/100 mL  
BUN ≥ 25 mg/100 mL  Hold treatment until BUN < 25 mg/100mL  
Platelets < 100 x 109/L Hold treatment until platelets ≥ 100 x 109/L 
WBC < 4 x 109/L Hold treatment until WBC ≥ 4 x 109/L 
Auditory acuity by [CONTACT_397781]: BUN, blood urea nitrogen; WBC, white blood cell  
Dose Modifications for Oxaliplatin  
Prolongation of infusion from 2 hours to 6 hours may mitigate acute toxicities.  
For patients who experience persistent Grade 2 neurosensory events that do not resolve, a dose 
reduction to 100 mg/m2 should be considered. For patients with persistent Grade 3 neurosensory 
events, discontinuing therapy should be considered. The infusional 5 -FU infusion re gimen need 
not be altered.  
A dose reduction to 100 mg/m2 and infusional 5 -FU to 300 mg/m2 bolus and 500 mg/m2 22-hour 
infusion is recommended for patients after recovery from Grade 3/4 gastrointestinal (despi[INVESTIGATOR_397676]) or grade 4 neutropenia or Grade 3/4 thrombocytopenia. The next dose 
should be delayed until neutrophils are ≥ 1.5 x 109 /L and pla telets are ≥ 75 x 109 /L. 
Adverse Event  Recommended Oxaliplatin Dose  
Neutrophils < 1.5 x 109/L Hold treatment until neutrophils ≥ 1.5 x 109/L 
Platelets < 75 x 109/L Hold treatment until platelets ≥ 75 x 109/L 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 62 In patients with normal renal function or mi ld to moderate renal impairment, the recommended 
dose is 130 mg/m2. In patients with severe renal impairment, the initial recommended dose should 
be reduced to 100 mg/m2. 
Dose Modifications for 5 -Fluorouracil  
5-FU dose modification scheme as described belo w is recommended for the management of 
adverse events.  
Adverse Event  Recommended 5 -Fluorouracil Dose  
Development of angina, myocardial 
infarction/ischemia, arrhythmia, or heart failure in 
patients with no history of coronary artery disease or 
myocardial dysfunction  Hold treatment until resolution  
Hyperammonemic encephalopathy  Hold treatment until resolution  
Acute cerebellar confusion, disorientation, ataxia, or 
visual disturbances  Hold treatment until resolution  
Grade 3 or 4 diarrhea  Hold tr eatment until resolution to 
Grade 2 or lower  
Grade 2 or 3 palmar -plantar erythrodysesthesia 
(hand -foot syndrome)  Hold treatment until resolution to 
Grade 1 or lower  
Grade 3 or 4 mucositis  Hold treatment until resolution to 
Grade 2 or lower  
Grade 4 myelosuppression  Hold treatment until resolution to 
Grade 3 or lower  
Dose Modifications for Capecitabine  
Capecitabine dose modification scheme as described below is recommended for the management 
of adverse reactions.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 63 Toxicity NCIC 
Grades*  During a Course of Therapy  Dose Adjustment for Next Treatment 
(% of starting dose)  
Grade [ADDRESS_500530] appearance  
Interrupt until resolved to Grade 0 -1 100%  
2nd appearance  75% 
3rd appearance  50% 
4th appearance  Discontinue treatment permanently  - 
Grade [ADDRESS_500531] appearance  Interrupt until resolved to Grade 0 -1 75% 
2nd appearance  50% 
3rd appearance  Discontinue treatment permanently  - 
Grade [ADDRESS_500532] appearance  Discontinue permanently  
OR 
If physician deems it to be in the 
patient’s best interest to continue, 
interrupt until resolved to Grade 0 -1 50% 
*National Cancer Institute of Canada (NCIC) Common Toxicity Criteria were used except for the hand -and-foot 
syndrome.  
Dose Modifications for Paclitaxel  
Paclitaxel Dose Modifications for Decreased Neutrophils  
Absolute Neutrophil Count (x 109/L) Paclitaxel Dose  
≥ 1.5 00 (Grade 1)  Dose Level 1  
1.000 – 1.499 (Grade 2)  Hold paclitaxel until recovery to Grade 1 and restart 
paclitaxel at Dose Level -1.  
If no recovery within 3 weeks of planned next cycle, 
consider appropriateness for growth factor support or 
discontinue pa clitaxel.  
0.500 – 0.999 (Grade 3)  Hold paclitaxel until recovery to Grade 1 and restart 
paclitaxel at Dose Level -2.  
Initiate growth factor support  
If no recovery within 3 weeks of planned next cycle 
despi[INVESTIGATOR_61779], discontinue paclitaxel.  
< 0.500 (Grade 4)  Initiate growth factor support  
If absolute neutrophil count < 0.500 for > 7 days 
despi[INVESTIGATOR_61779], discontinue paclitaxel  
If a patient experiences febrile neutropenia or ≥ Grade 2 infection at any time, granulocyte colony 
stimulating factor (G -CSF) should be added initially and in advance of any dose reduction for the 
next cycle of paclitaxel. In the event of a second epi[INVESTIGATOR_239132] ≥ Grade [ADDRESS_500533] epi[INVESTIGATOR_397677] ≥ Grade 2 infection, paclitaxel should be discontinued. Any dose reductions for 
neutropenic fever are permanent.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 64 Paclitaxel Dose Modifications for Decreased Platelet Counts  
Platelet Co unt (x 109/L) Paclitaxel Dose  
> 100  Dose Level 1  
75 - 100 (Grade 1)  Hold until recovery to a platelet count > 100 x 109/L 
Restart paclitaxel at Dose level 1  
50 - 74.999 (Grade 2)  Hold until recovery to a platelet count > 100 x 109/L 
Restart paclitaxel at Dose Level -1 
< 50 (Grade 3)  Hold until recovery to a platelet count > 100 x 109/L 
Restart paclitaxel at dose level -2 
< 25 (Grade 4) with 
clinically significant 
bleeding  Discontinue paclitaxel  
For any grade toxicity, if the platelet coun t does not recover by [CONTACT_397782], 
paclitaxel must be discontinued.  
Paclitaxel Dose Modifications for Neuropathy  
Neuropathy Grade  Recommended Paclitaxel Dose  
Grade 1  Dose Level 1  
Grade 2 lasting > 7 days or  
Grade 3 lasting < 7 days  Hold until neuropathy recovery to Grade 1  
Restart paclitaxel at Dose Level -1 
Grade 3 lasting > 7 days or Grade 4  Discontinue paclitaxel  
All dose reductions for neuropathy are permanent.  
Paclitaxel Dose Modification for Hepatic Impairment  
Degree of Hepatic Impairment  
Recommended Paclitaxel Dose  Transaminase levels   Bilirubin Levels  
< [ADDRESS_500534]  And ≤ 1.[ADDRESS_500535]  Continue dosing at Dose Level 1  
< [ADDRESS_500536]  Hold until recovery to Grade 1  
Restart paclitaxel at Dose Level -1 
< [ADDRESS_500537]  Hold until recovery to Grade 1  
Restart paclitaxel at Dose Level -2 
≥ [ADDRESS_500538]  OR > 5.[ADDRESS_500539]  Discontinue Paclitaxel  
Abbreviation: ULN = upper limit of normal.  
If the liver function test abnormalities do not recover by [CONTACT_319553], paclitaxel must be 
discontinued. All dose reductions for liver function abnormalities are permanent.  
Allergic Reaction/Hypersensitivity  
Patients who experience severe or life -threatening symptoms of hypersensitivity despi[INVESTIGATOR_397678].  
Approved Date 3/13/[ADDRESS_500540] occurrence and 
subsequently dose reduced to the next level once the toxicity has recovered to Grade 0 -1 in 
severity.  
5.5.3.  Blinding   
This is a randomized, double -blind, Phase 3 study. Patients will be randomized to receive 
tislelizumab or match ed placebo in a double -blind fashion such that neither the investigator, nor 
the patient, nor med ical or ancillary medical staff, nor the blinded s ponsor staff or its designees, 
will know which drug is being administered in addition to chemotherapy.  
Every effort should be made to avoid unblinding the patient’s treatment assignment unless 
necessary. U nblinding may be indicated and permissible only in specific situations as described 
below and if it’s necessary for the patient’s welfare. Unblinding would occur through Interactive 
Response Technology (IRT) as per the instructions in the IRT site user man ual. If unblinding has 
occurred, the sponsor must be notified immediately using the Unblinding Event Form. To ensure 
the continued blinding of study personnel, this form will not include the treatment assignment. 
Patients will remain on study for safety fo llow-up and, if applicable, for survival follow -up. 
• Emergency unblinding  
In case of an emergency, such as when a patient has an AE suspected to be related to 
the investigational drug product and for which management of the AE with one or 
more drug products with substantial toxicity or invasive procedures is being 
considered, unblinding can occur. The investigator has the sole responsibility for 
determining if unblinding of a patient’s treatment assignment is warranted. Patient 
safety must always be the first consideration in making such a determination. If the 
investigator decides that unblinding is warranted, the investigator should make every 
effort to inform the medical monitor of their intent before unblinding a patient’s 
treatment assignment unl ess this could delay emergency treatment of the patient. If a 
patient’s treatment assignment is unblinded, the sponsor must be notified immediately .  
The investigator performs the emergency unblinding for AEs through an IRT System. 
Unblinded patients may r emain on study treatment at the discretion of the investigator 
in consultation with the medical monitor and only as permissible per definitions in the 
study protocol.  
• Non-Emergency  Unblinding  
Non-emergency unblinding to Tislelizumab versus placebo adminis tration may occur 
on an individual patient basis and only after consultation with and approval from the 
medical monitor at the time of 1) documented disease progression and the patient has 
discontinued all study treatments, or 2) when the patient has disco ntinued all study 
treatments for toxicity and a new anticancer treatment is going to be started.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 66 • Inadvertent unblinding  
Every effort will be made to blind both the patient and the investigator to the identity 
of tislelizumab or placebo, but the inadverten t unblinding of a patient may occur. If an 
investigator, site personnel performing assessments, or patient is unblinded, the 
unblinding will not be sufficient cause (in and of itself) for that patient to be 
discontinued from study therapy or excluded from any safety or efficacy analyses.  
• Unblinding after interim  analysis  per IDMC recommendation  
Sponsor, i nvestigators  and site personnel, and patients will be unblinded to treatment 
arms a fter the preplanned interim  analysis  if a recommendation  is made by  [CONTACT_397783] .  Placebo administration will be discontinued after the 
unblinding.  Crossover between the treatment arms will not be allowed.  
On 20  April 2022, upon reviewing the efficacy and safety data of preplanned interim analysis,  
IDMC confirmed that the study met  the specified 1-sided p -value boundary for superiority  of the 
primary endpoin t and recommended to unblind/unmask the study due to compelling efficacy. The 
sponsor accepted  the IDMC recommendation , and the study w as unblinded after the interim 
analysis . An instruction was provided to investigators to discontinue placebo  in Arm B  after the 
unblinding.  
Approved Date 3/13/[ADDRESS_500541] concomitant medications and therapi[INVESTIGATOR_397679] (eg, anti -emetics, 
antidiarrheals) and in a patient’s interest are allowed. Opi[INVESTIGATOR_397680]. Patients must notify the investigator of all 
concurrent medications used during the study.   
Systemic corticosteroids given for the control of i mAEs must be tapered gradually (see 
Appendix  7) and be at non -immunosuppressive doses (≤ 10 mg/day of pr ednisone or equivalent) 
before the next tislelizumab administration. The short -term use of steroids as prophylactic 
treatments (eg, patients with contrast allergies to diagnostic imaging contrast dyes) is permitted.  
Patients with active hepatitis B define d as HBV DNA  ≥ 500 IU/mL  at screening must initiate 
treatment [ADDRESS_500542] dose, or per 
local guidelines/clinical practice. Patients should continue effective antiviral treatment during the 
study  to decrease potential viral re -activation risk. Tenofovir and entecavir are recommended in 
the American Association for the Study of Liver Disease (AASLD) guideline because they lack 
resistance with long -term use ( Terraul t et al 2018 ; AASLD/IDSA HCV Guidance Panel 2015 ). 
Management of antiviral therapy is at the discretion of the investigator; however, reason(s) must 
be provided in the eCRF if a patient with active hepatitis B is not treated with a ntiviral 
prophylaxis.  
BeiGene does not require patients with active hepatitis C to receive treatment with antiviral 
therapy. Patients with detectable HCV RNA and who are receiving treatment at screening should 
remain on continuous, effective antiviral ther apy during the study. Investigators can consider 
treatment with sofosbuvir alone or in combination with other antivirals following the AASLD 
guideline or the local guidelines as appropriate. However, interferon -based therapy for either 
HBV or HCV is not pe rmitted on study. Patients who are given antiviral therapy must initiate 
treatment at least 2 weeks prior to randomization.  
Palliative (limited -field) radiation therapy is permitted, but only for pain control or prophylaxis of 
bone fracture to sites of bon e disease present at baseline provided the following criteria are met:  
• Repeat imaging demonstrates no new sites of bone metastases  
• The lesion being considered for palliative radiation is not a target lesion for RECIST v1.1  
• The case is discussed with the medical monitor, and the medical monitor agrees that the 
conditions required to receive palliative radiation are met  
• Additionally, palliative radiation or other focally ablative therapy for other non -target sites 
of the disease is permitted if clinically i ndicated per investigator’s discretion and after 
consultation with the medical monitor. Whenever possible, these patients should have a 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 68 tumor assessment of the lesion(s) before receiving the radiotherapy to rule out progression 
of disease.  
6.1.2.  Prohibited Conco mitant Medications/Procedures   
The following medications are prohibited during the study:  
• Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, 
immunotherapy [including IL -2, interferon, thymosin , etc.] or standard or investigational 
agents [including Chinese herbal and patent medicines] for the treatment of cancer) is not 
allowed.  
• Live vaccines within [ADDRESS_500543] dose of study drug(s).  
• Herbal remedies with immune -stimulating properties (ie, mistletoe extract) or that are 
known to potentially interfere with liver or other major organ functions (ie, hypericin). 
Patients must notif y the investigator of all herbal remedies used during the study.  
6.1.3.  Restricted Concomitant Medications/Procedures   
The following medications are restricted during the study:  
• Immunosu ppressive agents (except to treat a drug -related AE).  
• Systemic corticosteroids > 10 mg daily (prednisone or equivalent), except to treat or 
control a drug related AE (per protocol) or for short -term use as prophylactic treatment.  
• Patients should avoid alcohol abuse or any other drug abuse during the study.  
• Use of potentially hepatotoxic drugs in patients with impaired hepatic function should be 
carefully monitored.  
• Radiation therapy is not allowed, except for palliative radiation therapy described in 
Section  6.1.1 . 
6.2. Potential Interactions Between the Study Drugs and Concomitant 
Medications   
• Tislelizumab  
The potential for drug -drug interaction between the study drug (tislelizumab) and 
small -molecule drug products is very low, given that tislelizumab is a therapeutic 
monoclonal antibody. Because tislelizumab is expected to be  degraded into amino 
acids and recycled into other proteins, it is unlikely to have an effect on drug 
metabolizing enzymes or transporters.  
• Cisplatin  
Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin 
therapy. In a randomized  trial in advanced ovarian cancer, response duration was 
adversely affected when pyridoxine was used in combination with altretamine 
(hexamethylmelamine) and cisplatin. Ototoxic medicinal products will potentiate toxic 
Approved Date 3/13/[ADDRESS_500544] Characteristics (SmPC) for all potential 
interactions with cisplatin.  
• Oxaliplatin  
No specific cytochrome P -450-based drug interaction studies have been conducted. 
Increases of 5 -FU plasma concentrations by [CONTACT_3450] 20% have been observed 
with doses of 130 mg/m2 dosed every 3 weeks. Because platinum -containing species 
are eliminated primarily through the kidney, clearance of these products may be 
decreased by [CONTACT_397784]; although this has 
not been specifically studied. The investigator should refer to the most current 
oxaliplatin SmPC for all potential interactions with oxaliplatin.  
• 5-Fluorouracil  
Elevated coa gulation times have been reported in patients taking fluorouracil 
concomitantly with warfarin. While pharmacokinetic data are not available to assess 
the effect of fluorouracil administration on warfarin pharmacokinetics, the elevation of 
coagulation times  that occurs with the fluorouracil prodrug capecitabine is 
accompanied by [CONTACT_397785]. Thus, the interaction may be 
due to inhibition of cytochrome P450 2C9 by [CONTACT_397786].  The 
investigator should refer to the  most current 5 -fluorouracil SmPC for all potential 
interactions with 5 -fluorouracil.  
• Capecitabine  
Altered coagulation parameters and/or bleeding have been reported in patients taking 
capecitabine concomitantly with coumarin -derivative anticoagulants such as warfarin 
and phenprocoumon. These events occurred within several days and up to several 
months after initiating capecitabine therapy and, in a few cases, within 1 month after 
stoppi[INVESTIGATOR_397681]. These events occurred in patients with and without live r 
metastases. In a drug interaction study with single -dose warfarin administration, there 
was a significant increase in the mean AUC of S -warfarin. The maximum observed 
international normalized ratio ( INR) value increased by 91%. This interaction is 
probab ly due to an inhibition of cytochrome P450 2C9 by [CONTACT_397787]/or its 
metabolites. The level of phenytoin should be carefully monitored in patients taking 
capecitabine and phenytoin dose may need to be reduced. Post -marketing reports 
indicate that some  patients receiving capecitabine and phenytoin had toxicity 
associated with elevated phenytoin levels. Formal drug -drug interaction studies with 
phenytoin have not been conducted, but the mechanism of interaction is presumed to 
be inhibition of the CYP2C9 isoenzyme by [CONTACT_397787]/or its metabolites. Other 
than warfarin, no formal drug -drug interaction studies between capecitabine and other 
CYP2C9 substrates have been conducted. Care should be exercised when capecitabine 
is co-administered with CYP2C9 s ubstrates. The investigator should refer to the most 
current capecitabine SmPC for all potential interactions with capecitabine.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 70 • Paclitaxel  
Caution should be exercised for patients receiving paclitaxel concomitantly with 
substrates, inhibitors or inducers of CYP2C8 or CYP3A4. The metabolism of 
paclitaxel is catalyzed by [CONTACT_9058] P450 isoenzymes CYP2C8 and CYP3A4. 
Caution should be exercised when paclitaxel is concomitantly administered with 
known substrates (eg, midazolam, buspi[INVESTIGATOR_5331], felodipi[INVESTIGATOR_050], lovastati n, eletriptan, 
sildenafil, simvastatin, and triazolam), inhibitors (eg, atazanavir, clarithromycin, 
indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and 
telithromycin), and inducers (eg, rifampin and carbamazepi[INVESTIGATOR_050]) of C YP3A4. Caution 
should also be exercised when paclitaxel is concomitantly administered with known 
substrates (eg, repaglinide and rosiglitazone), inhibitors (eg, gemfibrozil), and inducers 
(eg, rifampin) of CYP2C8. Potential interactions between paclitaxel,  a substrate of 
CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), 
which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical 
trials.  The investigator should refer to the most current paclitaxel S mPC for all 
potential interactions with paclitaxel.  
• COVID -19 vaccine  
Potential immune reactivity to the coronavirus disease 2019 ( COVID -19) vaccine in 
patients concurrently receiving checkpoint inhibitors or other immune -oncologic 
treatments cannot be rule d out, but current data suggest that instances are rare. As 
additional data emerge, the approach will be modified accordingly.  
Approved Date 3/13/[ADDRESS_500545] values (that must be 
available before any dosing) have been reviewed and found to be a cceptable per protocol 
guidelines.  
7.1. Screening   
Screening evaluations will be performed within [ADDRESS_500546] (refer to Appendix  1 for details). Screening evaluations may be repeated as needed 
within the screening period; the investigator is to assess patient eligibility according to the latest 
screening assessment results.  
Results of standard of care tests or examinations performed prior to obtaining informed consent 
and ≤  [ADDRESS_500547] of care tests unless otherwise indicated (only applicable if the same 
radiographic procedure will be used throughout the study).  
Procedures conducted during Screening only are described in this section. For the description of 
other assessments tha t are conducted during screening, as well as throughout the study, refer to 
Safety Assessments (Section  7.4), Tumor and Response Evaluations (Secti on 7.5) and Biomarkers 
(Section  7.8) sections. The PK sampling schedule is shown in Appendix  1. 
Rescreening under limi ted conditions may be allowed after consultation with BeiGene (eg, when a 
patient narrowly misses a laboratory criterion and it is correctable and not due to rapi[INVESTIGATOR_397682]). Rescreening is allowed only once.  
7.1.1.  Demogra phic Data and Medical History   
Demographic data will include age or year of birth, gender, and self -reported race/ethnicity.  
Medical history includes any history of clinically si gnificant disease, surgery, or cancer history; 
reproductive status (ie, of childbearing potential or no childbearing potential); history of alcohol 
consumption and tobacco (ie, former or current or never); and all medications (eg, prescription 
drugs, over -the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by 
[CONTACT_25701] [ADDRESS_500548] response , and reason for discontinuation. Cancer 
symptoms that are present at baseline will be recorded and assessed for severity using the 
NCI-CTCAE v4.03 criteria. Radiographic studies performed prior to study entry may be collected 
for review by [CONTACT_093].  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 72 7.1.2.  Females of Childbearing Potential and Contraception   
Childbearing potential is defined as being physiologically capable of becoming pregnant. Refer to 
Appendix  9 for contraception guidelines and defi nitions of “women of childbearing potential” and 
“no childbearing potential”  
7.1.3.  Informed Consent and Screening Log   
Voluntary, written informed consent for participation in the stud y must be obtained before 
performing any study -specific procedures.  Informed consent forms for enrolled patients and for 
patients who are screened but not enrolled will be maintained at the study site.  
All screening evaluations must be completed and revi ewed to confirm that patients meet all 
eligibility criteria before randomization. The investigator will maintain a screening log to record 
details of all patients screened and to confirm eligibility or record reasons for screening failure, as 
applicable.  
7.1.4.  Pulmonary Function Tests   
Patients who are suspected or known to have serious/severe respi[INVESTIGATOR_397683] a history of thoracic 
radiotherapy will undergo  pulmonary function testing which may include, but is not limited to, 
spi[INVESTIGATOR_397684].  
7.2. Enrollment   
7.2.1.  Confirmation of Eligibility   
The investigator will assess and confirm the el igibility of each patient. All screening procedure 
results and relevant medical history must be available before eligibility can be determined. All 
inclusion criteria must be met and none of the exclusion criteria may apply. No eligibility waivers 
will be granted.   
After a patient is screened and the investigator determines the patient is eligible for 
randomization, study site personnel will complete an Eligibility Authorization Packet and send it 
to the medical monitor or designee to confirm eligibility b efore the enrollment. Study site 
personnel should ensure that a medical monitor’s confirmation has been received before 
randomization.  
7.2.2.  Patient Numbering   
After obtaining informed consent, study site personnel will access the Interactive Response 
Technology (IRT) system to assign a unique patient number to a potential study participant.   
7.2.3.  Enrollment/Randomization   
Site personnel will access the IRT system to randomize to treatment assignment and to assign 
study drugs. Study treatment must commence within 2  business days after 
randomization/treatment assignment.   
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 73 7.3. Tislelizumab and Comparator Drug Dispensation   
Depending on the treatment arm and preferred chemotherapy doublet, tislelizumab (or matched 
placebo), cisplatin, oxaliplatin, 5 -FU, capecitabine, and paclitaxel will  be dispensed and 
administered as described in Section 5.2. 
7.4. Safety Assessments   
7.4.1.  Vital Signs   
Vital signs will include measurements of body temperature (˚C), pulse rate and blood pressure 
(systolic and diastolic) while the patient is in a seated position after resting for 10  minutes.    
7.4.2.  Physical Examinations   
During Screening, a complete physical examination will be conducted including evaluations of 1) 
head, eyes, ears, nose, throat, 2) cardiovascular, 3) dermatological, 4) musculoskeletal, 5) 
respi[INVESTIGATOR_696], 6) gastrointesti nal, and 7) neurological systems. Any abnormality identified during 
screening will be graded according to NCI -CTCAE v4.03 and recorded on the eCRF with 
appropriate disease/condition terms.  
At subsequent visits (and as clinically indicated), limited, sympt om-directed physical 
examinations will be performed.  Changes from baseline will be recorded. New or worsened 
clinically significant abnormalities are to be recorded as AEs on eCRF. Refer to Section  8.3 
regarding AE definitions and reporting and follow -up requirements.  
[IP_ADDRESS].  Ophthalmologic Examination   
Due to an increased risk of o phthalmologic adverse events in patients receiving PD -1 inhibitors 
(including, but not limited to uveitis and retinal disorders), eye exam, visual acuity test, and 
optical coherence tomography (or equivalent diagnostic test) will be assessed by [CONTACT_397788]. Eye exam, visual acuity test, and optical coherence tomography (or 
equivalent diagnostic test for retinal examination) captured as standard of care prior to obtaining 
written informed consent and within [ADDRESS_500549] 
approximately every 15 weeks (± 7 days) during study treatment and a final assessment at the 
EOT/Safety follow -up visit, [ADDRESS_500550] will be made for further management guidance (see 
Appendix  7). 
7.4.3.  Eastern Cooperative Oncology Group Performance Status   
ECOG Performance Status ( Appendix  3) will be assessed during the study.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 74 7.4.4.  Laboratory Safety Tests   
Local and/or central laborat ory assessments of serum chemistry, hematology, coagulation, and 
urinalysis will be conducted, of which certain elements will be collected as specified in 
Appendix  2.  
If laboratory tests at screening are not performed within 7 days prior to the administration of study 
drug(s) on Cycle 1 Day 1, these tests should be repeated and reviewed before study drug(s) 
administration. Hematology and serum chemi stry (including liver function tests) as specified in 
Appendix  [ADDRESS_500551] 3 cycles and at the beginning of subsequent 
cycles. After Cycle 1, results are to be reviewed within 48 hours before study drug administration.  
Details about sample collection and shipment will be provided in a sep arate instruction manual. 
Investigators may use results from local laboratories for assessing eligibility, safety monitoring 
and dosing decision.   
7.4.5.  Cardiac Enzyme Monitoring   
Although immune -mediated myocarditis is a rare complication of immune checkpoint inhibitors, 
serum creatinine kinase (CK) and CK cardiac isoenzyme (CK -MB) are monitored in all 
tislelizumab studies to protect study participants and to quantify the risk of muscl e inflammation 
(see Appendix  1 for the blood collection schedule and Appendix  7 for guidelines for management 
of suspected immune -mediated myocarditis). Serum troponins may be substituted per local 
guidelines if used consistently throughout the study.  
7.4.6.  Electrocardiograms   
For safety monitoring purposes, the investigator must review, sign, and date all ECG tracings. 
Paper or electronic copi[INVESTIGATOR_26650]'s permanent study 
file at the site.  
Patients should rest for at least 10  minutes prior to ECG collection.  
7.4.7.  Adverse Events   
AEs will be graded and recorded throughout the study according to NCI -CTCAE, v4.03. 
Characterization of toxicities will include severity, duration, and time to onset.  
All AEs, including SAEs, will be collected as described in Section  8.6. 
7.4.8.  Hepatitis B and C Testing   
Testing will be performed by a central laboratory and/or the  local laboratory at screening and will 
include HBV/HCV serology (HBsAg, hepatitis B surface antibody [HBsAb], hepatitis B core 
antibody [HBcAb], and HCV antibody). If HBsAg or HBcAb is positive, then an HBV DNA test 
will be triggered. If HCV antibody is p ositive, an HCV RNA test will be triggered.  
Patients who have detectable HBV DNA or HCV RNA at screening will have the viral load 
retested every 4 cycles.  
Approved Date 3/13/[ADDRESS_500552] of 
care tests or examinations performed prior to obtaining informed consent and ≤ [ADDRESS_500553] of 
care tests (only applicable if the same radiographic procedure will be used throughout the study). 
During the study, tumor imaging will be performed every 6 weeks (± 7 days) for the first 
48 weeks, then every  9 weeks (± 7 days) after [ADDRESS_500554] include computed tomography (CT) 
scans (with oral/IV contrast, unless contraindicated) or magnetic resonance imaging (MRI) of the 
chest, abdomen, and neck. Other known or suspected sites of disease must be included in the 
imaging assessments (pelvis, brain, etc.).  
Tumor assessments must include CT scans (with oral/IV contrast, unless contraindicated) or MRI, 
with preference for CT, of the neck, chest, and abdomen. All measurable and evaluable lesions 
should be assessed and documented at the Sc reening Visit and reassessed at each subsequent 
tumor evaluation. The same radiographic procedure used to assess disease sites at screening are 
required to be used throughout the study (eg, the same contrast protocol for CT scans). All known 
sites of disea se must be documented at screening and reassessed at each subsequent tumor 
evaluation.  
• Any patient with a history of CNS metastases will be required to undergo CT/MRI at 
baseline to ensure all sites of disease are evaluated per RECIST v1.[ADDRESS_500555]/MRI will be required to be treated for 
brain metastasis with standard of care treatments and be off corticosteroids prior to study 
entry.  
• If a patient is known to have a contraindicat ion to CT contrast media or develops a 
contraindication during the study, a non -contrast CT of the chest plus a contrast -enhanced 
MRI (if possible) of abdomen and neck should be performed.  
• If a CT scan for tumor assessment is performed in a positron emiss ion tomography 
(PET)/CT scanner, the CT acquisition must be consistent with the standards for a 
full-contrast diagnostic CT scan.  
• Bone scans (Technetium -99m [Tc -99m]) or PET should be performed at Screening if 
clinically indicated. If bone metastases are p resent at Screening and cannot be seen on CT 
or MRI scans afterwards, TC -99m or PET bone scans should be conducted when a 
complete response (CR) is suspected in target lesion.  
• CT scans of the extremities  should also be performed if clinically indicated and  followed 
throughout the study, if there is evidence of metastatic disease in these regions at 
Screening. At the investigator’s discretion, other methods of assessment of target lesion 
and nontarget lesions per RECIST v1.[ADDRESS_500556] v1.1 (see Appendix  4). 
The same evaluator should perform assessments, if possible, to ensure inter nal consistency across 
Approved Date 3/13/[ADDRESS_500557] be met in 
order to treat patients with suspected pseudoprogression  or confirmed evidence of disease 
progression :  
• Absence of clini cal symptoms and signs of disease progression (including clinically 
significantly worsening of laboratory values)  
• Stable ECOG performance status ≤ 1  
• Absence of rapid progression of disease or of progressive tumor at critical anatomical sites 
(eg, cord com pression) that requires urgent alternative medical intervention  
• Investigators must obtain written informed consent for treatment beyond radiologic 
disease progression and inform patients that this practice is not considered standard in the 
treatment of can cer.  
The decision to continue study drug(s) beyond initial investigator -assessed progression must be 
agreed with the sponsor medical monitor and documented in the study records.  
Tumor assessment should continue as planned in patients receiving study drug( s) beyond initial 
investigator -assessed progression. Tumor assessment in such patients should continue until study 
treatment discontinuation.  
Patients who discontinue study treatment early for reasons other than documented radiographic  
disease progression (eg,  toxicity) will continue to undergo tumor assessments following the 
original plan until the patient experiences disease progression, withdraws consent, is lost to 
follow -up, or dies , or until the study terminates, whichever occurs first.  
Tumor assessments are required to be performed on schedule regardless of whether study 
treatment has been administered or held.  That is, assessments should not be adjusted for delays in 
cycles.  
7.6. Pharmacokinetic and Anti -Drug Antibody Testing   
Tislelizumab may elicit an immune response. Patients with signs of any potential immune 
response to tislelizumab will be closely monitored. Validated screening and confirmatory assays 
will be employed to detect ADAs at multiple time points throughout the study (see Appendix  1). 
The immunogenicity evaluation will utilize a risk -based immunogenicity strategy ( Koren et al 
2008 ; Worobec and Rosenberg 2004a ; Worobec and Rosenberg 2004b ) to characterize ADA 
responses to tislelizum ab in support of the clinical development program. This tiered strategy will 
include an assessment of whether ADA responses correlate with relevant clinical endpoints. 
Implementation of ADA characterization assays will depend on the safety profile and clin ical 
immunogenicity data.  
The following assessments will be performed at a central laboratory:  
• ADA assays: serum samples will be tested for the presence of ADAs to tislelizumab using 
a validated immunoassay  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 77 • PK assay: serum samples will be assayed for tis lelizumab concentration with use of a 
validated immunoassay  
• PK and ADA samples collected from patients randomized to receive placebo will not be 
analyzed.  
Shippi[INVESTIGATOR_007], storage, and handling of samples for the assessment of tislelizumab PK and ADA 
assays will be managed through a central laboratory. Instruction manuals and supply kits will be 
provided for all central laboratory assessments.  
7.7. On-Study Biopsies   
If an on -study biopsy is performed for any reason while any patient is actively participating in the 
study, key histologic findings by [CONTACT_397789]. This information includes, at 
a minimum: date, type of biopsy (e.g. needle, surgical, etc.), location, and findings/results. This 
information will be collected regardless of whether the patient is actively receiving study 
treatment.  
7.8. Biomarkers   
Shippi[INVESTIGATOR_007], storage, and handling of blood, archival tumor, fresh tumor, and leftover tumor tissue 
for the assessment of biomarkers will be managed through a central laboratory. Ref er to the 
laboratory manual for details of sample handling.  
Archival tumor tissues (formalin -fixed paraffin -embedded block or approximately 15 [ at least 6 ] 
unstained slides) need to be sent to central laboratory for central immunohistochemistry assay of 
PD-L1 status. In the  PD-L1 vCPS  ≥ 10% population , PD-L1 expression will be assessed centrally 
using the  VENTANA PD‑L1 (SP263) assay . The vCPS is the total percentage of the tumor area  
covered by [CONTACT_397765] -L1 membrane staining and tumor‑associated immune cells with 
PD-L1 staining at any intensity.  In addition to PD -L1 expression, other exploratory biomarkers 
consisting of  gene expression profiling (GEP), tumor -infiltrating lymphocytes (TIL), 
TMB/MSI/gene mutation profile  that are related to response  or clinical benefit of tislelizumab  in 
combination with chemotherapy  may also be evaluated. Other assessments may be conducted as 
allowed by [CONTACT_427].   
If no archival samples are available, a fresh tumor biopsy at baseline (within 28 days before 
randomization) is needed. For fresh biopsy specimens, acceptable samples include core needle 
biopsies for deep tumor tissue or excisional, incisional, punch, or f orceps biopsies for cutaneous, 
subcutaneous, or mucosal lesions.  
An optional biopsy will also be taken for the patients who have confirmed disease progression 
during the study from accessible tumor sites to obtain samples to explore resistance mechanisms . 
If feasible, any follow -up biopsy should be ideally taken from the same tumor lesion as the 
baseline biopsy. Written patient consent is required for fresh tumor biopsies.   
Tumor tissue should be of good quality based on total and viable tumor content. Fin e-needle 
aspi[INVESTIGATOR_1516], brushing, cell pellets from pleural effusion, and lavage samples are not acceptable.  
Blood samples will be taken at baseline (predose on Day 1 of Cycle 1) for all randomized patients 
to explore the association of blood -based biomarkers  with response and prognosis to tislelizumab 
in combination with chemotherapy or chemotherapy alone. Blood samples are highly 
Approved Date 3/13/[ADDRESS_500558] tumor response (CR/PR) and/or at confirmed disease 
progression  to explore response and/or res istance mechanism to  tislelizumab in combination with 
chemotherapy or chemotherapy alone. Written patient consent is required for optional blood 
sample collections.  Blood -based b iomarkers consist of TMB /MSI/gene mutation profile . Other 
assessments may be c onducted as allowed by [CONTACT_427].  
7.9. Patient -Reported Outcomes   
Patients will be asked to complete the EORTC QLQ -C30, EORTC  QLQ -OES 18, and EQ -5D-5L 
questionnaires before any clinical activities are performed during on -study clinic visits according 
to the schedule in Appendix  1. The questionnair es will be provided in the patient’s preferred 
language.  
7.10. Visit Windows   
All visits must occur within ± 3 days from the scheduled date, unless otherwise noted (see 
Appendix  1). All assessments will be performed on the day of the specified visit unless an 
acceptable time window is specified. Assessments scheduled on the day of study treatment 
administration (Day 1) of each cycle should be performed prior to study treatment infusion/dose 
unless otherwise noted. Laboratory results are required to be reviewed prior to dosing.  
If the timing of a protocol -mandated study visit coincides with a holiday, weekend, or justifiable  
events, the visit should be scheduled on the nearest feasible date (the visit window is provided in 
Appendix  1), with subsequent visits conducted according to the planned schedule Q3W from 
Cycle  [ADDRESS_500559] rescheduled date if resynchronization happens . 
7.11. Unscheduled Visits   
Unscheduled visits may be performed at any time at the patient’s or the investigator’s request and 
may include vital signs/focused physical examination; ECOG performance status; AE review; 
concomitant medications and procedures review; radiogra phic assessments; physical examination 
of liver, spleen, and lymph nodes; review of disease -related constitutional symptoms; and 
hematology and chemistry laboratory assessments. The date and reason for the unscheduled visit 
must be recorded in the source d ocumentation.   
If an unscheduled visit is necessary to assess toxicity or for suspected disease progression, then 
diagnostic tests may be performed based on the investigator assessment as appropriate, and the 
results of these tests should be entered on th e unscheduled visit eCRF.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 79 8. SAFETY MONITORING AND REPORTING   
The investigator is responsible for the monitoring and documentation of events that meet the 
criteria and definition of an AE or SAE as provided in this protocol.  
8.1. Risks Associated with Study Drugs   
8.1.1.  Risks Associated with Tislelizumab   
Tislelizumab is an investigational agent that is currently in clinical development. The following 
recommendation is based o n results from nonclinical and clinical studies with tislelizumab and 
published data on other molecules within the same biologic class.  
The PD -L1/PD -[ADDRESS_500560] is involved in peripheral immune tolerance; therefore, such therapy 
may increase the risk of imAEs, specifically the induction or enhancement of autoimmune 
conditions. AEs observed with anti -PD-[ADDRESS_500561] been mild and self -limiting, 
such events should be recognized early and treated promptly to avoid potential major 
complications. Suggested evaluation and management guidelines  for suspected imAEs are 
provided in Appendix  7. 
8.1.2.  Risks Associated with Comparator Drugs   
Selected risks for each chemotherapy are listed below. Please refer to the package 
insert/prescribing information for each drug for more information.  
Cisplatin  
Cisplatin produce s cumulative nephrotoxicity which is potentiated by [CONTACT_210575]. 
The serum creatinine, BUN, creatinine clearance, and magnesium, sodium, potassium, and 
calcium levels should be measured prior to initiating therapy, and prior to each subseque nt course. 
At the recommended dosage, cisplatin should not be given more frequently than once every 3 to 4 
weeks. Elderly patients may be more susceptible to nephrotoxicity. A urine output of 100 
mL/hour or greater will tend to minimize cisplatin nephrotox icity. This can be accomplished by 
[CONTACT_397790], before and after treatment.  
There are reports of severe neuropathies in patients in whom regimens are employed using higher 
doses of cisplatin or greater dose frequencies than those recommended. These neuropathies may 
be irreversible and are seen as paresthesias in a stocking -glove d istribution, areflexia, and loss of 
proprioception and vibratory sensation. Elderly patients may be more susceptible to peripheral 
neuropathy.  
Loss of motor function has also been reported.  
Anaphylactic -like reactions to cisplatin have been reported. The se reactions have occurred within 
minutes of administration to patients with prior exposure to cisplatin, and have been alleviated by 
[CONTACT_121197][INVESTIGATOR_238], corticosteroids, and antihistamines.  
Ototoxicity has been observed in patients treated wit h a single dose of cisplatin. Hearing loss can 
be unilateral or bilateral and tends to become more frequent and severe with repeated doses; 
however, deafness after initial dose of cisplatin has been reported rarely. It is unclear whether 
Approved Date 3/13/[ADDRESS_500562] to the fetus. 
Patients should be advised to avoid becoming pregnant.  
The development of acute leukemia coincident with the use of cisplatin has been reported. In 
these reports, cisplatin was generally given in combination with other leukemogenic agents.  
Injection site reactions may occur during the administration of cisplatin. Given the possibility of 
extravasation, it is recommended to closely monitor the infusion site for possible infiltration 
during drug administration. A specific  treatment for extravasation reactions is unknown at this 
time.  
Oxaliplatin  
Grade 3/4 hypersensitivity to oxaliplatin, including anaphylactic/anaphylactoid reactions, has been 
observed in 2 to 3% of colon cancer patients ( Oxaliplatin prescribing information ). These allergic 
reactions which can be fatal, can occur within minutes of administration and at any cycle, and 
were similar in nature and severity to those reported with other platinum -containing c ompounds, 
such as rash, urticaria, erythema, pruritus, and, rarely, bronchospasm and hypotension. Symptoms 
associated with hypersensitivity reactions reported in previously untreated patients included 
urticaria, pruritus, flushing of the face, diarrhea ass ociated with oxaliplatin infusion, shortness of 
breath, bronchospasm, diaphoresis, chest pains, hypotension, disorientation , and syncope. These 
reactions are usually managed with standard epi[INVESTIGATOR_238], corticosteroid, antihistamine therapy, 
and require disc ontinuation of therapy.  Rechallenge is contraindicated in these patients. Drug -
related deaths associated with platinum compounds from anaphylaxis have been reported.  
Oxaliplatin is associated with 2 types of neuropathy: acute, reversible, primarily periph eral 
sensory neuropathy and persistent (> 14 days) primarily peripheral sensory neuropathy.   
• Acute, reversible, primarily peripheral, sensory neuropathy has an early onset (occurring 
within hours or 1 to 2 days of dosing), resolves within [ADDRESS_500563]  also been observed. 
The acute, reversible pattern of sensory neuropathy was observed in about 56% of study 
patients who received oxaliplatin with 5 -FU/leucovorin. In any individual cycle acute 
neurotoxicity was observed in approximately 30% of patients. I n adjuvant patients, the 
median cycle of onset for Grade 3 peripheral sensory neuropathy was 9, and in previously 
treated patients, the median number of cycles administered on the oxaliplatin with 
5FU/leucovorin combination arm was 6. An acute syndrome of pharyngolaryngeal 
dysesthesia, seen in 1  to 2%  (Grade  3/4) of previously untreated and treated patients with 
advanced colorectal cancer, is characterized by [CONTACT_397791], without any laryngospasm or bronchospasm (no stridor  or wheezing). Ice 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 81 (mucositis prophylaxis) should be avoided during the infusion of oxaliplatin because cold 
temperature can exacerbate acute neurological symptoms.   
• Persistent (> 14 days), primarily peripheral, sensory neuropathy is usually characterized  by 
[CONTACT_227790], dysesthesias, and hypoesthesias, but may also include deficits in 
proprioception that can interfere with daily activities (eg, writing, buttoning, swallowing, 
and difficulty walking from impaired proprioception). These forms of neuropathy  occurred 
in 48% of study patients receiving oxaliplatin with 5FU/leucovorin. Persistent neuropathy 
can occur without any prior acute neuropathy event.  Most patients (80%) who developed 
Grade 3 persistent neuropathy progressed from prior Grade 1 or 2 even ts. These symptoms 
may improve in some patients upon discontinuation of oxaliplatin. Peripheral sensory 
neuropathy was reported in adjuvant patients treated with the oxaliplatin combination with 
a frequency of 92% (all grades) and 13% (Grade 3). At the [ADDRESS_500564] 
treatment cycle, 60% of all patients had any grade (Grade  1: 40%; Grade 2: 16%; Grade 3: 
5%) peripheral sensory neuropathy decreasing to 39% at 6 months of follow -up (Grade 1: 
31%; Grade  2: 7%; Grade 3: 1%) and 21% at 18 months  of follow -up (Grade  1: 17%, 
Grade 2: 3%, Grade 3: 1%). Overall, neuropathy (all grades) was reported in 82% of 
previously untreated patients with advanced colorectal cancer (19% had Grade  3/4 
neuropathy), and in 74% of previously treated patients (7% had Grade 3/4 neuropathy). 
Information regarding reversibility of neuropathy was not available from the trial for 
patients who had not been previously treated for colorectal cancer.  
Reversible Posterior Leukoencephalopathy Syndrome (RPLS, also known as Posteri or Reversible 
Encephalopathy Syndrome [PRES]) has been observed in clinical trials (< 0.1%) and 
postmarketing experience. Signs and symptoms of RPLS can include headache, altered mental 
functioning, seizures, abnormal vision from blurriness to blindness, w hich may be associated with 
hypertension. Diagnosis of RPLS is based upon confirmation by [CONTACT_14548].  
Oxaliplatin has been associated with pulmonary fibrosis (<1% of study patients), which may be 
fatal. In adjuvant colon cancer patients, the combined in cidence of cough and dyspnea was 7.4% 
(any grade) and <1% (Grade 3) with no Grade 4 events in the oxaliplatin plus infusional 
5-FU/leucovorin arm compared to 4.5% (any grade) and no Grade 3 and 0.1% Grade 4 events in 
the infusional 5 -FU/leucovorin alone ar m. In this study, 1 patient died from eosinophilic 
pneumonia in the oxaliplatin combination arm. In patients with previously untreated colorectal 
cancer, the combined incidence of cough, dyspnea and hypoxia was 43% (any grade) and 7% 
(Grade 3 and 4) in the  oxaliplatin plus 5 -FU/leucovorin arm compared to 32% (any grade) and 5% 
(Grade 3 and 4) in the irinotecan plus 5 -FU/leucovorin arm of unknown duration. In case of 
unexplained respi[INVESTIGATOR_397685] -productive cough, dyspnea, crackles, or 
radiolo gical pulmonary infiltrates, oxaliplatin should be discontinued until further pulmonary 
investigation excludes interstitial lung disease or pulmonary fibrosis.  
Hepatotoxicity was observed more commonly in the oxaliplatin combination arm than in the 
control  arm, as evidenced in the adjuvant study by [CONTACT_79936] (57% vs 34%, 
respectively) and alkaline phosphatase (42% vs 20%, respectively). The incidence of increased 
bilirubin was similar on both arms.  Changes noted on liver biopsies include pe liosis, nodular 
regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis, and veno -occlusive 
lesions. Hepatic vascular disorders should be considered, and if appropriate, should be 
Approved Date 3/13/[ADDRESS_500565] res ults or portal hypertension which cannot be 
explained by [CONTACT_397792].  
Oxaliplatin may cause fetal harm when administered to a pregnant woman. There are no adequate 
and well -controlled studies of oxaliplatin in pregnant women. Women of childbearing pot ential 
should be advised to avoid becoming pregnant while receiving treatment with oxaliplatin.  
5-Fluorouracil  
The daily dose of fluorouracil is not to exceed 800 mg/m2. It is recommended that patients be 
hospi[INVESTIGATOR_397686] . The first [ADDRESS_500566] a widespread involvement 
of bone marrow by [CONTACT_397793].  
Rarely, unexpected, severe toxicity (eg, stomatitis, diarrhea, neutropenia and neurotoxicity) 
associated with [ADDRESS_500567] advise patients to take measures to minimize exposure to UV light for the 
duration of the study as 5 -FU has phototoxicity potential.  
Fluorouracil may cause fetal harm when administered to a pregnant woman. Fluorouraci l has been 
shown to be teratogenic in laboratory animals.  
There are no adequate and well -controlled studies with fluorouracil in pregnant women. While 
there is no evidence of teratogenicity in humans due to fluorouracil, it should be kept in mind that 
other drugs which inhibit DNA synthesis (eg, methotrexate and aminopterin) have been reported 
to be teratogenic in humans. Women of childbearing potential should be advised to avoid 
becoming pregnant. If the drug is used during pregnancy, or if the patient be comes pregnant while 
taking the drug, the patient should be told of the potential hazard to the fetus. Fluorouracil should 
be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  
Any form of therapy which adds to the stress of the patient, interferes with nutrition or depresses 
bone marrow function will increase the toxicity of fluorouracil.  
Capecitabine  
May result in bleeding, death. Monitor anticoagulant response (eg, INR) and adjust anticoagulant 
dose accordingl y.  
Diarrhea may be severe. Interrupt capecitabine treatment immediately until diarrhea resolves or 
decreases to Grade 1. Recommend standard antidiarrheal treatments.  
Cardiotoxicity is common in patients with a prior history of coronary artery disease.  
There is an increased risk of severe or fatal adverse reactions in patients with low or absent 
dihydropyrimidine dehydrogenase (DPD) activity. Withhold or permanently discontinue 
capecitabine in patients with evidence of acute early -onset or unusu ally severe toxicity, which 
Approved Date 3/13/[ADDRESS_500568] dehydration.  
Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and 
to use effective contraception.  
Severe muco cutaneous reactions, Steven -Johnson Syndrome (SJS) and Toxic Epi[INVESTIGATOR_199049] (TEN), have been reported. Capecitabine should be permanently discontinued in 
patients who experience a severe mucocutaneous reaction during treatment. Capecitabine may 
induc e hand -and-foot syndrome. Persistent or severe hand -and-foot syndrome can lead to loss of 
fingerprints which could impact patient identification. Interrupt capecitabine treatment until the 
hand -and-foot syndrome event resolves or decreases in intensity.  
Interrupt capecitabine treatment immediately until the hyperbilirubinemia resolves or decreases in 
intensity.  
Do not treat patients with neutrophil counts < 1.5 x 109/L or platelet counts < 100 x 109/L. If 
Grade  [ADDRESS_500569] occurred in 2 to 4% of patients 
receiving paclitaxel in clinical trials. Fatal reactions have occurred in patients despi[INVESTIGATOR_315230]. All pati ents should be pretreated with corticosteroids, diphenhydramine, and H2 
antagonists. Patients who experience severe hypersensitivity reactions to paclitaxel should not be 
rechallenged with the drug.  
Bone marrow suppression (primarily neutropenia) is dose -dependent and is the dose -limiting 
toxicity. Neutrophil nadirs occurred at a median of 11 days. Paclitaxel should not be administered 
to patients with baseline neutrophil counts of less than 1.5 x 109/L and platelets recover to a level 
> 100 x 109/L.  
Severe conduction abnormalities have been documented in < 1% of patients during paclitaxel 
therapy and in some cases requiring pacemaker placement. If patients develop significant 
conduction abnormalities during paclitaxel infusion, appropriate therapy sho uld be administered, 
and continuous cardiac monitoring should be performed during subsequent therapy with 
paclitaxel.  
8.2. General Plan to Manage Safety Concerns   
8.2.1.  Eligibility Criteria   
Eligibility criteria were selected to guard the safety of patients in this study. Results from the 
nonclinical toxicology studies and clinical data with tislelizumab, as well as the 
nonclinical/clinical data from other PD -L1/PD -1 inhibitors, were considered. Specifically, patients 
Approved Date 3/13/[ADDRESS_500570] received a live vaccine ≤ 28 days before randomization are excluded from the 
study. Patients with contraindications for platinum (cisplatin or oxaliplatin), fluoropyrimidine (5 -
FU or capecitabine), a nd paclitaxel treatment are also excluded from the study (see Section  4.[ADDRESS_500571] of exclusion criteria).  
8.2.2.  Safety Monitoring Plan   
Safety will be evaluated in this study through the monitoring of all AEs, defined and graded 
according to NCI -CTCAE v4.03. Patients will be assessed for safety (including laboratory val ues) 
according to the schedule in Appendix  1. Clinical laboratory results must be reviewed prior to the 
start of each cycle.  
All enrolled patient s will be evaluated clinically and with standard laboratory tests before and at 
regular intervals during their participation in this study. Safety evaluations will consist of medical 
interviews, recording of AEs, physical examinations, laboratory measureme nts (hematology, 
chemistry, etc.) and other assessments. In addition, patients will be closely monitored for the 
development of any signs or symptoms of autoimmune conditions and infection.  
Serum samples will be drawn for determination of ADAs to tisleliz umab in patients randomized 
to the tislelizumab arm, if treatment assignment is known. Samples will be drawn from all patients 
but will only be analyzed in patients who are treated with tislelizumab. Administration of 
tislelizumab will be performed in a se tting where emergency medical equipment and staff who are 
trained to respond to medical emergencies are available (for additional information, see 
Section  5.2.1 ).   
All AEs will be recorded during the study (AE from the time of the first dose and SAEs from the 
time of signing of informed consent) and for up to [ADDRESS_500572] dose of study drug(s) 
(including chemotherapy) or until the initiation of another anti cancer therapy, whichever occurs 
first.  At the EOT/Safety Follow -up Visit, all AEs will be followed until the event has resolved to 
baseline or ≤ Grade 1, the event is assessed by [CONTACT_226876], the patient is lost to 
follow -up, the patient w ithdraws consent, or it has been determined that study treatment or 
participation is not the cause of the AE.  
Immune -mediated AEs will be recorded up to [ADDRESS_500573].  
Investigators are instructed to report all AEs (including pregnanc y-related AEs).   
The potential safety issues anticipated in this study, as well as measures intended to avoid or 
minimize such toxicities, are outlined in the following sections.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 85 8.3. Adverse Events   
8.3.1.  Definitions and Reporting   
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacer bated) temporally associated with the use of a study 
drug, whether considered related to study drug or not.   
Examples of AEs include:  
• Worsening of a chronic or intermittent pre -existing condition, including an increase in 
severity, frequency, duration, and/or has an association with a significantly worse outcome  
• New conditions detected or diagnosed after study drug administration even t hough it may 
have been present before the start of the study  
• Signs, symptoms, or the clinical sequelae of a suspected interaction  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a 
concurrent medication (overdose per se should not be reported as an AE or SAE)  
When an AE or SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory results and diagnostics reports) relative to the AE or SAE. 
The inves tigator will then record all relevant information regarding an AE or SAE in the eCRF. 
However, there may be instances when copi[INVESTIGATOR_260050]. In this instance, all patient identifiers will be blinded o n the copi[INVESTIGATOR_397687].  
8.3.2.  Assessment of Severity   
The investigator will assess the severity of each AE and SAE reported during the s tudy. AEs and 
SAEs should be assessed and graded based upon the NCI -CTCAE v4.03.  
Toxicities that are not specified in the NCI -CTCAE will be defined as follows:  
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
interven tion not indicated  
• Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living (ADL)  
• Grade 3: Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_397688]; disabling; limiting self -care 
ADL  
• Grade 4: Life -threatening consequences; urgent intervention indicated  
• Grade 5: Death related to AE  
Note: The terms “severe” and “serious” are not synonymous.  Severity i s a measure of intensity 
(for example, grade of a specific AE, mild [Grade 1], moderate [Grade 2], severe [Grade 3], or 
life-threatening [Grade 4]), whereas seriousness is classified by [CONTACT_338539]. Seriousness serves a s the guide for defining regulatory reporting 
obligations from the sponsor to applicable regulatory authorities as described in Section  8.6.2 . 
Approved Date 3/13/[ADDRESS_500574] clinical judgment. Alternative causes, such as natural history of the 
underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the 
AE or SAE to the study drug should be consider ed and investigated. The investigator should 
consult the tislelizumab Investigator’s Brochure  in the determination of his/her assessment.  
There may be situations when an SAE has occurred, and the invest igator has minimal information 
to include in the initial report to the sponsor. However, it is very important that the investigator 
always assesses causality for every SAE prior to transmission of the SAE report to the sponsor, 
since the causality assessme nt is one of the criteria used when determining regulatory reporting 
requirements. The investigator may change his/her opi[INVESTIGATOR_114957] -up 
information, amending the SAE report accordingly.  
The causality of each AE should be assessed  and classified by [CONTACT_1694] “related” or “not 
related”. An AE is considered related if there is “a reasonable possibility” that the AE may have 
been caused by [CONTACT_5257] (ie, there are facts, evidence, or arguments to suggest possible 
causat ion). A number of factors should be considered in making this assessment, including:  
• Temporal relationship of the AE to the administration of study treatment/study 
procedure  
• Whether an alternative etiology has been identified  
• Mechanism of action of the study drug  
• Biological plausibility  
• An AE should be considered ‘related’ to study drug if any of the following are met, 
otherwise the event should be assessed as not related:  
− There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out  
− There is evidence to suggest a causal relationship, and the influence of other 
factors is unlikely  
− There is some evidence to suggest a causal relationship (eg, the AE occurred 
within a reasonable time after administrati on of the study drug). However, the 
influence of other factors may have contributed to the AE (eg, the patient’s clinical 
condition or other concomitant AEs).  
8.3.4.  Following Adverse Events   
After the initial AE or SAE report, the investigator is required to proactively follow each patient 
and provide further information to the sponsor on the patient’s condition.  
All AEs and SAEs documented at a previous visit/contact [CONTACT_69846]/contacts.  
All AEs and SAEs will be followed until resolution, the condition stabilizes or is considered 
chronic, the AE or SAE is otherwis e explained, the patient is lost to follow -up or the patient 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 87 withdraws consent. The investigator will ensure that follow -up includes any supplemental 
investigations as may be indicated to elucidate the nature and/or causality of the AE or SAE. This 
may inc lude additional laboratory tests or investigations, histopathological examinations, 
radiographic imaging, or consultation with other health care professionals.  
The sponsor may request that the investigator perform or arrange for the conduct of supplemental  
measurements and/or evaluations to elucidate as fully as possible the nature and/or causality of the 
AE or SAE. The investigator is obligated to assist. If a patient dies during participation in the 
study or during a recognized follow -up period, the spons or will be provided with a copy of any 
post-mortem findings, including histopathology.  
New or updated information should be reported to the sponsor according to the SAE instructions 
provided by [CONTACT_397794]  8.6.[ADDRESS_500575] Abnormalities   
Only abnormal laboratory finding s (eg, clinical chemistry, complete blood count [CBC], 
coagulation, or urinalysis) or other abnormal assessments (eg, ECGs, X -rays, or vital signs) that 
are judged by [CONTACT_397795]. This 
includes  clinically significant abnormal laboratory findings or other abnormal assessments that are 
present at baseline and significantly worsen during the study. The definition of clinically 
significant is left to the judgment of the investigator. In general, the se are the laboratory test 
abnormalities or other abnormal assessments that:  
• are associated with clinical signs or symptoms, or  
• require active medical intervention, or  
• lead to dose interruption or discontinuation, or  
• require close observation, more frequen t follow -up assessments, or further diagnostic 
investigation.  
If a clinically significant laboratory abnormality is a sign of a disease or syndrome (eg, alkaline 
phosphatase and bilirubin [ADDRESS_500576] associated with cholestasis), only the diagnosis (ie, 
choles tasis) should be recorded on the Adverse Event eCRF.  
If the laboratory abnormality can be characterized by a precise clinical term per standard 
definitions, the clinical term should be recorded as the AE. For example, an elevated serum 
potassium level of 7 .0 mEq/L should be recorded as “hyperkalemia”.  
8.4. Definition of a Serious Adverse Event   
An SAE is any untoward medical occurrence that, at any dose:  
• Results in death  
• Is life -threat ening  
Note: The term “life -threatening” in the definition of “serious” refers to an AE in 
which the patient was at risk of death at the time of the AE. It does not refer to an AE, 
which hypothetically might have caused death, if it were more severe.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 88 • Requi res hospi[INVESTIGATOR_91259]: In general, hospi[INVESTIGATOR_69783] (usually 
involving at least an overnight stay) to the hospi[INVESTIGATOR_12332]/or treatment that  would not have been appropriate in the physician’s office or 
outpatient setting.  
• Results in disability/incapacity  
Note: The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions. This definition is not inten ded to include experiences of 
relatively minor medical significance, such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), which may 
interfere or prevent everyday life functions, but do not const itute a substantial 
disruption.  
• Is a congenital anomaly/birth defect  
• Is considered a significant medical AE by [CONTACT_397796] 
(eg, may jeopardize the patient or may require medical/surgical intervention to prevent 
one of the outcomes listed above)  
The following are NOT  considered SAEs:  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline  
• Hospi[INVESTIGATOR_16739]/convenience considerations  
• Scheduled therapy for the target disease of the study, including admissions for 
transfusion support or convenience  
8.5. Suspected Unexpected Serious Adverse Reaction   
A suspected unexpected serious adverse reac tion is a serious adverse reaction that is both 
unexpected (ie, not present in the product’s Reference Safety Information [RSI]) and meets the 
definition of a serious adverse drug reaction (SADR), the specificity or severity of which is not 
consistent with  those noted in the Investigator’s Brochure.  
8.6. Timing, Frequency, and Method of Capturing Adverse Events and 
Serious Adverse Events   
8.6.1.  Adverse Event Reporting Period   
After informed consent has been signed but prior to the administration of the study drug, only 
SAEs should be reported.  
After initiation of study drug, all AEs and SAEs, regardless of relationsh ip to study drug, will be 
reported until either [ADDRESS_500577] dose of study drugs (including chemotherapy) or initiation 
of new anticancer therapy, whichever occurs first. Immune -mediated AEs (serious or non -serious) 
should be reported until [ADDRESS_500578] dose of tislelizumab, regardless of whether the 
patient starts a new anticancer therapy.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 89 All SAEs considered related to the study drug(s) that are brought to the attention of the 
investigator should be reported regardless of time since the la st dose of treatment.  
AEs and SAEs should be recorded according to the details in Table  4.  For the follow -up period 
for AEs, see Section 8.3.4 . For the definition of TEAEs, see Section 9.3.2 .  
Table  4: Guidance for Duration of Recording New or Worsening Adverse Events in Both 
Treatment Arms  
Event type  Record new or worsening events that 
occur during this period   
 Begin  End  
SAEs a Signing of informed consent  Up to [ADDRESS_500579] (see Section  8.6.4 )  
All nonserious AEs, except those due 
to PD  First dose of study drug  Up to [ADDRESS_500580]  
Immune -mediated AEs (serious or 
nonserious)    Up to [ADDRESS_500581] dose 
(regardless of initiation of new 
anticancer therapy), death, 
withdrawal of consent, or loss to 
follow -up, whichever occurs first  
Abbreviations: AE, a dverse event; PD, progressive disease; SAE, serious adverse event.  
All SAEs considered related to the study drug(s) that are brought to the attention of the Investigator should be 
reported regardless of time since the last dose of treatment.  
8.6.2.  Reporting Serious Adverse Events   
[IP_ADDRESS].  Prompt Reporting of Serious Adverse Events   
As soon as the investigator determines that an AE meets the protocol definition of an SAE, the 
event must be reported promptly (within 24 hours) to the sponsor or designee as de scribed in  
Table 5. 
Table 5.  Timeframes and Documentation Methods for Reporting Serious Adverse Events to 
the Sponsor or Design ee 
 Timeframe for 
Sending Initial 
Report  Documentation 
Method  Timeframe for 
Sending 
Follow -up 
Report  Documentation 
Method  Reporting 
Method  
All SAEs  Within 24h of first 
knowledge of the 
AE SAE Report  As expeditiously 
as possible  SAE Report  Email or fax 
SAE report  
form  
   Abbreviations: h, hours; SAE, serious adverse event.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 90 [IP_ADDRESS].  Completion and Transmission of the Serious Adverse Event Report   
Once an investigator becomes aware that an SAE has occurred in a patient, he/she is to report the 
information to the sponsor within 24  hours as outlined above in Section  [IP_ADDRESS] . The SAE Report 
will always be completed as thoroughly as possible with all available details of the event and 
forwarded to the sponsor or designee within the designated time frames.  
If the investigator does not have all information  regarding an SAE, he/she must not  wait to receive 
additional information before notifying the sponsor or designee of the SAE and completing the 
form. The form will be updated when additional information is received.  
The investigator must always provide an  assessment of causality for each SAE as described in 
Section  8.3.[ADDRESS_500582] information for SAE receipt.  
[IP_ADDRESS].  Regulatory Repor ting Requirements for Serious Adverse Events   
The investigator will report all SAEs to the sponsor in accordance with the procedures detailed in 
Section  [IP_ADDRESS] . The sponsor has a legal responsibility to notify, as appropriate, both the local 
regulatory authority and other regulatory agencies about the safety of a product un der clinical 
investigation.  
The investigator, or responsible person according to local requirements, will comply with the 
applicable local regulatory requirements related to the reporting of SAEs to regulatory authorities 
and the IRB/IEC.  
All suspected unexpected serious adverse reaction s (as defined in Section  8.5), will be submitted 
to all applicable regulatory authorities and investigators for tislelizumab studies.  
When a study center receives an initial or follow -up safety report or other safety inf ormation 
(eg, revised Investigator’s Brochure) from the sponsor, the investigator or designated responsible 
person is required to promptly notify his/her IRB or IEC. The investigator should place copi[INVESTIGATOR_397689] r Site File.  
8.6.3.  Eliciting Adverse Events   
The investigator or designee will ask patients about AEs by [CONTACT_397797]:  
• How are you feeling?  
• Have you had any  medical problems since your last visit?  
• Have you taken any new medicines since your last visit?  
8.6.4.  Disease Progression   
Disease progression, which is expected in this study popula tion and measured as an efficacy 
endpoint, should not be recorded as an AE term. Similarly, nonserious AEs  that are clearly 
consistent with the pattern of progression of the underlying disease and are considered 
unequivocally due to disease progression sho uld not be recorded. However, if there is any 
uncertainty to whether a nonserious AE is due to disease progression, it should be recorded as an 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 91 AE. All SAEs and deaths regardless of relatedness to disease progression should be recorded and 
reported (see Se ction 8.6.2 ). 
8.6.5.  Deaths   
Death is an outcome and not usually considered an event. If the only information available is 
death and the cause of death is unknown, then the death is reported as an AE (eg, “ death”, “death 
of unknown cause”, or “death unexplained ”). 
8.6.6.  Pregnancies   
If a female patient or the partner of a male patient becomes pregnant while receiving 
investigational thera py or within [ADDRESS_500583] dose of chemotherapy , a pregnancy report form is required to be completed and 
expeditiously submitted to the sponsor  to facilitate outcome follow -up. Information on  the status 
of the mother and child will be forwarded to the sponsor. Generally, follow -up will be no longer 
than 8 weeks following the estimated delivery date. Any  premature termination of the pregnancy 
will be  reported.  
While pregnancy itself is not cons idered to be an AE, any pregnancy complication or elective 
termination of a pregnancy for medical reasons will be recorded as an AE or SAE.  
An abortion, whether accidental, therapeutic, or spontaneous should be always reported as an 
SAE. Similarly, any co ngenital anomaly/birth defect in a child born to a patient exposed to the 
study drug should be recorded and reported as an SAE.  
8.6.7.  Expedited Reporting to Health Authorities, Investigators, Institutional Review 
Boards, and Independent Ethics Committees   
The sponsor will promptly assess all SAEs against cumulative study drug experience to identify 
and expeditiously communicate new safety findings to regulatory authorities, investigators , IRBs, 
and IECs based on applicable legislation.  
To determine the reporting requirements for individual SAEs, the sponsor will assess the 
expectedness of the SAEs using the following reference safety information (RSI) documents:  
• Tislelizumab Investigator’s Brochure  
• Cisplatin Package Insert  
• Oxaliplatin Package Insert  
• 5-FU Package Insert  
• Capecitabine Package Insert  
• Paclitaxel Package Insert  
8.6.8.  Assessing and Recording Immune -Mediated Adverse Events   
Since treatment with anti -PD-1 therapy can cause autoimmune disorders, AEs considered by [CONTACT_397798] -mediated (see Section  8.7.3 ) should be classified as imAEs and 
identified as such in the eCRF AE page until Day 90, after treatment discontinuation.  
Approved Date 3/13/[ADDRESS_500584] of potential imAEs appears in  Section  8.7.3 , Table 7. All conditions like those 
listed should be evaluated to determine whether they are imAEs , based on a similar diagnostic 
process to those reactions that are presented in more detail in Appendix  7. 
8.6.9.  Recording Infusion -Related Reactions   
The symptoms of infusion -related reactions  - may include, but are not limited to, fever, 
chills/rigor, nausea, pruritus, angioedema, hypotension, headache, bronchospasm, urticaria, rash, 
vomiting, myalgia, dizziness, or hypertension. Severe reactions may include acute respi[INVESTIGATOR_1421], myocardial infarction, ventricular fibrillati on, or cardiogenic shock.  These 
infusion -related AEs should be recorded as “infusion -related reaction” instead of the individual 
signs and symptoms.  
8.7. Management of AE of Special Interest   
As a routine precaution, after infusion of tislelizumab on Day [ADDRESS_500585], a minimum of a 30 -minute monitoring period is 
required in an area with resuscitation equipment and emergency agents.  
The management of infusion -related reactions, severe hypersensitivity reactions and imAEs 
according to the NCI -CTCAE criteria are outlined below.  
8.7.1.  Managing Infusion -Related Reactions   
Patients should be closely monitored for such reactions. Immediate access to an I ntensive Care 
Unit (ICU) or equivalent environment and appropriate medical therapy (including epi[INVESTIGATOR_238], 
corticosteroids, IV antihistamines, bronchodilators, and oxygen) must be available to treat 
infusion -related reactions.   
Treatment modification for symptoms of infusion -related reactions due to study drug(s) is 
provided in  Table 6.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 93 Table 6.  Treatment Modification for Sympto ms of Infusion -Related Reactions Due to 
Study Drug(s)  
NCI-CTCAE Grade  Treatment Modification for Tislelizumab  
Grade  1 - mild  
Mild transient reaction; infusion interruption not 
indicated; intervention not indicated.  Decrease infusion rate by 50%.  Any worsening is 
closely monitored.  Medical management as needed.  
Subsequent infusions should be given after 
premedication and at the reduced infusion rate.  
Grade  2 - moderate  
Therapy or infusion interruption indicated but 
responds promptly to symptomatic treatment (eg, 
antihistamines, NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated for ≤ 24h  Stop infusion.  Infusion may be resumed at 50% of 
previous rate once infusion -related reactions has 
resolved or decreased to Grade  1 in severity.  Any 
worsening is closely monitored. Proper medical 
management should be instituted as described below.  
Subsequent infusions should be given after 
premedication and at the reduced infusion rate.  
Grade  3 – sever e 
Prolonged (eg, not rapi[INVESTIGATOR_13081]/or brief interruption of infusion); 
recurrence of symptoms following initial 
improvement; hospi[INVESTIGATOR_5176].  Immediately stop the infusion.  Proper medical 
management should be instituted as described below.  
The patient should be withdrawn from study drug(s) 
treatment.  
Grade  4 – life threatening  
Life-threatening consequences; urgent intervention 
indicated.  Immediately stop the infusion.  Proper medical 
manag ement should be instituted as described below.  
The patient should be withdrawn from study drug(s) 
treatment.  
Hospi[INVESTIGATOR_44960].  
Abbreviations: h, hours; IV, intravenous; NCI -CTCAE, National Cancer Institute Common Terminology 
Criteria for Adverse Event; NSAIDs, nonsteroidal anti -inflammatory drugs.  
Once the tislelizumab infusion rate has been decreased by 50% or suspended due to an 
infusion -related reaction, it must remain decreased for all subsequent infusions with 
premedication. If the p atient has a second infusion -related reaction (≥ Grade 2) on the slower 
infusion rate, infusion should be discontinued, and the patient should be withdrawn from 
tislelizumab treatment.  
NCI-CTCAE Grade  1 or 2 infusion reaction: Proper medical management sho uld be instituted, 
as indicated per the type of reaction. This includes but is not limited to an antihistamine 
(eg, diphenhydramine or equivalent), antipyretic (eg, paracetamol or equivalent), and if 
considered indicated oral or IV glucocorticoids, epi[INVESTIGATOR_363816], bronchodilators, and oxygen. In the 
next cycle, patients should receive oral premedication with an antihistamine (eg, diphenhydramine 
or equivalent) and an antipyretic (eg, paracetamol or equivalent), and they should be closely 
monitored for clinical  signs and symptoms of an infusion reaction.  
NCI-CTCAE Grade  3 or 4 infusion reaction: Proper medical management should be instituted 
immediately, as indicated per type and severity of the reaction. This includes but is not limited to 
oral or IV antihista mine, antipyretic, glucocorticoids, epi[INVESTIGATOR_238], bronchodilators, and oxygen.  
Approved Date 3/13/[ADDRESS_500586] available 
medical practice as described in the complete guideline for emergency treatment of anaphylactic 
reactions according to the Working Group of the Resuscitation Council ([LOCATION_006]) ( Soar et al 2008 ). 
Patients should be instructed to report any delayed reactions to the investigator immediately.  
In the event o f a systemic anaphylactic/anaphylactoid reaction (typi[INVESTIGATOR_397690]/antigen, and characterized by: [CONTACT_15206][INVESTIGATOR_1506]; 
laryngeal edema; and/or intense bronchospasm; and often followed by [CONTACT_397799][INVESTIGATOR_60319]; cutaneous manifestations such as pruritus and urticaria 
with/without edema; and gastrointestinal manifestations such as nausea, vomiting, crampy 
abdominal pain, and diarrhea), the infusion must be i mmediately stopped and the patient 
discontinued from the study  drug(s) that cause d this kind of reaction . 
The patients will be administered epi[INVESTIGATOR_397691].  
For prophylaxis of flu -like symptoms, a dose of 25  mg indomethacin or a comparable dose of 
nonsteroidal anti -inflammatory drugs (ie, 600  mg ibuprofen , 500  mg naproxen sodium) may be 
administered 2  hours before and 8  hours after the start of each dose of study drugs(s) infusion. 
Alternative treatments for fever (ie, paracetamol) may be given to patients at the discretion of the 
investigator.  
8.7.3.  Immune -Medi ated Adverse Events   
Immune -mediated  AEs are of special interest in this study.  If the events listed below or similar 
events occur, the investigator should exclude alternative ex planations (eg, combination drugs, 
infectious disease, metabolic, toxin, disease progression or other neoplastic causes) with 
appropriate diagnostic tests, which may include but are not limited to serologic, immunologic, and 
histologic (biopsy) data. If al ternative causes have been ruled out; the AE required the use of 
systemic steroids, other immunosuppressants, or endocrine therapy and is consistent with an 
immune mediated mechanism of action, the imAE indicator in the eCRF AE page should be 
checked.  
A list of potential imAEs is shown below in Table 7. All conditions like those listed should be 
evaluated in patients receiving tislelizumab to determine whether they are immune -mediated .  
Recommendation for diagnostic evaluation and managemen t of imAEs is based on European 
Society for Medical Oncology (ESMO) and American Society for Clinical Oncology (ASCO) 
guidelines ( Haanen et al 2017 , Brahmer et al 2018 ) and common immune -mediated toxicities are 
detailed in Appendix  7. For any AEs not included in Appendix  7, please refer to the ASCO 
Clinical Practice Guideline ( Haanen et al 2017 , Brahmer et al 2018 ) for further guidance on 
diagnostic evaluation and management of immune -mediated toxicities.    
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 95 Table 7.  Immune -Mediated Adverse Events  
Body System Affected  Events  
Skin (mild -common)  pruritus or maculopapular rash; vitiligo  
Skin (moderate)  follicular or urticarial dermatitis; erythematous/lichenoid rash; Sweet’s 
syndrome  
Skin (severe -rare)  full-thickness necrolysis/Stevens -Johnson syndrome  
Gastrointestinal  colitis (includes diarrhea with abdominal pain or endoscopic/radiogr aphic 
evidence of inflammation); pancreatitis; hepatitis; aminotransferase (ALT/AST) 
elevation; bowel perforation  
Endocrine  thyroiditis, hypothyroidism, hyperthyroidism; hypophysitis with features of 
hypopi[INVESTIGATOR_297], eg, fatigue, weakness, weight gain; insulin -dependent diabetes 
mellitus; diabetic ketoacidosis; adrenal insufficiency  
Respi[INVESTIGATOR_397692]/diffuse alveolitis  
Eye epi[INVESTIGATOR_227]; conjunctivitis; iritis/uveitis  
Neuromuscular  arthritis; arthralgia; myalgia; neuropathy; Guillain -Barre syndrome; aseptic 
meningitis; myasthenic syndrome/myasthenia gravis, meningoencephalitis; 
myositis  
Blood  anemia; leukopenia; thrombocytopenia  
Renal  interstitial nephritis; glomerulonephritis; acute renal failure  
Cardiac  pericarditis; myocarditis; heart failure  
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.  
Recommendations for managing imAEs are detailed in Appendix  7. 
If a toxicity does not resolve to ≤ Grade 1 within 12 weeks, study drug(s) should be discontinued 
after consultation with the sponsor. Patients who experience a recurrence of any event at th e same 
or higher severity grade with rechallenge should permanently discontinue treatment.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 96 9. STATISTICAL METHODS AND SAMPLE SIZE 
DETERMINATION   
The statistical analyses will be perf ormed by [CONTACT_338545]. Details of the statistical analyses will be included in a 
separate Statistical Analysis Plan (SAP).  
9.1. Statistical Analysis   
9.1.1.  Randomization Methods   
As discussed in Section  7.2.3 , patients will be randomized using the IRT system for this study by 
[CONTACT_69851].  
9.1.2.  Analysis Sets   
The Intent -to-Treat (ITT) analysis set includes all randomized patients. Patients will be analyzed 
according to their randomized treatment arms. This will be the primary analysi s population for all 
efficacy analysis.  
The Safety analysis set includes all patients who received at least 1 dose of study drug; it will be 
the primary population for the safety analyses.  
The PK analysis set includes all patients who receive at least [ADDRESS_500587] 1 
non-missing postbaseline ADA results.  
9.1.3.  Patient Disposition   
The number of patients randomized, treated, and discontinued from study drug and/or study and 
those with important protocol deviations will be counted. The primary reason for study drug 
and/or study discontinuation will be summarized according to the categ ories in the eCRF. The end 
of study status (alive, dead, withdrew consent or lost to follow -up) at the data cutoff date will be 
summarized using the data from the eCRF.  
Important protocol deviations will be summarized and listed by [CONTACT_338546].  
9.1.4.  Demograp hic and Other Baseline Characteristics   
Demographic and other baseline characteristics of the ITT analysis set will be summarized using 
descriptive statistics. Continuous variable s include age, weight, vital signs, time since initial 
cancer diagnosis, and time since advanced/metastatic disease diagnosis; categorical variables 
include, region (Asia [excluding Japan] vs Japan vs Rest of World), prior definitive therapy (yes 
vs no), c hoice of chemotherapy doublet (platinum plus fluoropyrimidine vs platinum plus 
paclitaxel), ECOG (0 vs 1), previous radiotherapy (yes vs no), previous surgery (yes vs no), age 
(≤ 65 vs >  65 years), gender (female vs male), number of metastatic sites (1 vs 2 vs >  2), 
metastatic site (eg,  liver, lung, bone, lymph node, etc.), tumor location , smoking status, and 
alcohol use  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 97 9.1.5.  Prior and Concomitant Medications   
Prior and concomitant med ications will be coded using the World Health Organization Drug 
Dictionary drug codes. Concomitant medications will be further coded to the appropriate 
Anatomical Therapeutic Chemical (ATC) code indicating therapeutic classification. Prior and 
concomitant medications will be summarized and listed by [CONTACT_397800] (CSR) for this protocol. Prior medications will be defined as medications that 
stopped before the day of first dose of study drug. Concomitant medications will be  defined as 
medications that 1) started before the first dose of study drug and were continuing at the time of 
the first dose of study drug, or 2) started on or after the date of the first dose of study drug up to 
30 days after the patient’s last dose (as of Safety Follow -up Visit). In addition, telephone contacts 
with patients should be conducted to assess imAEs and concomitant medications (if appropriate, 
ie, associated with an imAE or is a new anticancer therapy) at 60 and 90  days (± 14 days) after the 
last dose of study drugs regardless of whether or not the patient starts a new anticancer therapy.  
9.2. Efficacy Analyses   
The primary endpoint of OS in the ITT analysis set will be tes ted at a one -sided alpha of 0.025.  
By [CONTACT_397743] ( 2009 ), if the null hypothesis for OS in the ITT 
analysis set is rejected, the corresponding alpha will be shifted to the hypothesis tests of the 
secondary endpoint s PFS by [CONTACT_397744] , ORR by [CONTACT_397801] , OS in the PD-L1 vCPS  ≥ 10% subgroup , and HRQoL  in the ITT analysis set , 
which will be tested sequentially. The inferential test will be stopped at the first non -significant 
endpoint.   
9.2.1.  Primary Efficacy Analysis   
OS in the ITT analysis set : 
The null hypothesis to be tested is:  
H0:  OS in Arm A  ≤ OS in Arm B  
against the alternative:  
H1:  OS in Arm A > OS in Arm B  
The primary analysis of O S will be carried out when approximately [ADDRESS_500588] using the 
stratification factors of pooled geographic region (Asia [ including Japan] vs Rest of World) , prior 
definitive therapy (yes vs no) , and the investigator choice of chemotherapy ( ICC) option 
(platinum with fluoropyrimidine vs platinum with paclitaxel) . A significance level of one -sided 
0.025 will be used in the OS testing.  
The median OS and the cumulative probability of OS at every 3 months including 9 -month OS 
and 18 -month OS, if estimable, will be calculated for each treatment arm and presented with 
2-sided 95% CIs. Kaplan -Meier survival probabilities for each arm will be plotted over time. OS 
rate at 9  and 18  months based on Kaplan -Meier estimate will be compared be tween the 2 
treatment arms for landmark analysis.  
Approved Date 3/13/[ADDRESS_500589] will be estimated by [CONTACT_6486] a Cox regression  model to the OS times including 
treatment arm as a covariate and geographical region  and prior definitive therapy  as strata.  From 
this mode l, the HR of OS  will be estimated and presented with a 2 -sided 95% CI.  
Primary Analyses of OS  
There will be 1 interim analysis of OS utilizing the O’Bri en-Fleming boundary approximated by  
[CONTACT_397746] -Shih-DeCani spending function with the gamma parameter set at -4. The interim analysis 
will be performed at the time when approximately 423 death events ( 87% of the target number of 
OS events) among the [ADDRESS_500590] been 
observed. Stoppi[INVESTIGATOR_397693] p -value and Z score for primary analyses of OS are shown in 
Table 8. The boundaries will be updated according to the actual numbers of events in the interim 
and final analyses, and the revised alpha level due to  alpha shifting as described above, using the 
above pre -specified alpha spending function.  
Table 8.  Stoppi[INVESTIGATOR_274353] (in p -Value and Z Score ) of Primary Analysis of Overall 
Survival   
Endpoint  Analysis  Analysis  
Time 
(month s) # Events  p-value1 (Z score)  
for Efficacy  Approximate HR 
Threshold  
OS Interim 
analysis  33 423 < 0.0145 (>  2.18)  0.809  
Final 
analysis  40 488 < 0.0216 (>  2.02) 0.833  
Abbreviations: HR  = hazard ratio; OS  = overall survival  
1one-sided  
Subgroup Analyses  
To determine if the treatment effect is consistent across various subgroups, the HR estimates of 
OS and their 95% CI will be estimated and plotted within each category of  the following 
variables: region (Asia [ excluding Japan] vs Japan vs  Rest of World), region (Asia [including 
Japan] vs Rest of World),  choice of chemotherapy doublet (platinum plus fluoropyrimidine vs 
platinum plus paclitaxel), ECOG (0 vs 1), age (≤  65 vs > 65 years), gender (female vs male) , 
smoking status , PD-L1 expression  (vCPS ≥ 10% vs vCPS  < 10%) . 
9.2.2.  Secondary Efficacy Analysis   
Progression Free Survival (PFS)   
There will be o ne analysis of PFS in the ITT analysis set, which will be carried out after 
superiority of OS in the ITT analysis set has been demonstrated.  Similar statistical analysis 
methods used for the OS testing will be applied to PFS analysis.  
The p -value from one -sided, stratified log -rank test will be presented using the stratification 
factors of pooled geographic region, prior definitive therapy , and ICC option.  
PFS assessed by [CONTACT_397802] -Meier method in the ITT 
analysis set. The PFS censoring rule will follow [LOCATION_002] (US) Food and Drug 
Administration (FDA) Guidance for Industry, Clinical Trial Endpoints for Approval of Cancer 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 99 drugs and Biologics (FDA 2018 ). Data for patients without disease progression or death at the 
time of analysis will be censored at the time of the last tumor assessment. Data for patients who 
are lost to follow -up prior to documente d disease progression will be censored at the last tumor 
assessment date when the patient is known to be progression -free. Data for patients who start to 
receive new anti -cancer therapy will be censored at the last tumor assessment date prior to the 
introd uction of a new therapy.  
The median PFS and the cumulative probability of PFS at every 3 months, including 6 -month 
PFS, if estimable, will be calculated for each treatment arm and presented with 2 -sided 95% CIs. 
Kaplan -Meier estimates of PFS for each arm will be plotted over time. The PFS rate at 6  months 
based on the Kaplan -Meier estimate will be compared between the 2 treatment arms for landmark 
analysis.  
HR estimated from a Cox regression model will be presented with its 95% CI.  
OS in the vCPS ≥ 10% subgroup   
This analysis for the baseline vCPS  ≥ 10% subgroup is similar to the OS analysis in the ITT 
analysis . 
Other secondary efficacy endpoints  
The null hypotheses of no difference in ORR per RECIST v1.1  by [CONTACT_397803] -Mantel -Haenszel (CMH) method , adjusting for stratification factors of pooled 
geographic region , prior definitive therapy , and ICC options in the ITT analysis set. Patients  with 
no post -baseline response assessment (for any rea son) will be considered non -responders. The 2 -
sided 95% CIs for the odds ratio in ORR will be calculated  along with  Clopper -Pearson 95% CIs 
of ORR for each treatment arm.  
DOR  assessed by [CONTACT_397804].  Median DOR  per arm, if estimable, will be presented.  
HRQoL will be analyzed and compared between treatment arms via the post -baseline scores of 
QLQ -C30’s Global Health Status/QoL (GHS), functional scales and symptom scores and 
symptoms single item scores, QLQ -OES18’s index score and symptoms scales and single item 
scores, and EQ -5D-5L descriptive scale scores as well as the visual analogue scale (VAS) scores. 
Observed values and changes from baseline will be summarized using des criptive statistics. A 
mixed -effect  model analys is for measuring clinically meaningful changes post -baseline will be 
performed  using the key patient -reported outcome  endpoints of GHS, physical function ing, and 
fatigue domains of QLQ -C30 and dysphagia, refl ux, pain and eating of QLQ -OES18.  
Time to clinically meaningful deterioration in the aforementioned scales will be estimated using 
the Kaplan -Meier method  and Cox regression model . Deterioration thresholds will be defined 
based on the published [ADDRESS_500591] v1.1  by [CONTACT_397805], progressive disease (PD) or start of new anti -cancer treatment . The 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 100 proportion and its corresponding Clopper -Pearson 95% CI for each of the response categories 
(CR, PR, SD , and PD) will be presented by [CONTACT_2939].  
DCR will be analyzed similarly as ORR in the ITT analysis set . 
To calculate PFS2, data from patients without disease progression after next line of treatment or 
death at the time of analysis will be censored at the last time known to be alive. Kaplan -Meier 
method as described in the PFS and OS analyses will be used in the analysis of PFS2.  
In addition, PF S, ORR, DOR , and DCR  assessed by [CONTACT_397741] v1.1 are summarized 
similarly as the data assessed by [CONTACT_397752].  
Exploratory biomarkers may also be assessed.  
9.3. Safety Analyses   
Safety will be assessed by [CONTACT_397753] -CTCAE v4.03. 
Laboratory values (eg, hematology, clinical chemistry, coagulation , and urinalysis) , dosing, vital 
signs, ECGs, and physician examinations will also be evaluated in defining the safety profile of 
each treatment arm. Descriptive statistics will be used to analyze all safety data in the Safety 
analysis set . 
9.3.1.  Extent of Exposure   
Extent of exposure to each study drug will be summarized descriptively as the number of doses 
received (number and percentage of patients), duration of exposure (days), cumulative total dose 
received per patient (mg), dose intensity, and relative dose intensity.  
The number (percentage) of patients requiring dose reduction, interruption, dose delay, and drug 
discontinuation due to AEs will be summarized for each study drug. Frequency of the abo ve dose 
adjustments and discontinuation will be summarized by [CONTACT_17203].  
Patient data listings will be provided for all dosing records and for calculated summary statistics.  
9.3.2.  Adverse Events   
The AE verbatim descriptions (the investigator’s description from the eCRF) will be coded using 
Medical Dictionary for Regulatory Activities (MedDRA). AEs will be coded to MedDRA 
(Version 20.0 or higher) lower level term, preferred term , and pri mary SOC.  
A TEAE is defined as an AE that had an onset date or a worsening in severity from baseline 
(pretreatment) on or after the first dose of study drug and up to [ADDRESS_500592]. The TEAE 
classification also applies to i mAEs that are recorded up to 90 days after discontinuation from 
tislelizumab or placebo, regardless of whether the patient starts a new anticancer therapy. Only 
those AEs that were treatment -emergent will be included in summary tables. All AEs, treatment -
emergent or otherwise, will be presented in patient data listings.  
The incidence of TEAEs will be reported as the number (percentage) of patients with TEAEs by 
[CONTACT_9315]. A patient will be counted only once by [CONTACT_397806]-CTCAE v4.03 within an SOC and preferred term, even if the patient experienced more than 
1 TEAE within a specific SOC and preferred term. The number (percentage) of patients with 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 101 TEAEs will als o be summarized by [CONTACT_53429]. Treatment -related AEs include 
those events considered by [CONTACT_397807].  SAEs, deaths, TEAE with ≥ Grade 3 severity , imAE, 
infusion -related reactions, treatment -related TEAEs and TEAEs that led to treatment 
discontinuation, dose interruption, dose reduction, or dose delay will be summarized.  
9.3.3.  Laboratory Analyses   
Clinical laboratory (eg, hematology, serum chemistry, urinalysis) values will be evaluated for 
each laboratory parameter as appropriate. Abnormal laboratory values will be flagged and 
identified as those outside (above or below) the normal range. Reference (normal) ranges for 
laboratory parameters will be included in the CSR for this protocol. Descriptive summary 
statistics (eg, n, mean, standard deviation, median, minimum, maximum for continuous variables; 
n [%] for categorical varia bles) for laboratory parameters and their changes from baseline will be 
calculated. Laboratory values will be summarized by [CONTACT_3595].  
Laboratory parameters that are graded in NCI -CTCAE v4.03 will be summarized by [CONTACT_12134] -CTCAE 
grade. In the summary of laboratory parameters by [CONTACT_12134] -CTCAE grade, parameters with 
NCI-CTCAE grading in both high and low directions (eg, glucose, potassium, sodium) will be 
summarized separately.  
9.3.4.  Vital Signs   
Descriptive statistics for vital sign parameters (systolic and diastolic blood pressure, pulse rate, 
temperature) and changes from baseline will be presented by [CONTACT_3597]. Vital signs will be 
listed by [CONTACT_397808] t. 
9.3.5.  Ophthalmologic Examination   
Ophthalmologic examination results will be listed by [CONTACT_4676].  
9.4. Pharmacokinetic Analysis   
Individual tislelizumab concentrations will be tabulated by [CONTACT_397809].  
Additional PK analyses such as population PK analysis may be conducted as appropriate. 
Exposure -response (efficacy or safety endpoints) analysis may be carried out if supported by [CONTACT_33653]. 
The results from these analyses will be reported separately from the main study report.  
9.5. Immunogenicity Analyses   
The immunogenicity results will be summarized using descriptive statistics by [CONTACT_397810]. The incidence of positive ADA and 
neutralizing ADA will be reported for evaluab le patients. The effect of immunogenicity on PK, 
efficacy and safety may be evaluated if data allow.  
9.6. Sample Size Consideration   
The initial sample size calculation was based on th e primary efficacy analysis of PFS and OS in 
the comparison between tislelizumab in combination with chemotherapy arm and placebo plus 
chemotherapy arm in the ITT analysis set. Hazard ratios in PFS and OS were assumed as 0.65 and 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 102 0.73, respectively, with m edian PFS of 5 months and OS of 9 months in the comparator arm. A 
total of 480 patients w ould be enrolled in a 1:1 randomization over 17 -month period at enrollment 
rates of 10 patients/month in the first month, 20 patients/month in the second month and 30 
patients/month in the next [ADDRESS_500593] a power of 90% with an alpha of 0.005. A group sequential testing of 
OS w ould be performed. The interim analysis was planned after approximately 67% of the total 
planned death events ha d occurred (241). The final analysis of OS w ould be performed when 
approximately 360 death events ha d been observed. The sample size calculation of OS was based 
on overall power of 82% and an alpha leve l of 0.02.  
The previous version of  protocol amendment 3.[ADDRESS_500594] and 
increased usage of subsequent immunotherapi[INVESTIGATOR_397694] -oncology  trials in the second -line ESCC ( Kojima et al 2019 ; Kato et al 20 19; Huang et al 
2019 ).  
By 24 November  2020 , enrollment was completed with 649 randomized patients. In the current 
protocol amendment, BIRC -assessed  PFS has been removed  from the primary efficacy analysis 
based on the results from KEYNOTE -590 ( Kato et al 2020 ) in the first-line treatment of ESCC. 
OS is the sole primary efficacy endpoint. The HR for OS is assumed to be 0.[ADDRESS_500595] (e.g. assuming HR  = [ADDRESS_500596] 
month), the number of deaths required in the final analysis will be approximately 488 with 90% 
power by [CONTACT_167889]. The planned interim analysis with a power of 81% will occur after 
approximately [ADDRESS_500597] been observed. A 5% annual dropout rate is assumed and one -
sided alpha of 0.025 is used in the sample size calculation.  
9.7. Interim Analyses   
An interim analysis of OS (see Section  9.2.1 ) will be performed by [CONTACT_397811]. The independent statistician will work with the blinded study statistician 
to provide statistical outputs to the IDM C as described in the IDMC charter and perform any ad -
hoc analyses requested by [CONTACT_31849].  
Approved Date 3/13/[ADDRESS_500598] v1.1 criteria, in addition to the local investigator review of radiographs.  The 
results from the investigator’s review of radiographic images will be used to determine whether 
patients should be enrolled or should continue on study treatment .  The tumor assessment by [CONTACT_397812].  
All decisions made during the performance of the study will be based on the local investigator’s 
assessment of radiographic images, clinical status, and relevant exami nation of the patients.  Sites 
will submit specific radiographic image files to the centralized data review facility during the 
study on an ongoing basis or at the sponsor’s request.  Detailed rules and guidelines for 
radiographic imaging and tumor assessm ents by [CONTACT_397813].  
10.2. Independent Data Monitoring Committee   
As described in Section  3.8, enrollment of Japanese patients will be gated to monitor for 
unexpected or new safety concerns.  IDMC will review safety data of the safety co hort of 
approximately 10  Japanese patients after they complete 1 cycle of treatment or whenever there is a 
safety concerns.  Enrollment will continue only when the safety and tolerability are deemed 
acceptable by [CONTACT_31849].  
Regular s afety monitoring (every [ADDRESS_500599] IDMC safety review if there are no significant safety concerns ), and efficacy monitoring will 
be performed by [CONTACT_41774].  The first IDMC safety review will occur after approximately [ADDRESS_500600] been randomized to study treatment (ie, at least 25 patients  per treatment arm) and 
have been on treatment for ≥  1 month to determine if the proposed dosing schedule of 
tislelizumab is safe and tolerable.   The IDMC may recommend study modificati on including 
termination of the study due to safety and/or efficacy concerns. The IDMC will also be 
responsible for reviewing the results from pre -defined analyses, including final analysis of PFS 
and interim analysis of OS and making the recommendations f or stoppi[INVESTIGATOR_397695] -
defined efficacy boundaries.  The function and membership of the IDMC will be described in the 
IDMC charter.  
In addition to the planned IDMC review(s), ad hoc reviews may be performed based on new 
information.  
Following IDMC review and discussion, the sponsor will make all final decisions regarding any 
changes in study conduct.  
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 104 11. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS   
The investigator must maintain adequate and accurate records to ensure that the conduct of the 
study may be fully documented.  Such records include, but are not limited to, the protocol, 
protocol amendments, ICFs, and documentation of IRB/IEC and governmen tal approvals.  In 
addition, at the end of the study, the investigator will receive patient data, which will include an 
audit trail containing a complete record of all changes to such data.  
11.1. Access to Information for Monitoring   
In accordance with International Conference on Harmonisation (ICH) GCP guidelines, the study 
monitor must have direct access to the investigator’s source documentation to verify the data 
recorded in the eCR Fs for consistency.  
The monitor is responsible for routine review of the eCRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them.  The monitor sho uld have access to any patient records needed to 
verify the entries on the eCRFs.  The investigator agrees to cooperate with the monitor to ensure 
that any problems detected during these monitoring visits are resolved.  
11.2. Access to Information for Auditing or  Inspections   
Representatives of regulatory authorities or of BeiGene may conduct inspections or audits any 
time during or after completion of this clinical study.  If the investi gator is notified of an 
inspection by a regulatory authority the investigator agrees to notify the sponsor or its designee 
immediately.  The investigator agrees to provide to representatives of a regulatory agency or 
BeiGene access to records, facilities, and personnel for the effective conduct of any inspection or 
audit.  
Approved Date 3/13/[ADDRESS_500601] a regulatory inspection 
of this study.  Such audits/inspections can occur at any time during or after completion of the 
study.  If an audit or inspection occurs, the investigator and  institution agree to allow the 
auditor/inspector direct access to all relevant documents and to allocate his/her time and the time 
of his/her personnel to the auditor/inspector to discuss findings and any relevant issues.  
12.3. Study Site Inspections   
This study will be organized, performed, and reported in compliance with the protocol, standard 
operating procedures, working practice documents, and applicable regulations and guidelines.   
Site audits may be performed periodically by [CONTACT_456]’s or the contract research organization’s 
qualified compliance auditing team, which is an independent function from the study team 
responsible for conduct of the study.  
Site visits will be conducte d by [CONTACT_338560], 
patients’ medical records, and eCRFs.  The investigator is to permit national and local health 
authorities; sponsor study monitors, representatives, and collaborators; and IRB/IEC memb ers to 
inspect all facilities and records relevant to this study.  
12.4. Drug Accountability   
The investigator or designee (ie, pharmacist) is responsible for ensuring adequate accounta bility 
of all used and unused study drug.  This includes acknowledgment of receipt of each shipment of 
study product (quantity and condition), patient drug dispensation records, and returned or 
destroyed study product.  Dispensation records will document q uantities received from BeiGene’s 
designated depot or its designee and quantities dispensed to patients, including batch/lot number, 
date dispensed, patient identifier number, patient initials, and the initials of the person dispensing 
the medication.  
The Investigator and/or study personnel will keep accurate records of drug dispensed and used by 
[CONTACT_6904]. This information must be captured in the source document at each patient visit. The 
Investigator is responsible for tislelizumab, cisplatin, oxalipla tin, [ADDRESS_500602] maintain tislelizumab, 
cisplatin, oxaliplatin, 5 -FU, capec itabine, and paclitaxel accountability records throughout the 
course of the study. This person will document the amount of tislelizumab, cisplatin, oxaliplatin, 
5-FU, capecitabine, and paclitaxel received from the sponsor, the amount supplied, and/or 
admin istered (and returned by [CONTACT_1962], if applicable).  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 106 At study initiation, the monitor will evaluate the site’s standard operating procedure for study drug 
disposal/destruction to ensure that it complies with BeiGene’s requirements specified in the 
Pharmacy M anual.  At appropriate times during the conduct of the study or at the end of the study, 
the study site will dispose of and/or destroy all unused study drug supplies following drug 
inventory reconciliation by [CONTACT_2037].  These include empty containers, a ccording to these 
procedures.  If the site cannot meet BeiGene’s requirements specified in the Pharmacy Manual for 
disposal, arrangements will be made between the site and BeiGene or its representative for 
destruction or return of unused study drug supplie s. 
All drug supplies and associated documentation will be periodically reviewed and verified by [CONTACT_69878].  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 107 13. ETHICS/PROTECTION OF HUMAN PATIENTS   
13.1. Ethical Standard   
This study will be conducted by [CONTACT_397814] E6 guideline for Good Clinical Practice and the princip les of the Declaration of Helsinki or 
the laws and regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
Definitions and Standards for Expedited Reporting  (ICH E2A 1994 ). 
13.2. Institutional Review Board/Independent Ethics Committee   
This protocol, the ICFs, any informatio n to be given to the patient, and relevant supporting 
information must be submitted ,  to the IRB/IEC by [CONTACT_397815]/IEC before the study is initiated.  In addition, any patient recruitment materials must be 
approve d by [CONTACT_1201]/IEC. . 
The investigator is responsible for providing written summaries of the status of the study to the 
IRB/IEC annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC.  Investigators are also responsi ble for promptly informing 
the IRB/IEC of any protocol amendments.  In addition to the requirements for reporting all AEs to 
the sponsor, investigators must comply with requirements for reporting SAEs to the local health 
authority and the IRB/IEC.  Investi gators may receive written investigational new drug (IND) 
safety reports or other safety -related communications from the sponsor.  Investigators are 
responsible for ensuring that such reports are reviewed and processed in accordance with health 
authority r equirements and the policies and procedures established by [CONTACT_11577]/IEC and archived 
in the site’s study file.  
13.2.1.  Protocol Amendments   
Any protocol amendments will be prepared by t he sponsor.  All protocol modifications must be 
submitted to competent authorities according to local requirements and to the IRB/IEC  together 
with, if applicable, a revised model ICF  in accordance with local requirements.  Written 
documentation from compe tent authorities (according to local requirements) and from the 
IRB/IEC and required site approval must be obtained by [CONTACT_397816], except for changes necessary to eliminate an immediate hazard to patients or 
changes that involve logistical or administrative aspects only (eg, change in sponsor medical 
monitor or contact [CONTACT_3031]).  
Information on any change in risk and /or change in scope must be provided to patients already 
actively participating in the study, and they m ust read, understand and sign each revised ICF 
confirming their willingness to remain in the study.  
13.3. Informed Consent   
The sponsor’s sample ICF will be provided to each site.  If applicable, it will be provided in a 
certified translation of the local language.  The final IRB/IEC -approved ICFs must be provided to 
the sponsor for health authority submission purposes accordin g to local requirements.  
Approved Date 3/13/[ADDRESS_500603] be signed and dated by [CONTACT_12718]’s legally authorized representative 
before his or her participation in the study.  The case history or clinical records for each patient 
shall document the informed c onsent process and that written informed consent was obtained 
before  participation in the study.  
The ICFs will be revised whenever there are changes to study procedures or when new 
information becomes available that may affect the willingness of the patie nt to participate.  The 
final revised IRB -/IEC -approved Consent Forms must be provided to the sponsor for health 
authority submission purposes.  
Patients must reconsent  to the most current version of the ICFs (or to a significant new 
information/findings a ddendum in accordance with applicable laws and IRB/IEC policy) during 
their participation in the study , if the updated information may be relevant to the patient’s 
willingness to continue participation in the study .  For any updated or revised ICFs, the ca se 
history or clinical records for each patient shall document the informed consent process and that 
written informed consent was obtained using the updated/revised ICFs for continued participation 
in the study. All patients in the survival follow -up will reconsent to the updated ICF if the updates 
may be relevant to the patient’s willingness to continue participation in the study, either during 
on-site visits or by [CONTACT_648]/video -call/mail, according to local regulations. The IRB/IEC submission 
letters, if ap plicable, should specify the approach taken (phone, video -call, or mail) according to 
local regulations. The process by [CONTACT_397817] a patient during the survival 
follow -up should be documented in the patient’s case history or clinica l records.  
A copy of each signed ICF must be provided to the patient or the patient’s legally authorized 
representative.  All signed and dated ICFs must remain in each patient’s study file or in the site 
file and must be available for verification by [CONTACT_397818].  
13.4. Patient and Data Confidentiality   
The investigator, institution, sponsor , and site  will maintain confidentiality and privacy standards 
for the collection, storage, transmission, and processing of patients’ personal and medical 
information by [CONTACT_397819], use, and 
protection of such information, including the ICH Good Clinical Practice Guideline, as  
implemented locally . Such laws may be more stringent than the requirements in this protocol . 
The investigator and site shall code the personal and medical information obtained during the 
study with a unique patient identification number assigned to each p atient enrolled in the study.  
The investigator must ensure that patients’ confidentiality will be strictly maintained and that their 
identities are protected from unauthorized parties.  Unless required to be provided by [CONTACT_397820], the investigator and site must ensure that any personal and medical information 
transmitted to or collected by [CONTACT_397821]: 1) required by [CONTACT_60797], 
and 2) appropriately de -identified (eg, via redaction and/or coding with the patient identification 
number) to ensure the following information about patients are NOT shared:  
• Names or initials (full or partial);  
• Full dates  of birth;  
• Contact [CONTACT_3031] (such as phone numbers or home or email addresses);  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 109 • Numerical identifiers (eg, hospi[INVESTIGATOR_397696], government, health insurance, or 
financial account numbers) other than patient identification numbers assigned as part 
of this st udy; 
• Geographic identifiers smaller than a state, province, or local equivalent (such as city, 
county, zip code, or other equivalent geographic identifiers); or  
• Information about marital status, family, or household members; employment, sex life, 
sexual p reference, or other sensitive data that is not relevant to the study.  
Medical information may be given to a patient’s personal physician or other appropriate medical 
personnel responsible for the patient’s welfare, for treatment purposes.  
Data generated d uring this study must be available for inspection upon request by [CONTACT_397822] (FDA), the China National Medical Products 
Administration, and all other national and local health authorities; by [CONTACT_397823], monitors, 
representatives, and collaborators; and by [CONTACT_1026]/IECs for each study site, as appropriate.  
The investigator must assure that patients’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties.  T he investigator agrees that all information 
received from the sponsor, including but not limited to the IB, this protocol, eCRFs, the 
investigational new drug, and any other study information, remain the sole and exclusive property 
of the sponsor during th e conduct of the study and thereafter.  This information is not to be 
disclosed to any third party (except employees or agents directly involved in the conduct of the 
study or as required by [CONTACT_2371]) without prior written consent from the sponsor.  The investi gator 
further agrees to take all reasonable precautions to prevent the disclosure by [CONTACT_397824].  
13.5. Financial Disclosure   
Investigators are required to provide the sponsor with sufficient accurate financial information in 
accordance with regulations to allow the sponsor to submit complete disclosure or certification to 
the absence of certain financial  interest of the clinical investigators and/or disclose those financial 
interests, as required to the appropriate health authorities. This is intended to ensure financial 
interests and arrangements of the clinical investigators with BeiGene that could affe ct reliability 
of data submitted to health authorities are identified and disclosed by [CONTACT_456].  Investigators 
are responsible for providing information about their financial interests before participation in the 
study, and to update this information i f any relevant changes occur during the study and for 1 year 
after completion of the study (ie, last patient, last visit).  
Approved Date 3/13/[ADDRESS_500604] KEEPI[INVESTIGATOR_1645]   
14.1. Data Collection and Management Responsibilities   
14.1.1.  Data Collection   
Data required by [CONTACT_397825] (EDC) system.  
Data collection in the eCRF should follow the instructions described in the eCRF Com pletion 
Guidelines.  The investigator has ultimate responsibility for the collection and reporting of all 
clinical data entered in the eCRF. The investigator or designee as identified on Form FDA [ADDRESS_500605] parties without written permission from BeiGene, except for authorized 
representatives of BeiG ene or appropriate regulatory authorities.  
14.1.2.  Data Management/Coding   
All final patient data, both eCRF and external data (eg, laboratory data), collected according to the 
protocol,  will be stored by [CONTACT_397826].  
Standard procedures (including following data review guidelines, computerized validation to 
produce queries and maintenance of an audit file that includes all database modifications) will be 
followed to support accurate data collection. Data will be reviewed for outliers, logic, data 
inconsistencies and completeness.  
During the study, a study monitor (clinical research associate) will make site visits to review 
protocol compliance, compare eCRFs against i ndividual patient’s medical records and ensure that 
the study is being conducted according to pertinent regulatory requirements.  
The eCRF entries will be verified with source documentation.  The review of medical records will 
be performed in a manner to en sure that patient confidentiality is maintained.  Checking the 
eCRFs for completeness, clarity, and cross -checking with source documents is required to monitor 
the progress of the study.  Direct access to source data is also required for inspections and au dits 
and will be carried out with due consideration given to data protection and medical 
confidentiality.  
AEs will be coded using the MedDRA Version 20.0 or higher.  Concomitant medications will be 
coded using the World Health Organization (WHO) Drug Dicti onary.  Concomitant 
diseases/medical history will be coded using the MedDRA Version 20.0 or higher.  
14.2. Data Integrity and In -House Blinding   
Due to the blinded design of the study, a ccess to the patient level clinical data in the EDC system 
will be assigned to predefined study personnel only.  Functions/persons with access to the EDC 
system shall be prohibited from using the EDC system to generate unnecessary listings/summaries 
that m ay introduce unwanted bias or share such outputs from the EDC system with other 
functions/persons who do not have access to the EDC.  In addition, the central imaging vendor 
will perform the central imaging review without knowledge of treatment arm assignm ent. 
Approved Date 3/13/[ADDRESS_500606] 1 the following categories: 1) investigator’s study file, and/or 2) patient 
clinical source documents.  
The investigator’s study file will contain the pr otocol/amendments, eCRF and query forms, 
IRB/IEC, and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.  
Patient clinical source doc uments (usually defined by [CONTACT_5280]/safety parameters independent of the eCRFs) would include documents such as (although 
not be limited to) the following: patient hospi[INVESTIGATOR_307]/clinic records, physician’s and nurse’s notes,  
appointment book, original laboratory reports, ECG, electroencephalogram, X -ray, pathology and 
special assessment reports, consultant letters, screening and enrollment log, etc.  
Following closure of the study, the investigator must maintain all study rec ords in a safe and 
secure location. The records must be maintained to allow easy and timely retrieval, when needed 
(eg, audit or inspection), and, whenever feasible, to allow any subsequent review of data in 
conjunction with assessment of the facility, sup porting systems, and personnel.  Where permitted 
by [CONTACT_1207]/regulations or institutional policy, some or all of these records can be maintained in 
a format other than hard copy (eg, microfiche, scanned, electronic); however, caution needs to be 
exercise d before such action is taken.  The investigator must assure that all reproductions are 
legible, are a true and accurate copy of the original, and meet accessibility and retrieval standards, 
including re -generating a hard copy, if required.  Furthermore, t he investigator must ensure there 
is an acceptable backup of these reproductions and that an acceptable quality control process 
exists for making these reproductions.  
The sponsor will inform the investigator of the time period for retaining these records t o comply 
with all applicable regulatory requirements.  The minimum retention time will meet the strictest 
standard applicable to that study center for the study, as dictated by [CONTACT_397827], or the sponsor’s s tandards/procedures; otherwise, the retention period 
will default to the [ADDRESS_500607] notify the sponsor of any changes in the archival arrangements, including, 
but not limited to, the following: archival at an off -site facility, or tran sfer of ownership of or 
responsibility for the records in the event the investigator leaves the study center.  
If the investigator cannot guarantee this archiving requirement at the study site for any or all the 
documents, special arrangements must be made between the investigator and BeiGene to store 
these in sealed containers outside of the site so that they can be returned sealed to the investigator 
in case of a regulatory audit.  When source documents are required for the continued care of the 
patient, a ppropriate copi[INVESTIGATOR_69786].  
Approved Date 3/13/[ADDRESS_500608] patient safety and/or 
data integrity to the sponsor and to the IRB/IEC, in accordance with established IRB/IEC policies 
and procedures.  
14.5. Publication and Data Sharing Policy   
A clinical study report will be prepared and provided to the regulatory agency(ies).  BeiGene will 
ensure that the report meets the standards set out in the ICH Guideline for Structure and Conten t 
of Clinical Study Reports (ICH E3).  Note that an abbreviated report may be prepared in certain 
cases.  
The results of this study will be published or presented at scientific meetings in a timely, 
objective, and clinically meaningful manner that is consis tent with good science, industry and 
regulator guidance, and the need to protect the intellectual property of the sponsor, regardless of 
the outcome of the study.  The data generated in this clinical study are the exclusive property of 
the sponsor and are confidential .  As this is a multicenter stud y, the first publication or disclosure 
of study results shall be a complete, joint multicenter publication or disclosure coordinated by [CONTACT_103].  Thereafter, any secondary publications will reference the orig inal publication(s).  
Authorship will be determined by [CONTACT_397828] (International Committee of Medical 
Journal Editors 201 8). 
Each investigator agrees to submit all manuscripts, abstracts, posters, publications, and 
presentations (both oral and written) to the sponsor f or review before submission or presentation 
in accordance with the clinical study agreement. This allows the sponsor to protect proprietary 
information, provide comments based on information from other studies that may not yet be 
available to the investiga tor, and ensure scientific and clinical accuracy. The details of the 
processes of producing and reviewing reports, manuscripts, and presentations based on the data 
from this trial will be presented in the investigator’s clinical study agreement. Each inves tigator 
agrees that, in accordance with the terms of the clinical study agreement, a further delay of the 
publication/presentation may be requested by [CONTACT_338562]/or 
protection in advance of the publication/presentation.  
14.6. Study and Study Center Closure   
Upon completion of the study, the monitor will conduct the following activities in conjunction 
with the investigator or study center personnel, as appropriate:  
• Return of all study data to the sponsor  
• Resolution and closure of all data queries  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 113 • Accountability, reconciliation, and arrangements for unused study drug(s)  
• Review of study records for completeness  
• Return of treatment codes to the sponsor  
• Shipment of PK samples to assay laboratories  
In addition, the sponsor reserves the right to suspend the enrollment or prematurely discontinue 
this study either at a single study center or at all study centers at any time for reasons including, 
but not limited to, safety or ethical issues or severe noncompliance.  If the sponsor determines 
such action is needed, the sponsor will discuss this with the investigator (including the reasons for 
taking such action) at that time.  When feasible, the sponsor will provid e advance notification to 
the investigator of the impending action prior to it taking effect.  
The sponsor will promptly inform all other investigators and/or institutions conducting the study if 
the study is suspended or terminated for safety reasons and w ill also inform the regulatory 
authorities of the suspension or termination of the study and the reason(s) for the action.  If 
required by [CONTACT_5279], the investigator must inform the IEC/IRB promptly and 
provide the reason for the suspension o r termination.  
If the study is prematurely discontinued, all study data must be returned to the sponsor.  In 
addition, arrangements will be made for the return of all unused study drug(s) in accordance with 
the applicable sponsor procedures for the study.  
Financial compensation to the investigators and/or institutions will be in accordance with the 
agreement established between the investigator and the sponsor.  
14.7. Information Disclosure and Inventions   
All rights, title, and interests in any inventions, know -how or other intellectual or industrial 
property rights which are conceived or reduced to practice by [CONTACT_5243] p ersonnel during 
the course of or as a result of the study are the sole property of the sponsor, and are hereby 
[CONTACT_69886].  
If a written contract for the conduct of the study which includes ownership provisions inconsistent 
with this statement is executed between the sponsor and the study center, that contract’s 
ownership provisions shall apply rather than this statement.  
All information provided by [CONTACT_397829] (othe r than a patient’s medical records) are the sole property of the 
sponsor and will be kept confidential by [CONTACT_5286].  This 
information and data will not be used by [CONTACT_397830].   
These restrictions do not apply to:  
• Information that becomes publicly available through no fault of the investigator or 
study center personnel  
• Information that  is necessary to disclose in confidence to an IEC/IRB solely for the 
evaluation of the study  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 114 • Information that is necessary to disclose to provide appropriate medical care to a 
patient  
• Study results that may be published as described in Section  14.[ADDRESS_500609]’s provisions shall  apply rather than this statement.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 115 15. REFERENCES   
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD -IDSA recommendations for 
testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932 -
54.  
Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of esophageal cancer by [CONTACT_397831] 2012. Gut. 2015;64(3):381 -7.   
Beers SA, Glennie MJ, White AL. Influen ce of immunoglobulin isotype on therapeutic antibody 
function. Blood. 2016;127(9):1097 -101.  
BeiGene Investigator’s Brochure, Tislelizumab. Edition 5.0, February 2018.   
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune -related adverse events in 
patients treated with immune checkpoint inhibitor therapy: American Society of Clinical 
Oncology  clinical practice guideline. J Clin Oncol. 2018;36(17):[ADDRESS_500610] 
procedures. Stat Med. 2009;28(4):586 -604.  
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 
2016;66(2): 115 -32.   
Dahan R, Sega E, Engelhardt J, et al. FcgRs modulate the antitumor activity of antibodies 
targeting the P D-1/PD -L1 axis. Cancer Cell. 2015;28(3):285 -95.  
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1997 -2007 by [CONTACT_397832]: results of EUROCARE --5-a population -based study. Lancet Oncol. 2014;15(1):23 -34.  
Doi T, Pi[INVESTIGATOR_43154] -Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti -programmed death -1 
antibody pembrolizumab in patients with advanced esophageal carcinoma. JCO. 2017;36(1):61 -7.  
Dolgin M, NYH A, Fox AC, Gorlin R, et al. Nomenclature and criteria for diagnosis of diseases of 
the heart and great vessels. 9th ed. [LOCATION_011], MA: Lippi[INVESTIGATOR_4603]; March 1, 1994.   
Drahos J, Wu M, Anderson WF, et al. Regional variations in esophageal cancer rates by [CONTACT_397833], 1999 -2008. PLoS One. 2013;8(7):e67913.   
Edge SB, By[CONTACT_3238], Compton CC, et al, editors. AJCC cancer staging manual (7th ed). [LOCATION_001], 
NY: Springer; 2010.   
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and 
Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr.   
Food and D rug Administration Center for Drug Evaluation Research (CDER) and Center for 
Biologics Evaluation and Research.  FDA guidance for industry: clinical trial endpoints for the 
approval of cancer drugs and biologics . 2018.  
Grunberger B, Raderer M, Schmidinger M, et al. Palliative chemotherapy for recurrent and 
metastatic esophageal cancer. Anticancer Res. 2007;27(4C):2705 -14.  
Gül N, van Egmond M. Antibody -dependent phagocytosis of tumor cells by [CONTACT_179968]: a 
potent effector mechanism of monoclonal antibody therapy of cancer . Cancer Res. 
2015;75(23):5008 -13.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 116 Haanen JBAG, Carbonnel F, Robert C, et al.  Management of toxicities from immunotherapy: 
ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow -up. Ann Oncol. 
2017:28(supplement 4):iv119 -42.  
Huang J, Xu J, Chen Y, et al. Phase 3 study of camrelizumab vs chemotherapy for locally 
advanced/metastatic esophageal cancer: The ESCORT Study (15th OESO World Conference for 
Esophageal Diseases  oral presentation). November 7 -9, 2019; Beijing, China .  
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for 
expedited reporting E2A. 1994 .  
Japanese Gastric Cancer Association. Japanese gastric cancer  treatment guidelines 2014 (ver. 4). 
Gastric Cancer. 2017;20(1):[ADDRESS_500611], 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 201 8. 
http://www.icmje.org. Accessed 20 May 2020.  
Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced 
oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy  
(ATTRACTION -3): a multicentre, randomised, open -label, phase 3 trial. Lancet Oncol. 
2019;20:[ADDRESS_500612]-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE -590 study  
[ESMO Abstract LBA8_PR] . Ann Oncol. 2020 ; 31:S1192 -3.  
Kojima T, Muro  K, Francois E, et al. Pembrolizumab versus chemotherapy as second -line therapy 
for advanced esophageal cancer: Phase III KEYNOTE -181 study ([ADDRESS_500613]) . J Clin Oncol . 2019; 37(suppl 4).   
Koren E, Smith HW, Shores E, et al. Recommendations on risk -based strategies for detection and 
characterization of antibodies against biotechnology products. J Immunol Methods. 
2008;333(1 -2):1-9.  
Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous -cell 
carcinoma: an open -label, multicentre, phase 2 trial. Lancet Onco l. 2017;18(5):631 -9.  
Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab -
arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27(8):767 -71.  
Li M, Wan X, Wang  Y, et al. Time trends of esophageal and gastric cancer mortality in China, 
1991 -2009: an age -period -cohort analysis. Sci Rep. 2017;7(1):6797.   
Lin MQ, Li YP, Wu SG, et al. Differences in esophageal cancer characteristics and survival 
between Chinese and Caucasian patients in the SEER database. Onco Targe ts Ther. 
2016;9:[ADDRESS_500614] -line 
treatment for patients with advanced squamous cell  esophageal cancer. Am J Cancer Res . 
2016;6(10):2345 -50.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 117 Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice 
Guidelines  for diagnosis, treatme nt, and follow -up. Ann Oncol . 2016 ;27(Suppl 5) :v50-7.  
Makarova -Rusher OV, Medina -Echeverz J, Duffy AG, et al. The yin and yang of evasion and 
immune activation in HCC. J Hepatol. 2015;62:1420 -9.  
National Comprehensive Cancer Network (NCCN) guidelines version 1. (2017). Esophageal and 
esophagogastric junction cancers . 
https://www.nccn.org/professi onals/physician_gls/f_guidelines.asp#esophageal   
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1 982;5(6):649 -55.  
Oxaliplatin (Eloxatin®) [prescribing information]. Bridgewater, NJ: [COMPANY_011] -Aventis ; 2014.   
Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular 
carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(12):681 -700.  
Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 
2015;33(16):1760 -9.  
Shirasu H, Tsushima T, Furut a M, et al. Prognostic significance of nutritional risk index in 
patients with metastatic esophageal squamous cell cancer. J Clin Oncol. 2018;36(4):156 .  
Siegel RL, Miller KD, Jem al A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7 -30.  
Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions --guidelines for 
healthcare prov iders. Resuscitation. 2008;77(2):157 -69.  
Stahl M, Oliveira J, ESMO Guidelines Working Group. Esophageal cancer: ESMO clinical 
recommendations for diagnosis, treatment and follow -up. Ann Oncol . 2009; [ADDRESS_500615] 4 : 32-3.  
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of 
chronic h epatitis B: AASLD 2018 hepati tis B guidance. Clin Liver Dis (Hoboken). 
2018;12(1):33 -4.  
Vahle JL. Immunogenicity and Immune Complex Disease in Preclinical Safety Studies. Toxicol  
Pathol. 2018;46(8):1013 -19.  
Worobec AS , Rosenberg AS. A risk-based approach to immunogenicity concerns of therapeutic 
protein products, part 1: considering consequences of the immune response to a protein . BioPharm 
Intl. 2004a;17(11). http://www.biopharminternational.com/risk -based -approach -immunogenicity -
concerns -therapeutic -protein -products -part-1-considering -conseque. Accessed [ADDRESS_500616] 2017.   
Worobec AS , Rosenberg AS. A risk-based approach to immunogenicity concerns of therapeutic 
protein products, part 2: considering host -specific and product -specific factors impacting 
immunogeni city. BioPharm Intl. 2004b;17(12). http://www.biopharminternational.com/risk -
based -approach -immunogenicity -concerns -therapeutic -protein -products -part-2-considering -host-
spe. Accessed [ADDRESS_500617] 2017.   
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 118 APPENDIX  1. SCHEDULE OF ASSESSMENTS   
Assessment  Screening1 Treatment Cycles  Safety Follow -up3 
Survival 
Follow -up4 Cycles 1 to 3  
(every 21 days)  Cycle 4 and 
Subsequent 
Cycles  
(Every 21 Days)  End of Treatment  
Visit2 
Days (Window)  -28 to ~ -1 1 (± 3)  8 (± 2)  15 (± 2)  1 (± 3)   
30 ± [ADDRESS_500618] 
Dose  Every 3 
Months  
(± 14 days)  
Informed consent  x       
Inclusion/exclusion criteria  x       
Randomization5 x       
Demographics/medical history/prior 
medications/ ongoing cancer symptoms6 x       
Cancer diagnosis and treatment history6 x       
Vital signs/height and weight7 x x x x x x  
Physical examination8 x x   x x  
ECOG Performance Status  x x   x x  
12-lead ECG9 x As clinically indicated  x  
Optical coherence tomography (or 
equivalent diagnostic test) and visual 
acuity tests10 x Approximately every 15 weeks  x  
Adverse events11 x x x25 x25 x x  
Concomitant medications12 x x x25 x25 x x  
Hematology13 x1 x x x x x  
Serum chemistry13 x1 x x x x x  
Coagulation  parameters 13 x x   x x  
Urinalysis13 x As clinically indicated   
Pregnancy test14 x x   x x  
Thyroid function15 x1    x x  
HBV/HCV tests16 x Every 4 cycles and as clinically indicated   
Pulmonary function tests17 x As clinically indicated    
Pharmacokinetics18  x   x x  
Anti-tislelizumab  antibodies19  x   x x  
Tumor assessment20 x    x x x 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 119 Assessment  Screening1 Treatment Cycles  Safety Follow -up3 
Survival 
Follow -up4 Cycles 1 to 3  
(every 21 days)  Cycle 4 and 
Subsequent 
Cycles  
(Every 21 Days)  End of Treatment  
Visit2 
Days (Window)  -28 to ~ -1 1 (± 3)  8 (± 2)  15 (± 2)  1 (± 3)   
30 ± [ADDRESS_500619] 
Dose  Every 3 
Months  
(± 14 days)  
Archival tumor tissue21 x       
Fresh tumor tissue22 x  x22 (when PD is assessed)   
Study drug administration23  x   x   
EQ-5D-5L24 x x   x x  
EORTC QLQ -C3024 x x   x x  
EORTC QLQ -OES1824 x x   x x  
Survival status        x 
Blood sample collection   x26 x27 (when CR/PR and/or PD is assessed)   
Abbreviations: ADA, antidrug antibodies; AE, adverse event; CT, computed tomography; DNA, deoxyribonucleic acid; ECG, electrocardiogram; ECOG, 
Eastern Cooperative Oncology Group; EORTC QLQ -OES18, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
Oesophageal Carcinoma -18 Questions; EORTC QLQ -C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire -Core 30; 
EOT, end of treatment; EQ -5D-5L, European Quality of Life  5 Dimensions (health questionnaire); FFPE, formalin fixed paraffin -embedded; HBcAb, hepatitis B 
core antibody; HBsAg, hepatitis B surface antigen; HBV,  hepatitis B virus; HCV, hepatitis C virus; HBsAb, hepatitis B surface antibody; imAE, immune -
mediated adverse event ; IRB, Institutional Review Board; IEC,  Independent Ethics Committee; IRT, interactive response technology; MRI, magnetic resonance 
imaging; NCI -CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; OCT, optical coher ence tomography; PET, positron 
emission tomography; PK, pharmacokinetic; RECIST, Response Evaluation Criteria in Solid Tumors; RNA, ribonucleic acid; SAE, s erious adverse event; T3, 
triiodothyronine; T4, thyroxine; TSH, thyroid stimulating hormone; v,  version. 
1. Written informed consent is required prior to performing any study -specific tests or procedures. Results of standard of care tests or examinations performed 
prior to obtaining informed consent and within 28 days prior to randomization may be used for screening assessments rather than repeating such tests (only 
applicable if the same radiographic procedure will be used throughout the study).  
2. The EOT/Safety Follow -up Visit is conducted when the Investigator determines that tislelizumab or chemotherapy wi ll no longer be used. If routine 
laboratory tests (eg, hematology, serum chemistry) are completed within [ADDRESS_500620] assessment.  
3. The EOT/Safety Follow -up Visit is required to be conducted 30 days (± 7 days) after the last dose of tislelizumab or chemotherapy, before the initi ation of a 
new anticancer treatment, or before the first dose administration in  the long-term extension /posttrial supply  study  for patients who are going to rollover to 
those studies , whichever occurs first . Patients receiving paclitaxel will need to be followed for safety and pregnancy for [ADDRESS_500621] dose.  
4. Survival Follow -up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months  after the 
Safety Follow -up Visit until death, loss to follow -up, withdrawal of consent, or study termination by [CONTACT_2728]. All patie nts will be followed for survival and 
subsequent anticancer therapy information unless a patient requests to be withdrawn from follow -up. 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 120 5. Patients will be randomized into either the tislelizumab with chemotherapy or placebo with chemotherapy arms via IRT. All patients are required to receive 
study treatment within 2 business days of randomization.  
6. Includes age or year of birth, gender, and self -reported race/ethnicity; history of treatment for the primary diagnosis, including prior medication, loco -
regional  treatment(s), and surgical treatment(s). Information on radiographic studies performed prior to study entry may be collected for review by [CONTACT_3786].  
7. Vital signs collected on study include body temperature, pulse rate, and blood pressure (systolic and diastolic) while the patient is in a seated position after 
resting for 10 minutes. The patient’s vital signs are required to be recorded within [ADDRESS_500622], and optical coherence tomography (OCT; or equivalent diagnostic test for retinal examination ) captured as standard of care 
prior to obtaining written informed consent and within [ADDRESS_500623], and optical coherence tomography (or  equivalent diagnostic test) will be assessed by [CONTACT_397834]. All patients will undergo repeat assessments approximately every 15 weeks (± 7 days) during study treatment and a final assessment at the 
EOT/Safety follow -up visit.  
11. The AEs and laboratory abnormalities will be graded per NCI -CTCAE v4.03. All AEs will also be evaluated for seriousness. After the informed consent 
form has been signed, but prior to the administration of study drug, only SAEs should be reported. After initiation of study drug, all AEs and SAEs, 
regardless of relationship to study drug, will be reported until either [ADDRESS_500624] dose of study drugs (including che motherapy) or the initiation of new 
anticancer therapy, whichever occur s first. Immune -mediated AEs (serious or non -serious) should be reported until [ADDRESS_500625] documentation of medications will be recorded. Only new anti -cancer treatment will b e collected at Survival 
Follow -up Visits.  
13. Local and/or central laboratory assessments on serum chemistry, hematology, coagulation, and urinalysis will be conducted, of  which certain elements will 
be collected as specified in Appendix  2. If laboratory tests at screening are not performed within 7 days of Cycle 1, Day 1, these tests should be repeated and 
reviewed before study drug(s) administration. H ematology and serum chemistry (including liver function tests) will be performed weekly for the first 3 
cycles and then at the beginning of subsequent cycles (data collected as specified in Appendix  2). After Cycle 1, results are to be reviewed within [ADDRESS_500626] ( for women of childbearing potential, including women who have had a tubal ligation) must be performed and documented as negat ive 
within 7 days prior to randomization. Serum pregnancy tests will be performed at each visit prior to dosing.  
15. Analysis of FT3, FT4, and TSH will be performed by a central laboratory or the local study site laboratory. Thyroid function tests will be per formed at 
Screening and every 3 cycles (ie, Day 1 of Cycles 4, 7, 10, et cetera), and at the Safety Follow -up Visit.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 121 16. Testing will b e performed by a central laboratory and/or the local laboratory at Screening and will include HBV/HCV serology (HBsAg, HBsAb,  HBcAb, 
and HCV antibody). If HBsAg or HBcAb is positive, then an HBV DNA test will be triggered. If HCV antibody is positive, an H CV RNA test will be 
triggered.  
17. Patients who are suspected or known to have serious/severe respi[INVESTIGATOR_397697] a history of thoracic radiotherapy will have pulmonary function testing which may include, but is not limited to, spi[INVESTIGATOR_397698].  
18. Procedures for collection of PK samples are described in th e Laboratory Manual. Predose (within 60 minutes before starting infusion) samples are required 
to be collected at Day 1 of Cycles 1, 2, 5, 9 and 17; A postdose (within 30 minutes after completing tislelizumab infusion) s ample is required to be collected 
at Day 1 of Cycles 1 and 5. If IP treatment is not given, the predose PK samples are still recommended to be collected when pati ents are available at the 
study site. An additional PK sample is required to be collected at the Safety Follow -up Visit. Should a patient present with any ≥  Grade  3 imAE, an 
additional blood PK sample may be taken to determine the serum concentration of tislelizumab. These tests are required when i t is allowed by [CONTACT_13125]/IRBs/ECs. PK sample collection will stop after patien ts finish [ADDRESS_500627] for anti -tislelizumab antibodies should be collected within 60 minutes before beginning the Day 1 infusion of Cycles 1, 2, 5, 9, and 1 7 and 
at the mandatory Safety Follow -up Visit. All samples should be drawn  at the same time as blood collection for predose PK analysis. If IP treatment is not 
given, the predose ADA samples are still recommended to be collected when patients are available at the study site. These tes ts are required when it is 
allowed by [CONTACT_5737] r egulations/IRBs/ECs.  ADA sample collection will stop after patients finish [ADDRESS_500628] of care prior to obtaining written informed consent and within 28  days of randomization may be used rather than 
repeating tests (only applicable if the same radiographic procedure will be used throughout the study). All measurable and evaluable le sions are required to 
be assessed and documented at Screening and reassessed at each subsequent tumor evaluation. An MRI (or CT sca n if MRI is contraindicated or not readily 
available) of the head may be required at screening based on clinical judgement; bone scan or PET is required if clinically i ndicated. The same radiographic 
procedure must be used throughout the study for each pat ient.  
The Investigator must review radiograph results before dosing at the next cycle. During the study, tumor imaging will be perf ormed every 6 weeks (± 7 
days) for the first 48 weeks, then every 9 weeks (± 7 days) after [ADDRESS_500629] v1.1. If a tumor assessment is missed or conducted outside of 
the specified assessment window, all subsequent scans should be conducted on the planned schedule. The Investigator may perform additional scans or more 
frequent assessments if clinically indicated. See  Section  7.5 for more information. Patients who discontinue study treatment early for reasons other than 
documented radiographic disease progression  (eg, toxicity) will continue to undergo tumor assessments following the original plan until the patient 
experiences disease progression, withdraws consent, is lost to follow -up, dies, or until the study terminates, whichever occurs first. Tumor assessment  should 
continue as planned in patients receiving study drug(s) beyond initial investigator -assessed progression. Tumor assessment in such patients should continue 
until study treatment discontinuation.   
21. Patients are required to provide archival tumor tiss ues (FFPE blocks or approximately 15 [≥ 6] unstained slides) for biomarker analysis.  
22. Fresh biopsy: In the absence of archival tumor tissues, a fresh biopsy of a tumor lesion at baseline (within 28 days before r andomization) is needed (written 
informed cons ent is required prior to fresh tumor biopsies). An optional biopsy will be taken for patients with confirmed disease progress ion during the 
study. See Section  7.[ADDRESS_500630], fo llowed by [CONTACT_181867] 30 -minute observation period for safety surveillance, then the chemotherapy doublet 
will be administered (see Section  5.2). The chemotherapy doublet may be administered without regard to the sequence of chemotherapy (note that in 
Chemotherapy Doublet B, capecitabine is given orally daily). Platinum therapy may be stopped after [ADDRESS_500631] 
practice. If platinum treatment is stopped, the non -platinum agent (fluoropyrimidine or paclitaxel) may continue at the regular schedule.  
24. To be completed prior to any clinical activities during on -study site visits. EQ -5D-5L, EORTC QLQ -C30, and E ORTC QLQ -OES18 will be completed at 
baseline, after randomization, prior to dosing or any clinical activities at every treatment cycle for the first 6 cycles, th en every other cycle thereafter, and at 
the EOT Visit.  Patient -reported outcome  collection will stop after patients finish 3 -year follow up.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 122 25. Review of AEs and concomitant medications may be conducted by [CONTACT_397835] 8 and 15.  
26. Blood sample will be taken at baseline (predose on Day 1 of Cycle 1) for all randomized patients to explore the associat ion of blood -based biomarkers with 
response and prognosis to tislelizumab in combination with chemotherapy or chemotherapy alone. Written patient consent is req uired for blood sample 
collection.  
27. Blood samples are highly recommended to be collected at first  tumor response (CR/PR) and/or at confirmed disease progression  to explore response and/or 
resistance mechanism to tislelizumab in combination with chemotherapy or chemotherapy alone. Written patient consent is requi red for optional blood 
sample collection. See Section 7.8 for more information.  
Approved Date 3/13/[ADDRESS_500632] bilirubin  
- Blood urea nitrogen or 
urea 
- Potassium  
- Sodium  
- Chloride  
- Magnesium  
- Phosphorous  
- Total  calciuma 
- Creatinine  
- Glucose  
- Lactate 
dehydrogenase  
- Total protein  
- Creatine kinase (CK)b 
- CK-MBb 
- Lipase and/or 
Amylase  - Hematocrit  
- Hemoglobin  
- Red blood cell 
count  
- Platelet counts  
- WBC count 
with automated 
differential  
- Lymphocyte 
count  
- Neutrophil 
count  - Prothrombin time  
- Partial thromboplastin 
time or activated 
partial thromboplastin 
time 
- International 
normalized ratio  - Glucose  
- Protein  
- Blood  
- Ketones  - TSH  
- Free T3  
- Free T4  - HBsAb  
- HBsAg  
- HBcAb  
- HBV DNAc 
- HCV Ab  
- HCV RNAc 
Abbreviations: Ab, antibody; CK -MB, creatine kinase cardiac isoenzyme ; DNA, deoxyribonucleic acid; HBcAb, 
hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; pH, negative of the 
logarithm to base 10 of the activity of the  (solvated) hydronium ion; RNA, ribonucleic acid; T3, triiodothyronine; 
T4, thyroxine; TSH, thyroid -stimulating hormone; WBC, white blood cells.  
a. For patients with hypoproteinemia, this value needs to be corrected, which means a corrected calcium is needed  
Formula  to calculate the corrected calcium : Corrected Calcium = (0.8*(Normal Albumin -Pt’s Albumin)) + Serum Calcium  
Note: above formula assumes albumin units in g/dL. (online calculator is available at http:// www.mdcalc.com/calcium -
correction -hypoalbumin emia#evidence)  
b. In the event CK -MB fractionation is not available, please assess troponin I and/or troponin T instead.  
c. If HBsAg or HBcAb is positive, then an HBV DNA test will be triggered. If HCV antibody is positive, an HCV RNA test 
will be triggered.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 124 APPENDIX  3. ECO G PERFORMANCE STATUS   
Grade  Description  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, eg, light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours  
3 Capable of only li mited self -care, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
As published by ( Oken et al 1982 ). Eastern Cooperat ive Oncology Group, Robert Comis M.D., Group Chair.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 125 APPENDIX  4. THE RESPONSE EVALUATION CRITERIA IN SOLID 
TUMORS (RECIST) GUIDELINES, VERSION 1.1   
The text below was obtained from the following reference:  
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST 
guidel ine (Version 1.1). Eur J Cancer. 2009;45:228 -247. 
DEFINITIONS  
Response and progression will be evaluated in this trial using the international criteria proposed 
by [CONTACT_8225] (RECIST) Committee (v1.1).  Changes in 
only the largest diameter (unidimensional measurement) of the tumor lesions are used in the 
RECIST criteria.  
 
Note: Lesions are either measurable or non -measurable using the criteria provided below.  The 
term “evaluable” in reference to measurability will not  be used because it does not provide 
additional meaning or accuracy.  
Measurable Disease  
Tumor lesions: Must be accurately measured in at least 1 dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:  
• [ADDRESS_500633] scan (irrespective of scanner type) and MRI (no less than double the 
slice thickness and a minimum of 10  mm)  
• 10 mm caliper measurement by [CONTACT_461] (when superficial)  
• [ADDRESS_500634] X -ray (if clearly defined and surrounded by [CONTACT_6776])  
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥  [ADDRESS_500635] scan (CT scan slice thickness 
recommended to be no greater than 5  mm).  At baseline and in follow -up, only the sh ort axis will 
be measured and followed.  
Nonmeasurable Disease  
All other lesions (or sites of disease), including small lesions (longest diameter ≥ 10 to < 15  mm 
with conventional techniques or <  [ADDRESS_500636] scan), are considered nonmeasurable 
disease.  Leptomeningeal disease, ascites, pleural, or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly 
identified by [CONTACT_397836] -measurable.  
Bone lesions:  
• Bone scan, PET scan, or plain films are not considered adequate imaging techniques 
to measure bone lesions.  However, these techniques can be used to confirm the 
presence or disappearance of bone lesions.  
• Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components, that can be evaluated by [CONTACT_397837] 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 126 or MRI can be considered as measurable lesions if the soft tissue component meets 
the definition of measurability described above  
• Blastic bone lesions are nonmeasurable  
Cystic lesions:  
• Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor nonmeasurab le) since they 
are, by [CONTACT_108], simple cysts  
• Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above.  However, if 
noncystic lesions are present in the s ame patient, these are preferred for selection as 
target lesions.  
Lesions with prior local treatment:  
• Tumor lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  Trial protocols should detail the conditions 
under which such lesions would be considered measurable.  
Target Lesions  
All measurable lesions up to a maximum of 2  lesions per organ and  5 lesions in total, should be 
identified as target lesions and recorded and measured at baseline.  Target lesions should be 
selected on the basis of their size (lesions with the longest diameter), be representative of all 
involved organ, but in addition s hould be those that lend themselves to reproducible repeated 
measurements.  
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by [CONTACT_33490].  Pathological nodes which are defined as  
measurable and may be identified as target lesions must meet the criterion of a short axis of 
≥ [ADDRESS_500637] in which 
the image is obtained (for CT scan, this is almost always the axial plane; for MRI, the plane of 
acquisition may be axial, sagittal,  or coronal).  The smaller of these measures is the short axis. 
For example, an abdominal node which is reported as being 20  mm × 30 mm has a short axis of 
20 mm and qualifies as a malignant, measurable node.  In this example, 20  mm should be 
recorded as t he node measurement.  All other pathological nodes (those with short axis ≥10  mm 
but < 15  mm) should be considered nontarget lesions.  Nodes that have a short axis < 10  mm are 
considered nonpathological and should not be recorded or followed.  
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added i nto the sum.  The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 127 Nontarget Lesions  
All other lesions (or sites of disease) including pathological lymph nod es should be identified as 
non-target lesions and should also be recorded at baseline.  Measurements are not required and 
these lesions should be followed as “present”, “absent”, or in rare cases “unequivocal 
progression” (more details to follow).  In addi tion, it is possible to record multiple nontarget 
lesions involving the same organ as a single item on the case record form (eg, “multiple enlarged 
pelvic lymph node” or “multiple liver metastases”).  
GUIDELINES FOR EVALUATION OF MEASURABLE DISEASE  
All meas urements should be recorded in metric notation, using calipers if clinically assessed.  All 
baseline evaluations should be performed as close as possible to the treatment start and never 
more than 4  weeks before the beginning of the treatment.  
The same met hod of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up.  Imaging based evaluation should 
always be done rather than clinical examination unless the lesion(s) being follow ed cannot be 
imaged but are accessible by [CONTACT_12148].  
Clinical lesions: Clinical lesions will only be considered measurable when they are superficial 
and P10  mm diameter as assessed using calipers (eg, skin nodules).  For the case of skin lesions , 
documentation by [CONTACT_3606] a ruler to estimate the size of the lesion is 
suggested.  As noted above, when lesions can be evaluated by [CONTACT_338573], imaging evaluation should be undertaken since it is more object ive and may also be 
reviewed at the end of the trial.  
• Chest X -ray: Chest CT is preferred over chest X -ray, particularly when progression is 
an important endpoint, since CT is more sensitive than X -ray, particularly in 
identifying new lesions.  However, les ions on chest X -ray may be considered 
measurable if they are clearly defined and surrounded by [CONTACT_6776].  
• CT, MRI: CT is the best currently available and reproducible method to measure 
lesions selected for response assessment.  This guideline has define d measurability of 
lesions on CT scan based on the assumption that CT slice thickness is [ADDRESS_500638] slice thickness greater than 5  mm, the minimum size for a 
measurable lesion should be twice the slice thickness. MRI is also acceptab le in 
certain situations (eg, for body scans).  
• Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be 
used as a method of measurement.  Ultrasound examinations cannot be reproduced in 
their entirety for independent review at a later date and, because they are operator 
dependent, it cannot be guaranteed that the same technique and measurements will be 
taken from one assessment to the next.  If new lesions are identified by [CONTACT_397838], confirmation by [CONTACT_118447].  If there is concern 
about radiation exposure at CT, MRI may be used instead of CT in selected instances.  
• Endoscopy, laparoscopy: The utilization of these techniques for objective tumor 
evaluation is not advised.  However, they can be u seful to confirm complete 
pathological response when biopsies are obtained or to determine relapse in trials 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 128 where recurrence following complete response (CR) or surgical resection is an 
endpoint.  
• Tumor markers: Tumor markers alone cannot be used to assess  objective tumor 
response.  If markers are initially above the upper normal limit, however, they must 
normalize for a patient to be considered in CR.  Because tumor markers are disease 
specific, instructions for their measurement should be incorporated int o protocols on a 
disease specific basis.  Specific guidelines for both CA -125 response (in recurrent 
ovarian cancer) and prostate -specific antigen response (in recurrent prostate cancer), 
have been published.  In addition, the Gynecologic Cancer Intergroup  has developed 
CA-[ADDRESS_500639] -line trials in ovarian cancer.  
• Cytology, histology: These techniques can be used to differentiate between PR and 
CR in rare cases if requ ired by [CONTACT_990] (for example, residual lesions in tumor types 
such as germ cell tumors, where known residual benign tumors can remain).  When 
effusions are known to be a potential adverse effect of treatment (eg, with certain 
taxane compounds or angiogene sis inhibitors), the cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens during treatment can be 
considered if the measurable tumor has met criteria for response or stable disease to 
differentiate between response (or stable disease) and progressive disease.  
RESPONSE CRITERIA  
Evaluation of Target Lesions  
• Complete Response (CR): Disappearance of all target lesions.  Any pathological 
lymph nodes (whether target or nontarget) must have reduction in short axis to 
< 10 mm. 
• Partial Response (PR): At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters  
• Progressive Disease (PD): At least a 20% increase in the sum of diameters of target 
lesions, taking as referen ce the smallest sum on study (this includes the baseline sum 
if that is the smallest on study).  In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5  mm.  (Note: the appearance 
of 1 or more new lesio ns is also considered progression).  
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on 
study  
• Lymph nodes: Lymph nodes identified as target l esions should always have the actual 
short axis measurement recorded (measured in the same anatomical plane as the 
baseline examination), even if the nodes regress to below 10  mm on study.  This 
means that when lymph nodes are included as target lesions, t he “sum” of lesions 
may not be zero even if CR criteria are met, since a normal lymph node is defined as 
having a short axis of <  [ADDRESS_500640] achieve a short axis <10  mm.  For PR, SD and PD, 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 129 the actual short axis measurement of the nodes is to be included in the sum of target 
lesions.  
• Target lesions that become “too small to measure”.  While on study, all lesions (nodal 
and non -nodal) recorded at baseline should have their actua l measurements recorded 
at each subsequent evaluation, even when very small (eg, 2  mm).  However, 
sometimes lesions or lymph nodes which are recorded as target lesions at baseline 
become so faint on CT scan that the radiologist may not feel comfortable ass igning an 
exact measure and may report them as being “too small to measure”.  
When this occurs, it is important that a value be recorded on the eCRF.  If it is the 
opi[INVESTIGATOR_26191], the measurement 
should be  recorded as 0  mm.  If the lesion is believed to be present and is faintly seen 
but too small to measure, a default value of 5  mm should be assigned (Note: It is less 
likely that this rule will be used for lymph nodes since they usually have a definable 
size when normal and are frequently surrounded by [CONTACT_104178]; however, if a lymph node is believed to be present and is faintly 
seen but too small to measure, a default value of 5  mm should be assigned in this 
circumstance as well).  This default value is derived from the [ADDRESS_500641] slice 
thickness (but should not be changed with varying CT slice thickness).  The 
measurement of these lesions is potentially non -reproducible, therefore providing this 
default value will prevent false respons es or progressions based upon measurement 
error.  To reiterate, however, if the radiologist is able to provide an actual measure, 
that should be recorded, even if it is below 5  mm. 
• Lesions that split or coalesce on treatment : When non -nodal lesions “fragment”, the 
longest diameters of the fragmented portions should be added together to calculate the 
target lesion sum.  Similarly, as lesions coalesce, a plane between them may be 
maintained that would aid in obtaining maximal diameter measurements of e ach 
individual lesion.  If the lesions have truly coalesced such that they are no longer 
separable, the vector of the longest diameter in this instance should be the maximal 
longest diameter for the “coalesced lesion”.  
Evaluation of Nontarget Lesions  
While  some nontarget lesions may actually be measurable, they need not be measured and 
instead should be assessed only qualitatively at the time points specified in the protocol.  
• CR: Disappearance of all nontarget lesions and normalization of tumor marker level .  
All lymph nodes must be nonpathological in size (<10  mm short axis).  
• PD: Unequivocal progression (as detailed below) of existing nontarget lesions.  
(Note: the appearance of 1 or more new lesions is also considered progression.)  
• Non-CR/Non -PD: Persisten ce of 1 or more nontarget lesion(s) and/or maintenance of 
tumor marker level above the normal limits  
• When the patient also has measurable disease : In this setting, to achieve “unequivocal 
progression” on the basis of the nontarget disease, there must be an  overall level of 
substantial worsening in nontarget disease such that, even in presence of SD or PR in 
Approved Date 3/13/[ADDRESS_500642] “increase” in the size of 1 or more n ontarget 
lesions is usually not sufficient to qualify for unequivocal progression status.  The 
designation of overall progression solely on the basis of change in nontarget disease 
in the face of SD or PR of target disease will therefore be extremely rare.  
• When the patient has only nonmeasurable disease:  This circumstance arises in some 
Phase  [ADDRESS_500643] measurable disease.  The 
same general concept applies here as noted above, however, in this instance there i s 
no measurable disease assessment to factor into the interpretation of an increase in 
nonmeasurable disease burden.  Because worsening in nontarget disease cannot be 
easily quantified (by [CONTACT_108]: if all lesions are truly nonmeasurable) a useful test 
that can be applied when assessing patients for unequivocal progression is to consider 
if the increase in overall disease burden based on the change in nonmeasurable 
disease is comparable in magnitude to the increase that would be required to declare 
PD for  measurable disease: ie, an increase in tumor burden representing an additional 
73% increase in “volume” (which is equivalent to a 20% increase diameter in a 
measurable lesion).  
• Examples include an increase in a pleural effusion from “trace” to “large”, a n 
increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as “sufficient to require a change in therapy”.  If “unequivocal progression” 
is seen, the patient should be considered to have had overall PD at that point.  While 
it would be ideal to have objective criteria to apply to nonmeasurable disease, the 
very nature of that disease makes it impossible to do so, therefore the increase must 
be substantial.  
New Lesions  
The appearance of new malignant lesions denotes dis ease progression; therefore, some 
comments on detection of new lesions are important.  There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal: ie, not attributable to di fferences in scanning technique, change in imaging 
modality or findings thought to represent something other than tumor (for example, some “new” 
bone lesions may be simply healing or flare of pre -existing lesions).  This is particularly 
important when the patient’s baseline lesions show PR or CR. For example, necrosis of a liver 
lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not.  
A lesion identified on a follow -up trial in an anatomical location that was not scanned at base line 
is considered a new lesion and will indicate disease progression.  An example of this is the 
patient who has visceral disease at baseline and while on trial has a CT or MRI brain ordered 
which reveals metastases.  The patient’s brain metastases are co nsidered to be evidence of PD 
even if he/she did not have brain imaging at baseline.  
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease. If repeat scans confirm there 
is definitely a new lesion, then progression should be declared using the date of the initial scan.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 131 While fluorodeoxyglucose (FDG) -PET response assessments need additional study, it is 
sometimes reasonable to incorporate the use of FDG -PET scanning to complement CT scanning 
in assessment of progression (particularly possible “new” disease).  New lesions on the basis of 
FDG -PET imaging can be identified according to the following algorithm:  
Negative FDG -PET at baseline, with a positive FD G-PET at follow -up, is a sign of PD based on 
a new lesion.  
• No FDG -PET at baseline and a positive FDG -PET at follow -up: If the positive 
FDG -PET at follow -up corresponds to a new site of disease confirmed by [CONTACT_4654], this is 
PD.  If the positive FDG -PET at follow -up is not confirmed as a new site of disease 
on CT, additional follow -up CT scans are needed to determine if there is truly 
progression occurring at that site (if so, the date of PD will be the date of the initial 
abnormal FDG -PET scan).  If the positive FDG -PET at follow -up corresponds to a 
pre-existing site of disease on CT that is not progressing on the basis of the anatomic 
images, this is not PD.  
Evaluation of Best Overall Response  
The BOR is the best response recorded from the start of the study drug treatment until the end of 
treatment taking into account any requirement for confirmation.  On occasion, a response may 
not be documented until after the end of therapy, so protocols should be clear if post -treatment 
assessments are to be considered i n determination of BOR.  Protocols must specify how any new 
therapy introduced before progression will affect best response designation.  The patient’s BOR 
assignment will depend on the findings of both target and nontarget disease and will also take 
into consideration the appearance of new lesions.  Furthermore, depending on the nature of the 
trial and the protocol requirements, it may also require confirmatory measurement.  Specifically, 
in non -randomized trials where response is the primary endpoint, con firmation of PR or CR is 
needed to deem either one the “best overall response”.  
The BOR is determined once all the data for the patient is known.  Best response determination 
in trials where confirmation of complete or partial response IS NOT required: Bes t response in 
these trials is defined as the best response across all time points (for example, a patient who has 
SD at first assessment, PR at second assessment, and PD on last assessment has a BOR of PR).  
When SD is believed to be best response, it must  also meet the protocol specified minimum time 
from baseline.  If the minimum time is not met when SD is otherwise the best time point 
response, the patient’s best response depends on the subsequent assessments.  For example, a 
patient who has SD at first assessment, PD at second and does not meet minimum duration for 
SD, will have a best response of PD. The same patient lost to follow -up after the first SD 
assessment would be considered unevaluable.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 132 Target Lesions  Nontarget Lesions  New Lesions  Overall Resp onse  
CR 
CR 
CR 
PR 
 
SD 
 
Not all evaluated  
PD 
Any 
Any CR 
Non-CR/non -PD 
Not evaluated  
Non-PD or not all 
evaluated  
Non-PD or not all 
evaluated  
Non-PD 
Any 
PD 
Any No 
No 
No 
No 
 
No 
 
No 
Yes or No  
Yes or No  
Yes CR 
PR 
PR 
PR 
 
SD 
 
NE 
PD 
PD 
PD 
Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable 
disease.  
When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” 
size (<  10 mm), they may still have a  measurement reported on scans.  This measurement should 
be recorded even though the nodes are normal in order not to overstate progression should it be 
based on increase in size of the nodes.  As noted earlier, this means that patients with CR may 
not hav e a total sum of “zero”.  
In trials where confirmation of response is required, repeated ”NE” time point assessments may 
complicate best response determination.  The analysis plan for the trial must address how 
missing data/assessments will be addressed in  determination of response and progression.  For 
example, in most trials it is reasonable to consider a patient with time point responses of 
PR-NE-PR as a confirmed response.  
Patients with a global deterioration of health status requiring discontinuation o f treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration”.  Every effort should be made to document objective progression 
even after discontinuation of treatment.  Symptomatic deterioration  is not a descriptor of an 
objective response: it is a reason for stoppi[INVESTIGATOR_397699].  
Conditions that define “early progression, early death, and unevaluability” are trial specific and 
should be clearly described in each protocol (depending on treatmen t duration, treatment 
periodicity).  
In some circumstances, it may be difficult to distinguish residual disease from normal tissue.  
When the evaluation of CR depends upon this determination, it is recommended that the residual 
lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) before assigning a status of CR.  FDG -PET 
may be used to upgrade a response to a CR in a manner like a biopsy in cases where a residual 
radiographic abnormality is thought to represent fibrosis or scarring.  The use of FDG -PET in 
this circumstance should be prospectively described in the protocol and supported by [CONTACT_397839]. However, it must be acknowledged that both 
approaches may lead to false positive CR due to limitations of FDG -PET and  biopsy resolution/ 
sensitivity.  
For equivocal findings of progression (eg, very small and uncertain new lesions; cystic changes, 
or necrosis in existing lesions), treatment may continue until the next scheduled assessment.  If at 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 133 the next scheduled assess ment, progression is confirmed, the date of progression should be the 
earlier date when progression was suspected.  
CONFIRMATORY MEASUREMENT/DURATION OF RESPONSE  
Confirmation  
In nonrandomized trials where response is the primary endpoint, confirmation of PR  and CR is 
required to ensure responses identified are not the result of measurement error.  This will also 
permit appropriate interpretation of results in the context of historical data where response has 
traditionally required confirmation in such trials .  However, in all other circumstances, ie, in 
randomized trials (Phase 2 or 3) or trials where stable disease or progression are the primary 
endpoints, confirmation of response is not required since it will not add value to the 
interpretation of trial res ults.  However, elimination of the requirement for response confirmation 
may increase the importance of central review to protect against bias, in particular in trials which 
are not blinded.  
In the case of SD, measurements must have met the SD criteria at least once after trial entry at a 
minimum interval (in general not less than 6 weeks).  
Duration of Overall Response  
The duration of overall response is measured from the time measurement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements 
recorded on study).  
The duration of overall CR is measured from the time measurement criteria are first me t for CR 
until the first date that recurrent disease is objectively documented.  
Duration of Stable Disease  
Stable disease is measured from the start of the treatment (in randomized trials, from date of 
randomization) until the criteria for progression are met, taking as reference the smallest sum on 
study (if the baseline sum is the smallest, this is the reference for calculation of PD).  
The clinical relevance of the duration of stable disease varies in different studies and diseases.  If 
the proportion of patients achieving stable disease for a minimum period of time is an endpoint 
of importance in a particular trial, the protocol should specify the minimal time interval required 
between 2 measurements for determination of stable disease.  
Note: The duration  of response and stable disease as well as the PFS are influenced by [CONTACT_118583] -up after baseline evaluation.  It is not in the scope of this guideline to define 
a standard follow -up frequency.  The frequency should take into account many para meters 
including disease types and stages, treatment periodicity, and standard practice.  However, these 
limitations of the precision of the measured endpoint should be taken into account if comparisons 
between trials are to be made.  
Approved Date 3/13/[ADDRESS_500644] the sponsor medical monitor regarding any uncertainty about immune 
deficien cy/autoimmune disease exclusions.  
Acute disseminated encephalomyelitis  Addison’s disease  
Ankylosing spondylitis  Antiphospholipid antibody syndrome  
Aplastic anemia  Autoimmune hemolytic anemia  
Autoimmune hepatitis  Autoimmune hypoparathyroidism  
Autoimmun e hypophysitis  Autoimmune myocarditis  
Autoimmune oophoritis  Autoimmune orchitis  
Autoimmune thrombocytopenic purpura  Behcet’s disease  
Bullous pemphigoid  Chronic inflammatory demyelinating 
polyneuropathy  
Chung -Strauss syndrome  Crohn’s disease  
Dermatomyositis  Dysautonomia  
Epi[INVESTIGATOR_397700]’s syndrome  
Granulomatosis with polyangiitis  Graves’ disease  
Guillain -Barré syndrome  Hashimoto’s disease  
Immunoglobulin A (IgA) nephropathy  Inflammatory bowel disease  
Interstitial cystitis  Kawasaki’s disease  
Lambert -Eaton myasthenia syndrome  Lupus erythematosus  
Lyme disease (chronic)  Mooren’s ulcer  
Morphea  Multiple sclerosis  
Myasthenia gravis  Neuromyotonia  
Opsoclonus myoclonus syndrome  Optic neuritis  
Ord’s thyroiditis  Pemphigus  
Pernicious anemia  Polyarteritis nodusa  
Polyarthritis  Polyglandular autoimmune syndrome  
Primary biliary cirrhosis  Psoriasis  
Reiter’s syndrome  Rheumatoid arthritis  
Sarcoidosis  Sjögren’s syndrome  
Stiff person syndrome  Takayasu’s arteritis  
Ulcerative colitis  Vogt -Kovangai -Harada disease  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 135 APPENDIX  6. NEW YORK HEART ASSOCIATION FUNCTIONAL 
CLASSIFICATION   
 
Class  Symptoms  
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
palpi[INVESTIGATOR_332], dyspnea (shortness of breath).  
II Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results 
in fatigue, palpi[INVESTIGATOR_332], dyspnea (shortness of breath).  
III Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity 
causes fa tigue, palpi[INVESTIGATOR_332], or dyspnea.  
IV Unable to carry on any physical activity without discomfort.  Symptoms of heart failure at rest. 
If any physical activity is undertaken, discomfort increases.  
Adapted from Dolgin et al 1994 . Criteria Committee. Nomenclature and criteria for diagnosis of diseases of the 
heart and great vessels. 9th ed. [LOCATION_011], MA: Lippi[INVESTIGATOR_4603]; March 1, 1994.  
Original source: Criteria Committee, [LOCATION_001] Heart Association, Inc .  Diseases of the Heart and Blood 
Vessels.  Nomenclature and Criteria for diagnosis, 6th edition  [LOCATION_011], Little, Brown and Co.  1964, p 114.  
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 136 APPENDIX  7. IMMUNE -MEDIATED ADVERSE EVENT EVALUATION 
AND MANAGEMENT   
The recommendations below for the diagnosis and management of any immune -mediated AE 
(imAE) are intended as a guidance.  This document should be used in conjunction with expert 
clinical judgement (by [CONTACT_397840]), and individual institutional guidelines or policies.  
Criteria used to diagnose imAEs include blood tests, diagnostic imaging, histopathology, a nd 
microbiology assessments to exclude alternative causes such as infection, disease progression, 
and adverse effects of concomitant drugs.  In addition to the results of these tests, the following 
factors should be considered when making an imAE diagnosis :  
• What was the temporal relationship between initiation of tislelizumab and the adverse 
event?  
• How did the patient respond to withdrawal of tislelizumab?  
• Did the event recur when tislelizumab was reintroduced?  
• Was there a clinical response to corticostero ids? 
• Is the event an autoimmune endocrinopathy?  
• Is disease progression or an alternative diagnosis a more likely explanation?  
When alternative explanations to autoimmune toxicity have been excluded, the imAE field 
associated with the adverse event (AE) in the electronic case report form (eCRF) should be 
checked.  
For any adverse events not included in this appendix, please refer to the recent guidelines 
(Haanen et al 2017 ; Brahmer et al 2018 ) for further guidance on diagnostic evaluation and 
management of immune -mediated toxicities.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 137 Recommended Diagnostic Tests in the Management of  
Possible Immune -Mediated Adverse Events  
Immune -mediated  
Toxicity  Diagnostic Evaluation Guideline  
Thyroid Disorders  Scheduled and repeat thyroid function tests (TSH and T4).  
Hypophysitis  Check visual fields and consider pi[INVESTIGATOR_397701].  Perform 
pi[INVESTIGATOR_397702], visual disturbance, 
unexplained fatigue, asthenia, weight loss and unexplained constitutional 
symptoms.  
Consider consultati on with an endocrinologist if an abnormality is detected.  
Pneumonitis  All patients presenting with new or worsened pulmonary symptoms or signs, such 
as an upper respi[INVESTIGATOR_4416], new cough, shortness of breath or hypoxia should 
be assessed by [CONTACT_5019] -resolution CT.  Consider pulmonary function test including 
DLCO .  
Radiographic appearance is often nonspecific.  Depending on the location of the 
abnormality, bronchoscopy and bronchoalveolar lavage or lung biopsy may be 
considered.  Consult with a respi[INVESTIGATOR_397703].  
Neurological Toxicity  Perform a comprehensive neurological examination and brain MRI for all CNS 
symptoms; review alcohol history and other medications.  Conduct a diabetic 
screen, and assess blood B12/ folate, HIV status, TFTs, and consider autoimmune 
serology.  Consider the need for brain/spi[INVESTIGATOR_25342]/MRA and nerve conduction study 
for peripheral neuropathy.  Consult with a neurologist if there are abnormal 
findings.  
Colitis  Review dietary intake and excl ude steatorrhea.  Consider comprehensive testing, 
including the following: FBC, UEC, LFTs, CRP, TFTs, stool microscopy and 
culture, viral PCR, Clostridium difficile toxin, cryptosporidia (drug -resistant 
organism).  
In case of abdominal discomfort, consider  imaging, eg, X -ray, CT scan.  If a patient 
experiences bleeding, pain or distension, consider colonoscopy with biopsy and 
surgical intervention, as appropriate.  
Eye Disorders  If a patient experiences acute, new onset, or worsening of eye inflammation, 
blurred vision, or other visual disturbances, refer the patient urgently to an 
ophthalmologist for evaluation and management.   
Hepatitis  Check ALT/AST/total bilirubin, INR/albumin; the frequency will depend on 
severity of the AE (eg, daily if Grade 3 -4; every 2 -3 days if Grade 2, until 
recovering).  Review medications (eg, statins, antibiotics) and alcohol history.  
Perform liver screen inc luding Hepatitis A/B/C serology, Hepatitis E PCR and 
assess anti -ANA/SMA/LKM/SLA/LP/LCI, iron studies.  Consider imaging, eg, 
ultrasound scan for metastases or thromboembolism.  Consult with a hepatologist 
and consider liver biopsy.  
Renal toxicity  Review  hydration status and medication history.  Test and culture urine.  Consider 
renal ultrasound scan, protein assessment (dipstick/24 -hour urine collection), or 
phase -contrast microscopy.  Refer to nephrology for further management 
assistance.  
Dermatology  Consider other causes by [CONTACT_14664] a physical examination, consider dermatology 
referral for skin biopsy.  
Approved Date 3/13/[ADDRESS_500645] musculoskeletal history and perform complete musculoskeletal 
examination.  Consider joint X -ray and other imagi ng as required to exclude 
metastatic disease.  Perform autoimmune serology and refer to rheumatology for 
further management assistance.  
For suspected myositis/rhabdomyolysis/myasthenia include: CK, ESR, CRP, 
troponin, and consider a muscle biopsy  
Myocard itis Perform ECG, echocardiogram, CK/CK -MB, troponin (I and/or T), and refer to a 
cardiologist.  
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; ANA, antinuclear antibody; AST, aspartate 
aminotransferase; CK, creatine kinase; CK -MB, creati ne kinase cardiac enzyme; CNS, central nervous system; CRP, 
C-reactive protein; CT, computed tomography; DLCO, diffusing capacity for carbon monoxide; ECG, 
electrocardiogram; ESR, erythrocyte sedimentation rate; FBC, full blood count; HIV, human immunodeficiency 
virus; INR, international normalized ratio; LCI, liver cytosolic antigen; LFT, liver function test; LKM, liver kidney 
microsomal antibody; LP, liver pancreas antigen; MRA, magnetic resonance angiogram; MRI, magnetic resonance 
imaging; PCR,  polymerase chain reaction; SLA, soluble liver antigen; SMA, smooth muscle antibody; T4, 
thyroxine; TFT, thyroid function tests; TSH, thyroid -stimulating hormone; UEC,  urea electrolytes and creatinine.  
 
Treatment of Immune -Mediated Adverse Events  
• Immune -mediated  AEs can escalate quickly; study treatment interruption, close 
monitoring, timely diagnostic work -up and treatment intervention, as appropriate, 
with patients is required  
• Immune -mediated AEs should improve promptly after introduction of 
immu nosuppressive therapy.  If this does not occur, review the diagnosis, seek further 
specialist advice and contact [CONTACT_138830]  
• For some Grade 3 toxicities that resolve quickly, rechallenge with study drug may be 
considered if there is evidence of a clinical response to study treatment, after 
consultation with the study medical monitor  
• Steroid dosages in the table below are for oral or intravenous (methyl)prednisolone.  
Equivalent dosages of other corticosteroids can be substituted.  For steroid -refractory 
imAEs, consider use of steroid -sparing agents (eg, mycophenolate mofetil [MMF])  
• Consider prophylactic antibiotics for opportunistic infections if the patient is 
receiving long -term immunosuppressive therapy  
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 139 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
Thyroid 
Disorders  1-[ADDRESS_500646] thyroxine if hypothyroid, 
until TSH/T4 levels return to normal 
range.  
Thyrotoxic patients should be 
referred to an endocrinologist.  In 
cases with systemic symptoms: 
withhold study treatment, treat with a 
beta blocker and consider oral 
prednisolone 0.5  mg/kg/day for 
thyroid pain.  Taper corticosteroids 
over [ADDRESS_500647] with 
thyroxine 0.5 -1.6 µg/kg/day (for the 
elderly or those with co -morbidities, 
the suggested starting dose is 
0.5 µg/kg/day).  Add oral 
prednisolone 0.5  mg/kg/day for 
thyroid pain.  Thyrotoxic patients 
require treatment with a beta blocker 
and may require carbimazole until 
thyroiditis resolves.  Hold study treatment; 
resume when 
resolved/improved to 
Grade [ADDRESS_500648] 
for hormone replacement.  Add oral 
prednisolone 0.5 -1 mg/kg/day for 
patients with pi[INVESTIGATOR_397704]. 
Taper corticosteroids over at least 
[ADDRESS_500649] 
for assessment and treatment.  
Initiate pulse IV methylprednisolone 
1 mg/kg for patients with 
headache/visual disturbance due to 
pi[INVESTIGATOR_397705].  Convert to 
oral prednisolone and taper over at 
least 1 month.  Maintain hormone 
replac ement according to 
endocrinology advice. Maintain 
hormone replacement according to 
endocrinology advice.  Hold study treatment 
for patients with 
headache/visual 
disturbance due to 
pi[INVESTIGATOR_397706]/improved 
to Grade 2 or less. 
Discontinu ation is 
usually not necessary.  
Pneumonitis  1 
Radiographic changes 
only Monitor symptoms every 2 -3 days.  
If appearance worsens, treat as 
Grade  2. Consider holding study 
treatment until 
appearance improves 
and cause is 
determined.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 140 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
2 
Symptomatic: exertional 
breathlessness  Commence antibiotics if infection 
suspected.  Add oral prednisolone 
1 mg/kg/day if symptoms/appearance 
persist for [ADDRESS_500650]  6 weeks.  
Consider prophylaxis for adverse 
steroid effects: eg, blood glucose 
monitoring, vitamin D/calcium 
supplement.  Hold study treatment. 
Retreatment is 
acceptable if symptoms 
resolve completely or 
are controlled on 
prednisolone 
≤ 10 mg/day.  
Discontin ue study 
treatment if symptoms 
persist with 
corticosteroid 
treatment.  
3-[ADDRESS_500651]  Admit to a hospi[INVESTIGATOR_397707] 2 -4 mg/kg/day.  
If there is no improvement, or 
worsenin g after 48 hours, add 
infliximab 5 mg/kg (if no hepatic 
involvement).  Convert to oral 
prednisolone and taper over at least 
2 months.  Cover with empi[INVESTIGATOR_397708], eg,  blood 
glucose monitoring, vitamin 
D/calcium supplement.  Discontinue study 
treatment.  
Neurological 
Toxicity  1 
Mild symptoms  N/A Continue study 
treatment.  
2 
Moderate symptoms  Treat with oral prednisolone 0.5 -1 
mg/kg/day.  Taper over at least 4 
weeks. Obtain neurology 
consultation.  Hold study treatment; 
resume when 
resolved/improved to 
Grade 0 -1. 
3-4 
Severe/life -threatening  Initiate treatment with oral 
prednisolone or IV 
methylprednisolone 1 -2 mg/kg/day, 
depending on symptoms.  Taper 
corticoste roids over at least 4 weeks.  
Consider azathioprine, MMF, 
cyclosporine if no response within 
72-96 hours.  Discontinue study 
treatment.  
Colitis/Diarrhea  1 
Mild symptoms: 
< 3 liquid stools per day 
over baseline and feeling 
well Symptomatic management: fluids, 
loperamide, avoid high fiber/lactose 
diet. 
If Grade 1 persists for > 14 days 
manage as a Grade 2 event.  Continue study 
treatment.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 141 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
2 
Moderate symptoms: 4 -6 
liquid stools per day 
over baseline, or 
abdominal pain, or blood 
in stool, or n ausea, or 
nocturnal epi[INVESTIGATOR_397709] 0.5 mg/kg/day 
(non-enteric coated).  
Do not wait for any diagnostic tests 
to start treatment.  Taper steroids 
over 2 -4 weeks, consider endoscopy 
if symptoms are recurring.  Hold study treatment; 
resume when 
resolved/improved to 
baseline grade.  
3 
Severe 
symptoms: >  6 liquid 
stools per day over 
baseline, or if epi[INVESTIGATOR_397710] 1  hour of eating  
 Initiate IV methylprednisolone 1 -2 
mg/kg/day.  
Convert to oral prednisolone and 
taper over at least 4 weeks.  Consider 
prophylaxis for adverse steroid 
effects, eg, blood glucose 
monitoring, vitamin D/calcium 
supplement.  
If no improvement in 72 hours or 
symptoms worsen, consider 
infliximab 5 mg/kg if no perforation, 
sepsis, TB, hepatitis, NYHA grade 
III/IV CHF or o ther 
immunosuppressive treatment: MMF 
or tacrolimus.  
Consult gastroenterologist to conduct 
colonoscopy/ sigmoidoscopy.  Hold study treatment; 
retreatment may be 
considered when 
resolved/improved to 
baseline grade and after 
discussion with the 
study medical monitor.  
 
4 
Life-threatening 
symptoms  Discontinue study 
treatment.  
Skin reactions  1 
Skin rash, with or 
without symptoms, 
< 10% BSA  Avoid skin irritants and sun 
exposure; topi[INVESTIGATOR_397711].  
 Continue study 
treatment.  
2 
Rash covers 10%-30% 
of BSA  Avoid skin irritants and sun 
exposure; topi[INVESTIGATOR_397711].  
Topi[INVESTIGATOR_8826] (moderate strength 
cream once a day or potent cream 
twice a day) ± oral or topi[INVESTIGATOR_397712]. Consider a 
short course of oral steroids.  Continue study 
treatment.  
3 
Rash covers >  30% BSA 
or Grade 2 with 
substantial symptoms  Avoid skin irritants and sun 
exposure; topi[INVESTIGATOR_397711].  
Initiate steroids as follows based on 
clinical judgement:  
For moderate symptoms: oral 
prednisolone 0.5 -1 mg/kg/day for 3 
days then taper over 2 -4 weeks.  
For severe symptoms: IV 
methylprednisolone 0.5 -1 mg/kg/day; 
convert to oral prednisolone and 
taper over at least 4 weeks.  Hold study treatment.  
Re-treat when AE is 
resolved or improved to 
mild rash (Grade 1 -2) 
after discussion with 
the study medical 
monitor.  
 
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 142 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
4 
Skin sloughing >  30% 
BSA with associated 
symptoms (eg, 
erythema, purpura, 
epi[INVESTIGATOR_89152])  Initiate IV methylprednisolone 1 -2 
mg/kg/day. Convert to oral 
prednisolone and taper  over at least [ADDRESS_500652] >  ULN to 
3X ULN  Check LFTs within [ADDRESS_500653]  Recheck LFTs e very 48 -72 hours:   
For persistent ALT/AST elevation: 
consider oral prednisolone 0.5 -1 
mg/kg/day for 3 days then taper over 
2-4 weeks.  
For rising ALT/AST: start oral 
prednisolone 1  mg/kg/day and taper 
over 2 -4 weeks; re -escalate dose if 
LFTs worsen, depend ing on clinical 
judgement.  Hold study treatment; 
treatment may be 
resumed when 
resolved/improved to 
baseline Grade and 
prednisolone tapered to 
≤ [ADDRESS_500654]  ALT/AST < 400 IU/L and normal 
bilirubin/INR/albumin: Initiate oral 
prednisolone 1  mg/kg and taper over 
at least 4 weeks.  
ALT/AST > 400 IU/L or raised 
bilirubin/INR/low albumin: Initiate 
IV (methyl)prednisolone 
2 mg/kg/day. When LFTs improve to 
Grade [ADDRESS_500655] 4 
weeks.   Hold study treatment 
until improved to 
baseline Grade; 
reintroduce only after 
discussion with the 
study medical monitor.  
[ADDRESS_500656] >  20X 
ULN  Initiate IV methylprednisolone 2 
mg/kg/day. Convert to oral 
prednisolone and taper over at least 6 
weeks.  Discontinue study 
treatment.  
Worsening LFTs despi[INVESTIGATOR_397713]:  
• If on oral prednisolone, change to pulsed IV methylprednisolone  
• If on IV, add MMF 500 -1000 mg twice a day  
• If worsens on MMF, consider addition of tacrolimus  
Duration and dose of steroid required will depend on severity of event  
Nephritis  1 
Creatinine 1.5X baseline  
or > ULN to 1.5X ULN  Repeat creatinine weekly.  
If symptoms worsen, manage as per 
criteria below.  Continue study 
treatment.  
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 143 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
2 
Creatinine >  1.5X -3X 
baseline or >  1.5X -3X 
ULN  Ensure hydration and review 
creatinine in 48 -72 hours; if not 
improving, consider creatinine 
clearance measurement by [ADDRESS_500657] the need for kidney 
biopsy.  
If attributed to study drug, initiate 
oral prednisolo ne 0.5 -1 mg/kg and 
taper over at least 2 weeks.  
Repeat creatinine/U&E every 
48-72 hours.  Hold study treatment.  
If not attributed to drug 
toxicity, restart 
treatment.  
If attributed to study 
drug and 
resolved/improved to 
baseline grade: Restart 
study drug if tapered to 
< 10 mg prednisolone.  
3 
Creatinine > 3X baseline 
or > 3X -6X ULN  Hospi[INVESTIGATOR_397714]; repeat creatinine 
every 24 hours; refer to a 
nephrologist and discuss need for 
biopsy.  If worsening, initiate IV 
(methyl)prednisolone 1 -2 mg/kg. 
Taper corticosteroids over at least 
4 weeks.  Hold study treatment 
until the cause is 
investigated.  
If study drug suspected: 
Discontinue study 
treatment.  
4 
Creatinine >  6X ULN  As per Grade 3, patient should be 
managed in a ho spi[INVESTIGATOR_397715].  Discontinue study 
treatment.  
Diabetes/  
Hyperglycemia  [ADDRESS_500658] to 160 mg/dL; 
ULN to 8.9 mmol/L  Monitor closely and treat according 
to local guideline.  Check for 
C-peptide and antibodi es against 
glutamic acid decarboxylase and islet 
cells are recommended  Continue study 
treatment.  
2 
Fasting glucose value 
160-250 mg/dL; 
8.9-13.9 mmol/L  Obtain a repeat blood glucose level 
at least every week.  Manage 
according to local guideline.  Continue study 
treatment or hold 
treatment if 
hyperglycemia is 
worsening.  Resume 
treatment when blood 
glucose is stabilized at 
baseline or Grade 0 -1. 
3 
Fasting glucose value 
250-500 mg/dL; 
13.9-27.8 mmol/L  Admit patient to hospi[INVESTIGATOR_397716] 
a diabetologist for hyperglycemia 
management.  Corticosteroids may 
exacerbate hyperglycemia and should 
be avoided.  Hold study treatment 
until patient is 
hyperglycemia 
symptom -free, and 
blood glucose has been 
stabilized at baseline or 
Grade 0 -1. 4 
Fasting glucose 
value >  500 mg/dL;  
> 27.8 mmol/L  Admit patient to hospi[INVESTIGATOR_397717].  Refer the patient to a 
diabetologist for insulin maintenance 
and monitoring.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 144 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
Diabetic Ketoacidosis  Admit patient to hospi[INVESTIGATOR_397718]. 
Refer to endocrinologist for further 
diabetic management.  Hold study treatment 
until blood glucose 
stabilized at baseline.  
Ocular Toxicity  1 
Asymptomatic eye 
exam/test abnormality  Consider alternative causes and 
prescribe topi[INVESTIGATOR_397719].  Continue study 
treatment.  
[ADDRESS_500659] 
for assessment and topi[INVESTIGATOR_397720].  Consider a 
course of oral steroids.  Continue study 
treatment or hold 
treatment if symptoms 
worsen or if there are 
symptoms of visual 
disturbance.  
3 
Posterior uveitis/ 
panuveitis or significant 
symptoms  Refer patient urgently to an 
ophthalmologist.  Initiate oral 
prednisolone 1-2 mg/kg and taper 
over at least 4 weeks.  Hold study treatment 
until improved to 
Grade  0-1; reintroduce 
only after discussion 
with the study medical 
monitor.  
4 
Blindness (at least 
20/200) in the affected 
eyes Initiate IV (methyl)prednisolone 
2 mg/kg/day .  Convert to oral 
prednisolone and taper over at least 
[ADDRESS_500660] abnormalities  Monitor pancreatic enzymes.  Continue study 
treatment.  
3 
Abdominal pain, nausea 
and vomiting  Admit to hospi[INVESTIGATOR_397721].  Initiate IV 
(methyl)prednisolone 1 -2 mg/kg/day. 
Convert to oral prednisolone when 
amylase/lipase improved to Grade 2, 
and taper over at least 4  weeks.  Hold study treatment; 
reintroduce only after 
discussion with the 
study m edical monitor.  
4 
Acute abdominal pain, 
surgical emergency  Admit to hospi[INVESTIGATOR_397722].  Discontinue study 
treatment.  
Arthritis  1 
Mild pain with 
inflammation, swelling  Management per local guideline.  Continue study 
treatment.  
2 
Moderate pain with 
inflammation, swelling, 
limited instrumental 
(fine motor) activities  Management as per local guideline.  
Consider referring patient to a 
rheumatologist.  If symptoms worsen 
on treatment manage as a Grade 3 
event.  Continue treatment or, 
if symptoms continue 
worsens, hold study 
treatment until 
symptoms improve to 
baseline or Grade 0 -1. 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 145 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
[ADDRESS_500661] for assessment and 
management.  Initiate oral 
prednisolone 0.5 -1 mg/kg and taper 
over at least 4 weeks.  Hold study treatment 
unless improved to 
Grade 0 -1; reintroduce 
only after discussion 
with the study m edical 
monitor.  
Mucositis/  
stomatitis  [ADDRESS_500662] findings only or 
minimal symptoms  Consider topi[INVESTIGATOR_397723].  Continue study 
treatment.  
2 
Moderate pain, reduced 
oral intake, limited 
instrumental activities  As per local guidelines, treat with 
analgesics, topi[INVESTIGATOR_397724].  Ensure adequate 
hydration.  If symptoms worsen or 
there is sepsis or bleeding, manage as 
a Grade 3 event.  Continue study 
treatment.  
3 
Severe pain, limited 
food and fluid intake, 
daily living activity 
limited  Admit to hospi[INVESTIGATOR_397725].  Initiate IV 
(methyl)prednisolone 1 -2 mg/kg/day. 
Convert to oral prednisolone when 
symptoms improved to Grade [ADDRESS_500663] 4  weeks.  Hold study treatment 
until improved to 
Grade  0-1. 
4 
Life-threatening 
complications or 
dehydration  Admit to hospi[INVESTIGATOR_397726].  Consider IV corticosteroids if 
not contraindicated by [CONTACT_80601].  Discontinue study 
treatment.  
Myositis/  
Rhabdomyolysis  1 
Mild weakness 
with/without pain  Prescribe analgesics.  
If CK is significantly elevated and 
patient has symptoms, consider oral 
steroids and treat as Grade 2.  Continue study 
treatment.  
2 
Moderate weakness 
with/without pain  If CK is 3X ULN or worse, initiate 
oral prednis olone 0.5 -1 mg/kg and 
taper over at least 4 weeks.  Hold study treatment 
until improved to 
Grade  0-1. 
3-4 
Severe weakness, 
limiting self -care Admit to hospi[INVESTIGATOR_397727] 1 mg/kg.  Consider 
bolus IV (methyl)prednisolone and 
1-2 mg/kg/day maintenance for 
severe activity restriction or 
dysphagia.  If symptoms do not 
improve add immunosuppressant 
therapy.  Taper oral steroids over at 
least 4 weeks.  Hold study treatment 
until improved to 
Grade  0-1. Discon tinue 
if any evidence of 
myocardial 
involvement.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 146 Autoimmune 
Toxicity  Grade  Treatment G uidelines  
(Subject to Clinical Judgement)  Study Drug 
Management  
Myocarditis  < 2 
Asymptomatic but 
significantly increased 
CK-MB or increased 
troponin OR clinically 
significant 
intraventricular 
conduction delay  Initiate cardiac evaluation under 
close monitoring with repea t serum 
testing; consider referral to a 
cardiologist.  
If diagnosis of myocarditis is 
confirmed, treat as Grade 2.  Hold study treatment.  
 
If a diagnosis of 
myocarditis is 
confirmed, permanently 
discontinue study 
treatment in patients 
with moderate or severe  
symptoms.  Patients 
with no symptoms or 
mild symptoms may 
not restart tislelizumab 
unless cardiac 
parameters have 
returned to baseline and 
after discussion with 
the study medical 
monitor.  2 
Symptoms on mild -
moderate exertion  Admit to hospi[INVESTIGATOR_397728] 
(methyl)prednisolone at 
1-2 mg/kg/day.   Consult with a 
cardiologist and manage symptoms 
of cardiac failure according to local 
guidelines.  
If no immediate response change to 
pulsed doses of (methyl)prednisolone 
1g/day and ad d MMF, infliximab or 
anti-thymocyte globulin.  3 
Severe symptoms with 
mild exertion  
4 
Life-threatening  
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body 
surface area; CHF, congestive heart failure; CK, creatine kinase; CK -MB, creatine kinase cardiac isoenzyme; INR, 
international normalized ratio; IV,  intravenous; LFT, liver function test; MMF, mycophenolate mofetil;  N/A, not 
applicable; NYHA, [LOCATION_001] Heart Association; T4, thyroxine; TB, tuberculosis; TFT, thyroid function test; TSH, 
thyroid -stimulating hormone; U&E, urea and electrolytes; ULN, upper  limit of normal.  
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 147 APPENDIX  8. CHRONIC KIDNEY DISEASE EPI[INVESTIGATOR_397664] (CKD -EPI) EQUATION   
In adults, the most widely -used equations for estimating glomerular filtration rate (GFR) from 
serum creatinine are the Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD -EPI) 
equation1 and the Modification of Diet in Renal Disease (MDRD) Study equation. The National 
Kidney Disease Education Program (NKDEP) calculators rely on creatinine determinations 
which are isotope dilution mass spectrometry (IDMS) traceable.  All laboratories shoul d be using 
creatinine methods calibrated to be IDMS traceable.   
This CKD -EPI [INVESTIGATOR_397729]/dL.  This equation is 
recommended when eGFR values above 60 mL/min/1.73 m2 are desired.  
GFR = 141 × min (Scr /κ, 1) α ×  max (Scr /κ, 1) -1.209 × 0.993Age × 1.018 [if female] × 1.159 
[if black]  
where:  
Scr is serum creatinine in mg/dL,  
κ is 0.7 for females and 0.9 for males,  
α is -0.329 for females and -0.411 for males,  
min indicates the minimum of Scr /κ or 1, and  
max indicates the maximum of Scr /κ or 1.  
The equation does not require weight because the results are reported normalized to 1.73 m2 
body surface area, which is an accepted average adult surface area.  
The online calculator for CKD -EPI [INVESTIGATOR_397730]: https ://www.niddk.nih.gov/health -
information/communication -programs/nkdep/laboratory -evaluation/glomerular -filtration -rate-
calculators.  
Sites may use a different equation than the one listed above if consistent with local guidance.  
 
1. Levey AS, Stevens LA, Sch mid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 
2009;150(9):604 -12). 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 148 APPENDIX  9. CONTRACEPTION GUIDELINES AND DEFINITIONS 
OF “WOMEN OF CHILDBEARING POTENTIAL”, “NO 
CHILDBEARING POTENTIAL”   
Contraception Guidelines  
The Clinical Trials Facilitation Group’s recommendations related to contraception and 
pregnancy testing in clinical trials include the use of highly effective forms of birth control. 
These method s include the following:  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated 
with the inhibition of ovulation (oral, intravaginal, or transdermal). If oral (birth 
control pi[INVESTIGATOR_397731]/or progestogen, below) are sele cted, they must be used 
with a barrier form of contraception (see below) simultaneously.  
• Progestogen -only hormonal contraception associated with the inhibition of ovulation 
(oral, injectable, or implantable)  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized male partner, provided that the vasectomized partner is the sole sexual 
partner of the woman of childbearing potential study participant and that the 
vasectomized partner has received medical ass essment of surgical success  
• Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of exposure associated with the study treatment).  
− NOTE:  Total sexual abstinence should only be used as a contraceptive method if 
it is in line with the patient’s usual and preferred lifestyle. Periodic abstinence (eg, 
calendar, ovulation, symptothermal, postovulation methods), declaration of 
abstinence for the duration of exposure to study drug, and withdrawal are not 
acceptable method s of contraception.  
Of note, barrier contraception (including male and female condoms with or without spermicide) 
is not considered a highly effective method of contraception and if used, this method must be 
combined with a highly effective form of birth c ontrol listed above.  
Definitions of “Women of Childbearing Potential,” “Women of No Childbearing Potential”  
As defined in this protocol, “women of childbearing potential” are female patients who are 
physiologically capable of becoming pregnant.  
Conversely , “women of no childbearing potential” are defined as female patients meeting any of 
the following criteria:  
• Surgically sterile (ie, through bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy, or 
hysterectomy)  
• Postmenopausal, defined as:  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 149 − ≥ 55 years of age with no spontaneous menses for ≥ 12 months OR  
− < 55 years of age with no spontaneous menses for ≥ 12 months AND with 
postmenopausal follicle -stimulating hormone (FSH) concentration > 30 IU/mL 
and all alternative medical causes for lack of spontaneous menses for ≥ [ADDRESS_500664] been ruled out, such as polycystic ovarian syndrome, hyperprolactinemia, 
etc.  
If an FSH measurement is required to confirm postmenopausal state, concomitant 
use of hormonal contraception or hormonal replacement therapy should be 
excluded.  
 
Adapted from Clinical  Trials Facilitati on Group (CTFG).  Recommendations related to contraception 
and pregnancy testing in clinical trials.  September 15, 2014. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 150 APPENDIX  10.  EORTC -QLQ -C30 QUESTIONNAIRE   
 
 
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 151  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 152 APPENDIX  11.  EORTC QLQ -OES18 QUESTIONNAIRE   
 
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 153 APPENDIX  12.  EQ-5D-5L QUESTIONNAIRE   
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 154  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 155 APPENDIX  13. FLOW CHART   
 
Abbreviations: ESCC, esophageal squamous cell carcinoma; mets, metastasis; NCCN, National Comprehensive 
Cancer Network; TFI, treatment -free interval  
1. Combinations include any combination of surgery, chemotherapy and radiotherapy.  
2. TFI: treatment -free interval. Duration from the last day of prior treatment therapy.  
3. Patients who had surgery or radio therapy alone, local chemotherapy (e.g., intrathoracic chemotherapy), or any 
systemic chemotherapy (neoadjuvant, concurrent, or adjuvant) with a nonplatinum -based regimen (except for 
paclitaxel monotherapy), even if the TF I was ≤ 6 months, are eligible for platinum -based chemotherapy doublet 
and are appropriate for this study.  
4. Patients who had progression after receiving ≥ 2 definitive therapi[INVESTIGATOR_397732] > 6 mo. Patients with TFI ≤ 6 m onths with no prior platinum -based chemotherapy are also eligible.  
5. The chemotherapy in concurrent chemoradiotherapy is usually deemed as a chemosensitizer. In this case, 
patients may be enrolled into the study, even if the TFI is ≤ 6 months.  
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 156 APPENDIX  14. AMERICAN JOINT COMMITTEE ON CANCER TNM 
CLASSIFICATION OF CARCINOMA OF THE 
ESOPHAGUS AND ESOPAGOGASTRIC JUNCTION (7TH 
ED, 2010)   
 
Approved Date 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 157 Squamous -cell carcinoma stage groupi[INVESTIGATOR_397733] 3/13/2024

BGB -A317 -306 BeiGene 
Protocol Amendment  5.0  
 
CONFIDENTIAL  Page 158 APPENDIX  15. NUTRI TIONAL RISK INDEX   
 
Recent weight loss history of the patient may not always be known and the body weight loss 
does not take the albumin level into consideration, so the Nutrition al Risk Index (NRI) is 
referenced as an alternative per investigator’s choice to assess the patient’s nutritional status for 
the purpose of eligibility. The formula is provided below ( Shirasu et al 2018 ): 
 
NRI = (1.489 × serum al bumin) + (41.7 × present body weight / ideal body weight)  
 
The Ideal Body Weight (IBW) formula is based on the Peterson formula (Peterson, 2016):  
IBW (kg) = 2.2 x Target BMI + [3.5 x Target BMI x (Height (m) - 1.5 m)]. For the purpose of 
this study, we wi ll use a Target BMI of 22, so the formula becomes:  
IBW (kg) = 48.4 + [77 x (Height (m) - 1.5 m)]  
 
Or you can use below online calculator to calculate the IBW, and please choose the calculation 
results of the Peterson formula:  
https://www.gigacalculator.com /calculators/ideal -weight -calculator.php  
Approved Date 3/13/2024

Signature [CONTACT_397841]
13-Mar-2024 14:18:12 GMT[PHONE_006]
Approved Date 3/13/2024
